| The codes contained in this document require Prior Authorization for Ascension |
|--|
| SmartHealth Members |

Due to the sheer volume of information contained in this document and that codes are grouped by category, please use the search function (CTRL F) to locate the code or word you are looking for. Services may be listed more than once and have different instructions on obtaining authorization.

All inpatient confinements require authorization even if the procedure is not on this list.

Emergency and Observation visits *do not* require authorization. However if those visits result in being admitted to the hospital, the hospitalization will require Authorization.

All Genetic Testing requires *Prior* Authorization and will not be reviewed retroactively.

All Cell and Gene Therapy requires Prior Authorization. All must be FDA approved or it is not covered.

Some items on this list have been retired and do not currently/or may NOT at a future date require authorization. Please read all notes carefully for each item.

| СРТ, НСРСЅ | | |
|--------------------|--|--------------------------|
| or Revenue Code | Inpatient Revenue Code Description | Comments/ Limitations |
| Pleas | e note any elective procedure done as an inpatient also requires prior authorization even if the | code is not listed here. |
| | All Cell/Gene Therapy requires prior authorization. | |
| 0100 | All-inclusive room and board plus ancillary - POS 21 | |
| 0101 | All-inclusive room and board - POS 21 | |
| 0110 | Room and Board Private (one bed) - General - POS 21 | |
| 0111 | Room and Board Private (one bed) - Medical/Surgical/GYN - POS 21 | |
| 0112 | Room and Board Private (one bed) - OB - POS 21 | |
| 0113 | Room and Board Private (one bed) - Pediatric - POS 21 | |
| 0114 | Room and Board Private (one bed) - Psychiatric - POS 21 | |
| 0115 | Room and Board Private (one bed) - Hospice - POS 21 | |
| 0116 | Room and Board Private (one bed) - Detoxification - POS 21 | |
| 0117 | Room and Board Private (one bed) - Oncology - POS 21 | |
| 0118 | Room and Board Private (one bed) - Rehab - POS 21 | |
| 0119 | Room and Board Private (one bed) - Other - POS 21 | |
| 0120 | Long term acute care | |
| 0121 | Room and Board Semi Private (two beds) - Medical/Surgical/GYN - POS 21 | |
| 0122 | Room and Board Semi Private (two beds) - OB - POS 21 | |
| 0123 | Room and Board Semi Private (two beds) - Pediatric - POS 21 | |
| 0124 | Room and Board Semi Private (two beds) - Psychiatric - POS 21 | |
| 0125 | Room and Board Semi Private (two beds) - Hospice - POS 21 | |
| 0126 | Room and Board Semi Private (two beds) - Detoxification - POS 21 | |
| 0127 | Room and Board Semi Private (two beds) - Oncology - POS 21 | |
| 0128 | Level 1 Rehab | |
| 0129 | Level 2 Rehab - acute complex | |
| 0130 | Room & Board - Three and Four Beds General Classification - POS 21 | |
| 0131 | Room & Board - Three and Four Beds Medical/Surgical/Gyn - POS 21 | |
| 0132 | Room & Board - Three and Four Beds Obstetrics (OB) - POS 21 | |
| 0133 | Room & Board - Three and Four Beds Pediatric - POS 21 | |
| 0133 | Room & Board - Three and Four Beds Psychiatric - POS 21 | |
| 0135 | Room & Board - Three and Four Beds Hospice - POS 21 | |
| 0136 | Room & Board - Three and Four Beds Detoxification - POS 21 | |
| 0130 | Room & Board - Three and Four Beds Oncology - POS 21 | |
| 0137 | Room & Board - Three and Four Beds Rehabilitation - POS 21 | |
| 0138 | Room & Board - Three and Four Beds Nehabilitation - FOS 21 | |
| 0139 | Room & Board - Deluxe Private General Classification - POS 21 | |
| 0140 | Room & Board - Deluxe Private General Classification - POS 21 | |
| 0141 | Room & Board - Deluxe Private Medical/Surgical/Syl1 - POS 21 Room & Board - Deluxe Private Obstetrics (OB) - POS 21 | |
| 0142 | Room & Board - Deluxe Private Obstetrics (OB) - POS 21 | |
| 0143 | Room & Board - Deluxe Private Pediatric - POS 21 Room & Board - Deluxe Private Psychiatric - POS 21 | |
| | | |
| 0145 | Room & Board - Deluxe Private Hospice - POS 21 | |
| 0146 | Room & Board - Deluxe Private Detoxification - POS 21 | |
| 0147 | Room & Board - Deluxe Private Oncology - POS 21 | |
| 0148 | Room & Board - Deluxe Private Rehabilitation - POS 21 | |

| CPT, HCPCS or Revenue Code | Inpatient Revenue Code Description | Comments/ Limitations |
|----------------------------------|---|---|
| Plea | se note any elective procedure done as an inpatient also requires prior authorization even if th | e code is not listed here. |
| | All Cell/Gene Therapy requires prior authorization. | |
| 0149 | Room & Board - Deluxe Private Other - POS 21 | |
| 0150 | Room & Board - Ward General Classification - POS 21 | |
| 0151 | Room & Board - Ward Medical/Surgical/Gyn - POS 21 | |
| 0152 | Room & Board - Ward Obstetrics (OB) - POS 21 | |
| 0153 | Room & Board - Ward Pediatric - POS 21 | |
| 0154 | Room & Board - Ward Psychiatric - POS 21 | |
| 0155 | Room & Board - Ward Hospice - POS 21 | |
| 0156 | Room & Board - Ward Detoxification - POS 21 | |
| 0157 | Room & Board - Ward Oncology - POS 21 | |
| 0158 | Room & Board - Ward Rehabilitation - POS 21 | |
| 0159 | Room & Board - Ward Other - POS 21 | |
| 0160 | Room & Board - Other General Classification - POS 21 | |
| 0161 | Hosptial at home | Effective 8/1/2024 |
| 0164 | Other Room & Board - Sterile Environment - POS 21 | |
| 0167 | Room & Board - Other Self Care - POS 21 | |
| 0169 | Room & Board - Other Other - POS 21 | |
| 0170 | Nursery General Classification - POS 21 | |
| 0171 | Nursery Newborn - Level I - POS 21 | |
| 0172 | Nursery Newborn - Level II - POS 21 | |
| 0173 | Nursery Newborn - Level III - POS 21 | |
| 0174 | Nursery Newborn - Level IV - POS 21 | |
| 0179 | Nursery Other - POS 21 | |
| 0190 | General classification - SNF | |
| 0191 | Subacute Care - Level I - SNF | |
| 0192 | Subacute Care - Level II - SNF | |
| 0193 | Subacute Care - Level III - SNF | |
| 0194 | Subacute Care - Level IV - SNF | |
| 0199 | Other Subacute Care - SNF | |
| 0362 | Transplant- small intestine; small intestine/liver; liver; multivisceral; lung/heart/lung; heart; bone marrow; pancreas; cornea | |
| 0367 | Transplant – kidney | |
| 0413 | Hyperbaric Oxygen Therapy outpatient revenue code | |
| 0540 | Ambulance – General | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| 0542 | Ambulance – Medical Transport | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| 0543 | Ambulance – Heart Mobile | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |

| CPT, HCPCS or Revenue Code | Inpatient Revenue Code Description | Comments/ Limitations |
|----------------------------------|---|---|
| Pleas | se note any elective procedure done as an inpatient also requires prior authorization even if the | code is not listed here. |
| | All Cell/Gene Therapy requires prior authorization. | |
| 0546 | Ambulance – Neonatal | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| 0549 | Ambulance – Other | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| 1000 | General Behavioral Health Accommodations | |
| 1001 | Residential treatment - psychiatric | |
| 1002 | Residential treatment - chemical dependency | |

| CPT, HCPCS or Revenue Code | HCPCS (not contained in other categories) Description | Comments/ Limitations |
|----------------------------------|---|---|
| | any elective procedure done as an inpatient also requires authorization even if the code is not li | |
| ** S2066, S2067, S2068 ** | These are non-covered codes. Please use the proper procedure codes instead: 19361, 19364, 19366, 19367, 19368, 19369 | Effective 1/1/2020 |
| A0130 | Wheelchair Van | |
| A0140 | Air travel (private or commercial) intra-or interstate, non emergency transport | |
| A0426 | Ambulance, advanced life support, non emergency transport | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| A0428 | Ambulance, basic life support, non emergency transport | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| A0430 | Ambulance service, conventional air services, transport, one way (fixed wing) | |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | |
| A0432 | Paramedic intercept (PI)0632 rural area, transport furnished by volunteer ambulance company which is prohibited by state law from billing third party payers | |
| A0434 | Specialty Care Transport (SCT) | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| A0435 | Fixed wing air mileage | |
| A0436 | Rotary wing air mileage | |
| A0999 | Unlisted ambulance service | No auth required If service will be billed with 2nd position modifier of D, H, I, N, or S |
| A9599 | Radiopharmaceutical, diagnostic for beta-amyloid PET imaging | |
| C1781 | Mesh (implantable) | Removed from PA requirement 8/1/24 |
| C1826 | Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system | Effective 1/1/23 |
| C1827 | Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller | Effective 1/1/23 |
| C1831 | Custom cage for spine | Effective 1/1/2022 |
| C1832 | Autograft suspension, including cell processing and application, and all system components | Effective 9/1/2022 |
| C7504 | Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance | Effective 1/1/2023 |
| C7505 | Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance | Effective 1/1/2023 |
| C7507 | Percutaneous vertebral augmentations, first thoracic and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance | Effective 1/1/2023 |
| C7508 | Percutaneous vertebral augmentations, first lumbar and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance | Effective 1/1/2023 |
| C9352 | Microporous collagen implantable tube (NeuraGen Nerve Guide) per cm length | Effective 1/1/2022 |
| C9353 | Microporous collagen implantable slit tube (Neurawrap Nerve Protector), per cm length | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | HCPCS (not contained in other categories) Description | Comments/ Limitations |
|----------------------------------|--|--|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not li | sted here. |
| C9354 | Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm | Effective 1/1/2022 |
| C9355 | Collagen nerve cuff (NeuroMatrix), per 0.5cm length | Effective 1/1/2022 |
| C9356 | Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet) | Effective 1/1/2022 |
| C9361 | Collagen matrix nerve wrap (Neuromend Collagen Nerve Wrap), per 0.5cm length | Effective 1/1/2022 |
| C9362 | Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5cc | Effective 1/1/2022 |
| C9363 | Integra meshed bil wound mat | Effective 1/1/2022 |
| C9364 | Porcine implant, Permacol, per sq cm | Effective 1/1/2022 |
| C9751 | Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s] /biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s) | |
| C9776 | Intraoperative Near-Infrared Fluorescence Imaging Of Major Extrahepatic Bile Duct(S) (E.G., Cystic Duct, Common Bile Duct And Common Hepatic Duct) With Intravenous Administration Of Indocyanine Green (Icg) (List Separately In Addition To Code For Primary Procedure) | Effective 6/1/21 |
| C9777 | Esophageal Mucosal Integrity Testing By Electrical Impedance, Transoral (List Separately In Addition To Code For Primary Procedure) | Effective 6/1/21 |
| C9781 | Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed | Effective 9/1/2022 |
| C9784 | Gastric restrictive procedure, endoscopic sleeve gastroplasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components | Effective 10/1/2023 |
| C9785 | Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components | Effective 10/1/2023 |
| D9223 | General Anesthesia in 15 minute increments | Pre-certification of Anesthesia is only applicable when dental services are performed in a hospital/facility setting. |
| G0277 | Hyperbaric Oxygen Therapy | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | Effective 1/1/2023 |
| G2020 | Services For High Intensity Clinical Services Associated With The Initial Engagement And Outreach Of Beneficiaries Assigned To The Sip Component Of The Pcf Model (Do Not Bill With Chronic Care Management Codes) | Effective 6/1/21 |
| G2082 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation | Effective 10/1/2022. Removed from PA 11/1/23 |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified healthcare professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation | Effective 10/1/2022. Removed from PA 11/1/23 |
| G2172 | All Inclusive Payment For Services Related To Highly Coordinated And Integrated Opioid Use Disorder (Oud) Treatment Services Furnished For The Demonstration Project | Effective 6/1/21 |
| S2083 | Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of | Effective 7/1/2020 |

| CPT, HCPCS or Revenue Code | HCPCS (not contained in other categories) Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not li | sted here. |
| S9960 | Ambulance service, conventional air services, non emergency transport, one way (fixed wing) | |
| \$9961 | Ambulance service, conventional air services, non emergency transport, one way (rotary wing) | |
| V2790 | Amniotic membrane for surgical reconstruction per procedure | |

| CPT, HCPCS or Revenue Code | Skin Substitutes Description | Comments/ Limitations |
|----------------------------------|---|--|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not l authorization for a skin grafting procedure, the material must be authorized or it may not | |
| A2002 | Mirragen advanced wound matrix, per square centimeter | Effective 9/1/2022 |
| A2003 | Bio-connekt wound matrix, per square centimeter | Effective 9/1/2022 |
| A2004 | Xcellistem, per square centimeter | Effective 9/1/2022 |
| A2005 | Microlyte matrix, per square centimeter | Effective 9/1/2022 |
| A2006 | Novosorb synpath dermal matrix, per square centimeter | Effective 9/1/2022 |
| A2007 | Restrata, per square centimeter | Effective 9/1/2022 |
| A2008 | Theragenesis, per square centimeter | Effective 9/1/2022 |
| A2009 | Symphony, per square centimeter | Effective 9/1/2022 |
| A2010 | Apis, per square centimeter | Effective 9/1/2022 |
| A2011 | Supra sdrm, per square centimeter | Effective 9/1/2022 |
| A2011 | Suprathel, per square centimeter | Effective 9/1/2022 |
| A2012 | Innovamatrix fs, per square centimeter | Effective 9/1/2022 |
| A2013 | Omeza collagen matrix, per 100 mg | Effective 10/1/2022 |
| A2014 | Phoenix wound matrix, per square centimeter | Effective 10/1/2022 |
| A2015 | Permeaderm b, per square centimeter | Effective 10/1/2022 |
| A2010 | Permeaderm glove, each | Effective 10/1/2022 |
| A2017 A2018 | Permeaderm c, per square centimeter | Effective 10/1/2022 |
| A2018 A2019 | Kerecis Omega3 MariGen Shield, per sq cm | Effective 10/1/2023 |
| A2020 | AC5 Advanced Wound System (AC5) | Effective 10/1/2023 |
| A2020 | NeoMatriX, per sq cm | Effective 10/1/2023 |
| A2026 | Restrata minimatrix, 5 mg | Effective 4/1/24 (added on 5/1/24 list) |
| A4100 | Skin substitute | Effective 9/1/2022 |
| A9592 | Copper Cu-64, Dotatate, Diagnostic, 1 Millicurie | Effective 6/1/2021 |
| A9599 | Radiopharmaceutical, diagnostic for beta-amyloid PET imaging | |
| C1781 | Mesh (implantable) | |
| C1832 | Autograft suspension, including cell processing and application, and all system components | Effective 9/1/2022 |
| C5271 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area | |
| C5272 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure) | |
| C5273 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children | |
| C5274 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure) | |
| C5275 | Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure) | |

| CPT, HCPCS | | |
|--------------------|--|------------------------------|
| or Revenue Code | Skin Substitutes Description | Comments/ Limitations |
| Please note | e any elective procedure done as an inpatient also requires authorization even if the code is not l | listed here. When requesting |
| | authorization for a skin grafting procedure, the material must be authorized or it may not | be covered. |
| | Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, | |
| C5276 | genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code | |
| | for primary procedure) | |
| | Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, | |
| C5277 | genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal | |
| | to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children | |
| | Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal | |
| C5278 | to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each | |
| | additional 1% of body area of infants and children, or part thereof (list separately in addition | |
| | to code for primary procedure) | |
| C9352 | Microporous collagen implantable tube (NeuraGen Nerve Guide) per cm length | Effective 1/1/2022 |
| C9353 | Microporous collagen implantable slit tube (Neurawrap Nerve Protector), per cm length | Effective 1/1/2022 |
| C9354 | Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm | Effective 1/1/2022 |
| C9355 | Collagen nerve cuff (NeuroMatrix), per 0.5cm length | Effective 1/1/2022 |
| C9356 | Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide | Effective 1/1/2022 |
| | Tendon Protector Sheet) | |
| C9358 | Dermal substitute, native, nondenatured collagen, fetal bovine origin (Surgiment Collagen Matrix), per 0.5 sq cm | Effective 1/1/2022 |
| C9359 | Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5cc | Effective 1/1/2022 |
| | Dermal substitute, native nondenatured collagen, neonatal bovine origin (SurgiMend | |
| C9360 | Collagen Matrix, per 0.5 sq cm | Effective 1/1/2022 |
| C9361 | Collagen matrix nerve wrap (Neuromend Collagen Nerve Wrap), per 0.5cm length | Effective 1/1/2022 |
| C9362 | Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5cc | Effective 1/1/2022 |
| C9363 | Integra meshed bil wound mat | Effective 1/1/2022 |
| C9364 | Porcine implant, Permacol, per sq cm | Effective 1/1/2022 |
| Q4100 | Skin substitutes, not otherwise specified | |
| Q4101 | Apligraf, per square centimeter | |
| Q4102 | Oasis wound matrix, per sq cm | |
| Q4103 | Oasis burn matrix | Effective 1/1/2022 |
| Q4104 | Integra bilayer matrix wound dressing (bmwd), per square centimeter | , , |
| Q4105 | Integra dermal regeneration template (drt), per square centimeter | |
| Q4106 | Dermagraft, per square centimeter | |
| Q4107 | Graftjacket, per square centimeter | |
| Q4108 | Integra matrix, per sq cm | |
| Q4110 | Primatrix | Effective 1/1/2022 |
| Q4111 | Gammagraft | Effective 1/1/2022 |
| Q4112 | Cymetra, injectable, 1cc | Effective 1/1/2022 |
| Q4112 Q4113 | Graft Jacket Xpress, injectable 1cc | Effective 1/1/2022 |
| Q4113 Q4114 | Integra flowable wound matrix, injectable, 1cc | Effective 1/1/2022 |
| Q4114 Q4115 | Alloskin | Effective 1/1/2022 |
| Q4115 Q4116 | Alloderm, per square centimeter | |
| Q4110 | Allouenn, per square centimeter | |

| CPT, HCPCS or Revenue Code | Skin Substitutes Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not authorization for a skin grafting procedure, the material must be authorized or it may not | |
| Q4117 | Hyalomatrix | Effective 1/1/2022 |
| Q4118 | MatriStem micromatric, 1mg | Effective 1/1/2022 |
| Q4121 | TheraSkin, per square centimeter | |
| Q4122 | Dermacell, awm, porous sq cm | |
| Q4123 | Alloskin | Effective 1/1/2022 |
| Q4124 | Oasis ultra tri-layer wound matrix, per square centimeter | |
| Q4125 | ArthroFlex, per sq cm | Effective 1/1/2022 |
| Q4126 | Memoderm/derma/tranz/integup | Effective 1/1/2022 |
| Q4127 | Talymed | Effective 1/1/2022 |
| Q4128 | FlexHd, Allopatch HD, or Matrix HD per square centimeter | |
| Q4130 | Strattice tm, per square centimeter | Effective 6/1/2021 |
| Q4132 | Grafix core, per square centimeter | |
| Q4133 | Grafix prime, per square centimeter | |
| Q4134 | Hmatrix, per square centimeter | |
| Q4135 | Mediskin, per square centimeter | |
| Q4136 | Ez-derm, per square centimeter | |
| Q4137 | Amnioexcel biodexcel 1sq cm | Effective 1/1/2022 |
| Q4138 | Biodfence dryflex, 1cm | Effective 1/1/2022 |
| Q4139 | AminoMatrix or BioDMatrix, injectable 1cc | Effective 1/1/2022 |
| Q4140 | Biodfence 1cm | Effective 1/1/2022 |
| Q4141 | Alloskin ac, 1cm | Effective 1/1/2022 |
| Q4142 | XCM biologic tissue matrix, per sq cm | Effective 1/1/2022 |
| Q4143 | Repriza, 1cm | Effective 1/1/2022 |
| Q4145 | EpiFix, injectable, 1mg | Effective 1/1/2022 |
| Q4146 | Tensix, 1cm | Effective 1/1/2022 |
| Q4147 | Architect ecm px fx 1 sq cm | Effective 1/1/2022 |
| Q4148 | Neox neox rt or clarix cord | Effective 1/1/2022 |
| Q4149 | Excellagen, 0.1cc | Effective 1/1/2022 |
| Q4150 | Allowrap ds or dry 1 sq cm | Effective 1/1/2022 |
| Q4151 | AminoBand or guardian per sqcm | |
| Q4152 | Dermapure 1 square cm | Effective 1/1/2022 |
| Q4153 | Dermavest, plurivest sq cm | Effective 1/1/2022 |
| Q4154 | Biovance 1 square cm | Effective 1/1/2022 |
| Q4155 | Neox Flo or Clariz Flo 1mg | Effective 1/1/2022 |
| Q4156 | Neoxflo or clarixflo 1 mg | Effective 1/1/2022 |
| Q4157 | Revitalon 1 square cm | Effective 1/1/2022 |
| Q4158 | Kerecis omega3, per sq cm | Effective 1/1/2022 |
| Q4159 | Affinity1 square cm | Effective 1/1/2022 |
| Q4160 | Nushield 1 square cm | Effective 1/1/2022 |
| Q4161 | Bio-connekt per square cm | Effective 1/1/2022 |
| Q4162 | WoundEx Flow, BioSkin Flow, 0.5cc | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | Skin Substitutes Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not | |
| | authorization for a skin grafting procedure, the material must be authorized or it may not | |
| Q4163 | Woundex, bioskin, per sq cm | Effective 1/1/2022 |
| Q4164 | Helicoll, per square cm | Effective 1/1/2022 |
| Q4165 | Keramatrix, Kerasorb sq cm | Effective 8/1/2020 |
| Q4166 | Cytal, per square centimeter | Effective 1/1/2022 |
| Q4167 | Truskin, per sq centimeter | Effective 1/1/2022 |
| Q4168 | AminoBand 1 mg | |
| Q4169 | Artacent wound, per sq cm | Effective 1/1/2022 |
| Q4170 | Cygnus, per square cm | Effective 1/1/2022 |
| Q4171 | Interfyl, 1mg | Effective 1/1/2022 |
| Q4173 | Palingen or palingen xplus | Effective 1/1/2022 |
| Q4174 | PalinGen or ProMatrX, 0.36mg per0.25cc | Effective 1/1/2022 |
| Q4175 | Miroderm | Effective 1/1/2022 |
| Q4176 | Neopatch, per sq centimeter | Effective 1/1/2022 |
| Q4177 | FlowerAmnioFlo, 0.1cc | Effective 1/1/2022 |
| Q4178 | Floweramniopatch, per sq cm | Effective 1/1/2022 |
| Q4179 | Flowerderm, per sq cm | Effective 1/1/2022 |
| Q4180 | Revita, per sq cm | Effective 1/1/2022 |
| Q4181 | Amnio wound, per square cm | Effective 1/1/2022 |
| Q4182 | Transcyte per sqcm | |
| Q4183 | Surgigraft, per square centimeter | |
| Q4184 | Cellesta or duo per sq cm | |
| Q4185 | Cellesta flowable amnion (25 mg per cc); per 0.5 cc | |
| Q4186 | EpiFix, per square centimeter | |
| Q4187 | Epicord, per square centimeter | |
| Q4188 | Amnioarmor, per square centimeter | |
| Q4189 | Artacent ac, 1 mg | |
| Q4190 | Artacent ac, per square centimeter | |
| Q4191 | Restorigin, per square centimeter | |
| Q4192 | Restorigin, 1 cc | |
| Q4193 | Coll-e-derm, per square centimeter | |
| Q4194 | Novachor, per square centimeter | |
| Q4195 | Puraply, per square centimeter | |
| Q4196 | Puraply am, per square centimeter | |
| Q4197 | Puraply xt, per square centimeter | |
| Q4198 | Genesis amniotic membrane, per square centimeter | |
| q4199 | Cygnus matrix, per square centimeter | Effective 9/1/2022 |
| Q4200 | Skin te, per square centimeter | |
| Q4200 | Matrion, per square centimeter | |
| Q4201 Q4202 | Keroxx (2.5g/cc), 1cc | |
| Q4202 Q4203 | Derma-gide, per square centimeter | |
| | | |
| Q4204 | Xwrap, per square centimeter | |

| CPT, HCPCS or Revenue | Skin Substitutes Description | Comments/ Limitations |
|--------------------------|---|--|
| Code | | Procedule and the second |
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not authorization for a skin grafting procedure, the material must be authorized or it may not | · · · · · |
| Q4205 | Membrane graft or membrane wrap, per square centimeter | be covered. |
| Q4206 | Fluid flow or fluid GF, 1 cc | Effective 8/1/2020 |
| Q4208 | Novafix, per square centimeter | |
| Q4209 | Surgraft, per square centimeter | |
| Q4210 | Axolotl graft or axolotl dualgraft, per square centimeter | |
| Q4211 | Amnion bio or Axobiomembrane, per square centimeter | |
| Q4212 | Allogen, per cc | Effective 8/1/2020 |
| Q4213 | Ascent, 0.5 mg | Effective 8/1/2020 |
| Q4214 | Cellesta cord, per square centimeter | Effective 8/1/2020 |
| Q4215 | Axolotl ambient or axolotl cryo, 0.1 mg | Effective 8/1/2020 |
| Q4216 | Artacent cord, per square centimeter | Effective 8/1/2020 |
| Q4217 | Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter | |
| Q4218 | Surgicord, per square centimeter | |
| Q4219 | Surgigraft-dual, per square centimeter | |
| Q4220 | BellaCell HD or Surederm, per square centimeter | |
| Q4221 | Amniowrap2, per square centimeter | |
| Q4222 | Progenamatrix, per square centimeter | |
| Q4224 | Human health factor 10 amniotic patch (hhf10-p), per square centimeter | Effective 9/1/2022 |
| Q4225 | Amniobind or dermabind tl, per square centimeter | Effective 9/1/2022 |
| Q4226 | MyOwn skin, includes harvesting and preparation procedures, per square centimeter | |
| Q4227 | AmnioCoreTM, per sq cm | Effective 1/1/2022 |
| Q4229 | Cogenex Amniotic Membrane, per sq cm | Effective 1/1/2022 |
| Q4230 | Cogenex Flowable Amnion, per 0.5cc | Effective 1/1/2022 |
| Q4231 | Corplex P, per cc | Effective 1/1/2022 |
| Q4232 | Corplex, per sq cm | Effective 1/1/2022 |
| Q4233 | SurFactor or NuDyn, per 0.5cc | Effective 1/1/2022 |
| Q4234 | XcCellerate, per sq cm | Effective 1/1/2022 |
| Q4235 | AMNIOREPAIR or AltiPly, per sq cm | Effective 1/1/2022 |
| Q4236 | Carepatch, per square centimeter | Effective 1/1/2023 |
| Q4237 | Cryo-Cord, per sq cm | Effective 1/1/2022 |
| Q4238 | Derm-Maxx, per sq cm | Effective 1/1/2022 |
| Q4239 | Amnio-Maxx or Amnio-Maxx Lite, per sq cm | Effective 1/1/2022 |
| Q4240 | CoreCyte, for topical use only, per 0.5cc | Effective 1/1/2022 |
| Q4241 | PolyCyte, for topical use only, per 0.5cc | Effective 1/1/2022 |
| Q4242 | AmnioCyte Plus, per 0.5cc | Effective 1/1/2022 |
| Q4244 | Procenta, per 200mg | Effective 1/1/2022, Code retired 4/1/24 |
| Q4245 | AmnioText, per cc | Effective 1/1/2022 |
| Q4246 | CoreText or ProText, per cc | Effective 1/1/2022 |
| Q4247 | Amniotext patch, per sq cm | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | Skin Substitutes Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| Please note | any elective procedure done as an inpatient also requires authorization even if the code is not | |
| | authorization for a skin grafting procedure, the material must be authorized or it may not | |
| Q4248 | Dermacyte Amniotic Membrane Allograft, per sq cm | Effective 1/1/2022 |
| Q4249 | AMNIPLY, for topical use only, per sq cm | Effective 1/1/2022 |
| Q4250 | AmnioAmp-MP, per sq cm | Effective 1/1/2022 |
| Q4251 | Vim, per sq cm | Effective 1/1/2022 |
| Q4252 | Vendaje, per sq cm | Effective 1/1/2022 |
| Q4253 | Zenith Amniotic Membrane, per sq cm | Effective 1/1/2022 |
| Q4254 | Novafix DL, per sq cm | Effective 1/1/2022 |
| Q4255 | REGUaRD, for topical use only, per sq cm | Effective 1/1/2022 |
| Q4256 | Mlg-complete, per square centimeter | Effective 9/1/2022 |
| Q4257 | Relese, per square centimeter | Effective 9/1/2022 |
| Q4258 | Enverse, per square centimeter | Effective 9/1/2022 |
| Q4259 | Celera dual layer or celera dual membrane, per square centimeter | Effective 7/1/2022 |
| Q4260 | Signature apatch, per square centimeter | Effective 7/1/2022 |
| Q4261 | Tag, per square centimeter | Effective 7/1/2022 |
| Q4262 | Dual layer impax membrane, per square centimeter | Effective 1/1/2023 |
| Q4263 | Surgraft tl, per square centimeter | Effective 1/1/2023 |
| Q4264 | Cocoon membrane, per square centimeter | Effective 1/1/2023 |
| Q4265 | NeoStim TL, per sq cm | Effective 10/1/2023 |
| Q4266 | NeoStim Membrane, per sq cm | Effective 10/1/2023 |
| Q4267 | NeoStim DL, per sq cm | Effective 10/1/2023 |
| Q4268 | SurGraft FT, per sq cm | Effective 10/1/2023 |
| Q4269 | SurGraft XT, per sq cm | Effective 10/1/2023 |
| Q4270 | Complete SL, per sq cm | Effective 10/1/2023 |
| Q4271 | Complete FT, per sq cm | Effective 10/1/2023 |
| Q4272 | Esano a, per square centimeter | Effective 10/1/2023 |
| Q4273 | Esano aaa, per square centimeter | Effective 10/1/2023 |
| Q4274 | Esano ac, per square centimeter | Effective 10/1/2023 |
| Q4275 | Esano aca, per square centimeter | Effective 10/1/2023 |
| Q4276 | Orion, per square centimeter | Effective 10/1/2023 |
| Q4270 | Woundplus membrane or e-graft, per square centimeter | Effective 10/1/2023 |
| Q4277 | Epieffect, per square centimeter | Effective 10/1/2023 |
| Q4278 | Vendaje ac, per square centimeter | Effective 1/1/2024 |
| Q4279 Q4280 | Xcell amnio matrix, per square centimeter | Effective 10/1/2023 |
| Q4280 | Barrera sl or barrera dl, per square centimeter | Effective 10/1/2023 |
| Q4281 Q4282 | Cygnus dual, per square centimeter | Effective 10/1/2023 |
| Q4282 | Biovance tri-layer or biovance 3I, per square centimeter | Effective 10/1/2023 |
| Q4283 | Dermabind sl, per square centimeter | Effective 10/1/2023 |
| Q4284 Q4285 | | Effective 1/1/2024 |
| | NuDYN DL or NuDYN DL MESH, per sq cm | |
| Q4286 | NuDYN SL or NuDYN SLW, per sq cm | Effective 1/1/2024 |
| Q4287 | Dermabind dl, per square centimeter | Effective 1/1/2024 |
| Q4288 | Dermabind ch, per square centimeter | Effective 1/1/2024 |

| CPT, HCPCS or Revenue Code | Skin Substitutes Description | Comments/ Limitations | | | | | |
|----------------------------------|---|--|--|--|--|--|--|
| Please note | Please note any elective procedure done as an inpatient also requires authorization even if the code is not listed here. When requesting authorization for a skin grafting procedure, the material must be authorized or it may not be covered. | | | | | | |
| Q4289 | Revoshield + amniotic barrier, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4290 | Membrane wrap-hydro, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4291 | Lamellas xt, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4292 | Lamellas, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4293 | Acesso dl, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4294 | Amnio quad-core, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4295 | Amnio tri-core amniotic, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4296 | Rebound matrix, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4297 | Emerge matrix, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4298 | Amnicore pro, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4299 | Amnicore pro+, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4300 | Acesso tl, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4301 | Activate matrix, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4302 | Complete aca, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4303 | Complete aa, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4304 | Grafix plus, per square centimeter | Effective 1/1/2024 | | | | | |
| Q4305 | American amnion ac tri-layer, per square centimeter | Effective 4/1/24 (added on 5/1/24 list) | | | | | |
| Q4306 | American amnion ac, per square centimeter | Effective 4/1/24 (added on 5/1/24 list) | | | | | |
| Q4307 | American amnion, per square centimeter | Effective 4/1/24 (added on 5/1/24 list) | | | | | |
| Q4308 | Sanopellis, per square centimeter | Effective 4/1/24 (added on 5/1/24 list) | | | | | |
| Q4309 | Via matrix, per square centimeter | Effective 4/1/24 (added on 5/1/24 list) | | | | | |
| Q4310 | Procenta, per 100 mg | Effective 4/1/24 (added on 5/1/24 list) | | | | | |

| Code(s) | Cell/Gene Description | Comments/ Limitations | Notes | Notes |
|------------------------|---|---|--|-------|
| Various | All Cell/Gene Therapy requires prior-authorization. | Effective 5.1.21 | | |
| 38205 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 38206 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 38207 | Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 38241 | Hematopoietic progenitor cell (HPC); autologous transplantation | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 88240 | Cryopreservation, freezing and storage of cells, each cell line | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| ** 96365 if >\$7500 | Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Co. | Effective 1/1/23 changed to \$7500 Effective 10.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | |
| ** 96366 if >\$7500 | Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug | Effective 10.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | |
| ** C9399 if >\$7500 | Unclassified drugs | Effective 10.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | |
| ** J3490 if >\$7500 | Unclassified drugs | Effective 10.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | |

| Code(s) | Cell/Gene Description | Comments/ Limitations | Notes | Notes |
|-------------------------|--|--|--|---|
| Various | All Cell/Gene Therapy requires prior-authorization. | Effective 5.1.21 | | |
| ** J3590 if >\$7500 | Unclassified drugs | Effective 10.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | |
| ** J9999 if > \$7500 | Not otherwise classified, antineoplastic drugs | Effective 11.1.23 | Requests for prior authorization for this code if billing > \$7500, should be sent to 586- 693-4768. Click here for link to form. | If This code is being billed for glofitamab-gxbm or epcoritamab-bysp (Columvi or Epkinly) please use this form and send to fax number 512-831- 5499 |
| 0537T | Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day | | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 0538T | preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage) | | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 0539T | receipt and preparation of CAR-T cells for administration | | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| 0540T | CAR-T cell administration, autologous | | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| C9098 | Carvykti (Ciltacabtagene autoleucel) CAR-T | Effective 7.1.22 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J1411 | Hemgenix (Etranacogene Dezaparvovec-drib) Gene Therapy | Effective 1.1.23 New code 4.1.23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J1412 | Roctavian (Valoctocgene Roxaparvovec or BMN 270) Gene Therapy (Miscellaneous codes require authorization when used for this therapy) | Effective 8.1.23. New Code Assigned 1/1/24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |

| Code(s) | Cell/Gene Description | Comments/ Limitations | Notes | Notes |
|---------|--|--|---|-------|
| Various | All Cell/Gene Therapy requires prior-authorization. | Effective 5.1.21 | | |
| J1413 | Elevidys (delandistrogene moxeparvovec) Gene Therapy (Miscellaneous codes require authorization when used for this therapy) | Effective 8.1.23. New Code assigned 1/1/24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J1426 | AMONDYS 45 (Casimersen) Gene Therapy | Effective 9.1.22 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J2998 | Ryplazim (Plasminogen human-tvmh) Gene Therapy | Effective 7.1.22 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J3398 | Luxterna (vortigene-neparvovec-ryzl) Gene Therapy | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J3399 | Zolgensma (onasemnogene abeparvovec -xioi) Gene Therapy | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J7330 | MACI (Autologous Cultured Chrondocytes on a Porcine Collagen Membrane) Gene Therapy | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J9029 | Adstiladrin (Nadofaragene firadenovec-vncg) Gene Therapy. (Miscellaneous codes require authorization when used for this therapy) | Effective 1.1.23 New code 7.1.23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| J9325 | Imlygic (talimogene laherparepvec) Gene Therapy | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| Q2040 | Kymriah (tisagenlecleucel) CAR-T | Effective 5/1/21. Code assigned 10/1/23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| Q2041 | Yescarta (axicabtagene ciloleucel) CAR-T | Effective 11.1.21 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |

| Code(s) | Cell/Gene Description | Comments/ Limitations | Notes | Notes |
|---------|---|------------------------------------|---|-------|
| Various | All Cell/Gene Therapy requires prior-authorization. | Effective 5.1.21 | | |
| | | Effective E /1 /21 | Requests for prior authorization for this | |
| Q2042 | Kymriah (tisagenlecleucel) CAR-T | Effective 5/1/21. Code assigned | code should be sent to | |
| 02042 | | 11/1/21 | <u>586-693-4768. Click</u> | |
| | | | here for link to form. | |
| | | | Requests for prior | |
| 02042 | Descence (similar and T) CAD T | Fff + | authorization for this | |
| Q2043 | Provenge (sipuleucel-T) CAR-T | Effective 11.1.21 | code should be sent to | |
| | | | 586-693-4768. Click | |
| | | | here for link to form. Requests for prior | |
| | Tecartus (Brexucabtagene autoleucel), up to 200 million | | authorization for this | |
| Q2053 | autologous anti-CD19 CAR positive viable T cells | Effective | code should be sent to | |
| Q2055 | including leukapheresis and dose preparation | 11/1/2021 | <u>586-693-4768. Click</u> | |
| | procedures per therapeutic dose . CAR-T | | here for link to form. | |
| | | | Requests for prior | |
| | | | authorization for this | |
| Q2054 | Breyanzi (lisocabtagene maraleucel) CAR-T | Effective 11/1/21 | code should be sent to | |
| Q2034 | | | <u>586-693-4768. Click</u> | |
| | | | here for link to form. | |
| | | | Requests for prior | |
| | | Effective 11.1.21. | authorization for this | |
| Q2055 | Abecma (idecabtagene vicleucel) CAR-T | New code | code should be sent to | |
| | | assigned 1/1/22 | 586-693-4768. Click | |
| | | 0 | here for link to form. | |
| | | | Requests for prior | |
| | | Effective 10/1/22 | authorization for this | |
| Q2056 | Carvykti (Ciltacabtagene autoleucel) CAR-T | | code should be sent to | |
| | | | 586-693-4768. Click | |
| | | | here for link to form. | |
| | Cord blood harvesting for transplantation, allogeneic | | Requests for prior | |
| | (Allocord; Clevecord;Ducord; Hemacord; HPC Cord Blood | | authorization for this | |
| S2140 | Clinimmune labs; HPC Cord Blood MD Anderson Blood | Effective 11/1/21 | code should be sent to | |
| | Bank;HPC Cord Blood LifeSouth Community Blood | | 586-693-4768. Click | |
| | Centers; HPC, Cord Blood Bloodworks. | | here for link to form. | |
| | | | Requests for prior | |
| TOD | | Fffe et a 2 24 24 | authorization for this | |
| TBD | Amtagvi (Lifileucel) CAR-T | Effective 2.21.24 | code should be sent to | |
| | | | 586-693-4768. Click | |
| | | | here for link to form. | |
| | Cargoun (ovagamglagona autotamcal) Cono Therany | | Requests for prior | |
| TBD | Casgevy (exagamglogene autotemcel) Gene Therapy. (Unclassified codes require authorization when used for | Effective 1.16.24 | authorization for this | |
| עסו | this therapy) | LITECTIVE 1.10.24 | code should be sent to 586-693-4768. Click | |
| | | | here for link to form. | |
| | | | Requests for prior | |
| | Gintuit (Allogeneic Cultured Keratinocytes and | | authorization for this | |
| TBD | Fibroblasts in Bovine Collagen) CAR-T. (Unclassified | Effective 1.1.24 | <u>code should be sent to</u> | |
| | codes require authorization when used for this therapy) | | <u>586-693-4768. Click</u> | |
| | | | here for link to form. | |

| Code(s) | Cell/Gene Description | Comments/ Limitations | Notes | Notes |
|---------|---|--------------------------|---|-------|
| Various | All Cell/Gene Therapy requires prior-authorization. | Effective 5.1.21 | | |
| TBD | Lantrida (donislecel) CAR-T (Unclassified codes require authorization when used for this therapy) | Effective 1.1.24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Lenmeldy (vortigene-neparvovec-ryzl. Gene Therapy. (Unclassified codes require authorization when used for this therapy) | Effective 3.18.24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Lyfgenia (lkovotibeglogene autotemcel). Gene Therapy. (Unclassified codes require authorization when used for this therapy) | Effective 1.1.24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Omisirge (omidubicel) CAR-T. (Unclassified codes require authorization when used for this therapy) | Effective 1.1.24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Rethymic (Allogenic processed thymus tissue-agdc) Gene Therapy (Unclassified codes require authorization when used for this therapy) | Effective 10/1/23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Skysona (Elivaldogene autotemcel FKA eli-cel) Autologous Gene Cell Therapy. (Unclassified codes require authorization when used for this therapy) | Effective 1.1.23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Vyjuvek (beremagene geperpavec) Gene Therapy. (Unclassified codes require authorization when used for this therapy) | Effective 1.1.24 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| TBD | Zynteglo beti-cel (betbeglogene darolentivec) Gene Therapy. (Unclassified codes require authorization when used for this therapy) | Effective 1.1.23 | Requests for prior authorization for this code should be sent to 586-693-4768. Click here for link to form. | |
| ** | Codes in Orange require authorization if billing >\$7500. | Effective 10.1.23 | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | |
|----------|--|--------------------------------|---|---------------------------------|---|------|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | |
| | Med | lical Benefit Drug Forr | nuarly List on Smart | Health Pharmacy P | age | | | | |
| J9264 | Abraxane | paclitaxel protein- bound | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J3262 | Actemra | tocilizumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0791 | Adakveo | crizanlizumab-tmca | 1/1/2023 | Sickle Cell Disease | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J9042 | Adcetris | brentuximab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0172 | ADUHELM | aducanumab-avwa | 1/1/2022 | Antidementia Agent | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J1454 | Akynzeo | fosnetupitant/palonose tron | Precertification Notification 8/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J1931 | ALDURAZYME | Laronidase | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0220 | Alglucosidase alfa | Alglucosidase alfa | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J9305 | Alimta | pemetrexed | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | | |
|----------|--|------------------|--|---|---|--|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J9057 | Aliqopa | copanlisib | 1/1/2023 | Oncology | Requires PriorAuthorizationForm be faxedto 512-831-5499 | | | | | |
| J1426 | AMONDYS 45 | Casimersen | Prior to 12/31/23 required medical PA. Effective 1/1/24 requires Medical Specialty Pharmacy Prior Authorization | Duchenne Muscular Dystrophy | After 1/1/24 Requires Prior Authorization Form be faxed to 512-831- 5499 | Through 12/31/23 this code requires authorization 586-693-4768 | | | | |
| J0225 | Amvuttra | vutrisiran | 11/1/2023 | Hereditary Transthyretin (hATTR) Amyloidosis with Polyneuropathy | Requires PriorAuthorizationForm be faxedto 512-831-5499 | | | | | |
| J2277 | APHEXDA | Motixafortide | Not covered until 9/1/24 with prior authorization. | Multiple Myeloma | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9302 | Arzerra | ofatumumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9035 | AVASTIN | bevacizumab | Requires authorization 8/1/22 - 5/1/24. Then covered without authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9036 | Belrapzo | bendamustine hcl | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9034 | BENDEKA | Bendamustine | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0490 | Benlysta IV | belimumab | 1/1/2023 | Systemic Lupus Erythematosus (SLE) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | |
|----------|--|-----------------------|--|----------------------------|---|------|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | |
| J0179 | BEOVU | Brolucizumab | 10/1/2022 | Macular Degeneration | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J9229 | Besponsa | inotuzumab ozogamicin | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J9039 | BLINCYTO | blinatumomab | 1/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0585 | вотох | onabotulinumtoxina | 6/1/2022 | Neurotoxins | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0567 | BRINEURA | cerliponase alfa | 1/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J2329 | Briumvi | ublituximab-xiiy | Not Covered until 1/1/2024, Then covered with Prior Authorization | Multiple Sclerosis (MS) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |
| J0741 | CABENUVA | cabotegravir | Required auth 10/1/22-5/1/23 then no auth until 1/1/2024 when precertification notification is required. | HIV/AIDS | | | | | |
| J0741 | CABENUVA | rilpivirine | Required auth 10/1/22-5/1/23 then no auth until 1/1/2024 when precertification notification is required. | HIV/AIDS | | | | | |
| J9206 | CAMPTOSAR | Irinotecan (HCL) | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | | |
|----------------------------|--|-----------------|--|---------------------------------|---|---|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J1786 | CEREZYME | Imiglucerase | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0717 | Cimzia | certolizumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2786 | CINQAIR | reslizumab | 8/1/2022 | Asthma | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9027 | CLOLAR | Clofarabine | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| ** J9999 if > \$7500 | Columvi | glofitamab-gxbm | This code for this particular drug is not Covered . New code assigned J9286 effective 1/1/24. Not covered until that date with Prior Authorization. See all notes for information on this unclassified code. | Oncology | | If requesting authorization for any drug other than glofitamab- gxbm use this link to form and fax to 586- 693-4768 | | | | |
| J9286 | Columvi | glofitamab-gxbm | Not Covered until 1/1/2024, Then covered with Prior Authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0584 | Crysvita | burosumab | 1/1/2023 | Metabolic Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1551 | Cutaquig | immune globulin | Not Covered until 1/1/2024, Then covered with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | |
|--|-----------------|-------------------------------------|---|-------------------|---|------|--|--|
| To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | |
| J1555 | CUVITRU | immune globulin | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9308 | Cyramza | ramucirumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9348 | DANYELZA | naxitamab-gqgk | 1/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9145 | Darzalex | daratumumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9144 | Darzalex Faspro | daratumumab / hyaluronidase-fihj | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J0589 | DAXXIFY | Daxibotulinumtoxina- lanm | Not covered until 9/1/24 with prior authorization. | Neurotoxins | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J7318 | DUROLANE | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J0586 | DYSPORT | abobotulinumtoxina | 6/1/2022 | Neurotoxins | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9063 | Elahere | mirvetuximab soravtansine-gynx | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J1743 | ELAPRASE | idursulfase | 5/1/2023 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | | | |
|----------|--|------------------------------------|--|--|---|------|--|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | | |
| J3060 | ELELYSO | Taliglucerase Alfa | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J2508 | ELFABRIO | Pegunigalsidase alfa- iwxj | Not covered until 9/1/24 with prior authorization. | Enzyme Replacement Therapy (ERT) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9217 | ELIGARD | leuprolide acetate (depot) | 1/1/2023-8/31/24. As of 9/1/24 covered without authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J2783 | ELITEK | Rasburicase | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Chemo Protectant (TLS) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J1323 | ELREXFIO | Elranatamab-bcmm | Not covered until 9/1/24 with prior authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9269 | ELZONRIS | tagraxofusp-erzs | 5/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9176 | Empliciti | elotuzumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J1438 | ENBREL | etanercept | 8/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9358 | Enhertu | fam-trastuzumab deruxtecan-nxki | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J1302 | Enjaymo | sutimlimab-jome | Not Covered until 1/1/2024, Then covered with Prior Authorization | Anti-Inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | | | | |
|----------------------------|---|------------------|---|--------------------------------------|---|---|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | | | | |
| J3380 | ENTYVIO | Vedolizumab | 10/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| ** J9999 if > \$7500 | Epkinly | epcoritamab-bysp | This code for this particular drug is not Covered . New code assigned J9321 effective 1/1/24. Not covered until that date and only with Prior Authorization. | Oncology | | <u>This code</u> <u>requires</u> <u>authorization if</u> <u>for any drug</u> <u>other than</u> <u>epcoritamab-</u> <u>bysp at 586-</u> <u>693-4768</u> | | | | |
| J9321 | Epkinly | epcoritamab-bysp | This code for this particular drug is not Covered until 1/1/24 and then only with prior authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| Q4081 | EPOGEN | epoetin alfa | 8/1/2022 | Anemia (Dialysis) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0885 | EPOGEN | epoetin alfa | 8/1/2022 | Anemia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9055 | Erbitux | cetuximab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J3111 | Evenity | romosozumab | 1/1/2023 | Osteoporosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1305 | Evkeeza | evinacumab-dgnb | 11/1/2023 | Hypercholesterolemi a | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1428 | Exondys 51 | eteplirsen | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Duchenne Muscular Dystrophy (DMD) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note |
|----------|-----------------------|---------------------------------------|---|-------------------------|---|-------------|
| To see a | product list of physi | ician-administered sp notification | ecialty medications information please | • | es along with c | overage and |
| J0178 | EYLEA | Aflibercept | 10/1/2022 | Macular Degeneration | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J0177 | EYLEA HD | Afilbercept | Not covered until 9/1/24 with prior authorization. | Ophthalmic Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J0180 | FABRAZYME | Agalsidase beta | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J0517 | FASENRA | benralizumab | 8/1/2022 | Asthma | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9155 | Firmagon | degarelix | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9307 | FOLOTYN | pralatrexate | 1/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J1561 | GAMMAKED | immune globulin | Requires Precertification Notification 1/1/21- 4/30/24. Requires Prior Authorization as of 5/1/2024. | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J1561 | GAMUNEX-C | immune globulin | Requires Precertification Notification 1/1/21- 4/30/24. Requires Prior Authorization as of 5/1/2024. | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9301 | Gazyva | obinutuzumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |

| Code | Medical Sp | Medical Specialty Drugs | | Clinical Category | Note | Note | | | | |
|----------|--|-------------------------------------|--|----------------------------|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J7326 | GEL-ONE | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J7328 | GELSYN-3 | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J7320 | GENVISC 850 | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0223 | GIVLAARI | Givosiran | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Acute Hepatic Porphyria | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9179 | Halaven | eribulin mesylate | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J7170 | HEMLIBRA | Emicizumab | 10/1/2022 | Hemophilia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9248 | HEPZATO | Melphalan | Not covered until 9/1/24 with prior authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9355 | HERCEPTIN | trastuzumab | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9356 | HERCEPTIN HYLECTA | trastuzumab / hyaluronidase-oysk | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | | |
|----------|--|----------------------------------|---|---------------------------------|---|------|--|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | | |
| J1559 | Hizentra | immune globulin | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J0135 | HUMIRA | adalimumab | 8/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J7322 | HYMOVIS | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J1575 | Hyqvia | immune globulin/hyaluronidase | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J0638 | llaris | canakinumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J3245 | llumya | tildrakizumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J7313 | lluvien | iluvien | 1/1/2023 | Ophthalmic Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9173 | Imfinzi | durvalumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |
| J9347 | Imjudo | tremelimumab-actl | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note |
|----------|----------------------|---------------------------------------|--|---------------------------------|---|-------------|
| To see a | product list of phys | ician-administered sp notification | ecialty medications information please | | es along with c | overage and |
| J1745 | INFLIXIMAB | infliximab, excludes biosimilar | 8/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9198 | INFUGEM | Gemcitabine hcl | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J1439 | INJECTAFER | Ferric carboxymaltose | 10/1/2022 | Anemia | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J2782 | IZERVAY | Avacincaptad Pegol | Not covered until 9/1/24 with prior authorization. | Ophthalmic Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9272 | JEMPERLI | Dostarlimab-gxly | Not covered until 9/1/24 with prior authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9043 | JEVTANA | Cabazitaxel | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9354 | Kadcyla | ado-trastuzumab emtansine | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J2840 | KANUMA | Sebelipase alfa | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J2425 | Kepivance | palifermin | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |

| Code | Medical Sp | Medical Specialty Drugs | | Clinical Category | Note | Note | | | | |
|----------|--|-------------------------|--|---|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J9271 | KEYTRUDA | pembrolizumab | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9274 | KIMMTRAK | tebentafusp-tebn | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0879 | Korsuva | difelikefalin | Not Covered until 1/1/2024, Then covered with Prior Authorization | Pruritis associated with chronic kidney disease (CKD) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2507 | Krystexxa | pegloticase | 1/1/23 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9047 | Kyprolis | carfilzomib | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0217 | LAMZEDE | Velmanase alfa-tycv | Not covered until 9/1/24 with prior authorization. | Enzyme Replacement Therapy | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0202 | Lemtrada | alemtuzumab | 1/1/2023 | Multiple Sclerosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0174 | LEQEMBI | Lecanemab | Requires authorization as of 5/1/2024. Not covered prior to that date. | Antidementia Agent | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1306 | LEQVIO | Inclisiran | 10/1/2022 | Hypercholesterolemi a | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | |
|----------|--|------------------------------|--|-------------------------|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J1954 | LEUPROLIDE ACETATE | leuprolide acetate | Precertification Notification 5/1/21- 12/31/2023, Then covered 1/1/2024- 8/31/24 with Prior Authorization. As of 9/1/24 covered without authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9119 | Libtayo | cemiplimab-rwlc | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2778 | LUCENTIS | ranibizumab | 8/1/2022 | Macular Degeneration | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0221 | LUMIZYME | Alglucosidase alfa | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9350 | Lunsumio | mosunetuzumab-axgb | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9217 | Lupron Depot | leuoprolide acetate depot | 1/1/2023 - 8/31/24 Requires auth. After 9/1/24 Covered with no authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1950 | Lupron Depot | leuoprolide acetate depot | authorization required 1/1/2023- 8/31/24. As of 9/1/24 covered without authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2503 | MACUGEN | Pegaptanib | Prior Authorization effective 10/1/22- 11/1/23. Then removed from Market and not covered. | Macular Degeneration | | | | | | |
| J3397 | MEPSEVII | Vestronidase alfa-vjbk | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | |
|----------|--|---|----------------|-------------------|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J9349 | Monjuvi | tafasitamab-cxix | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1437 | MONOFERRIC | Ferric derisomaltose | 10/1/2022 | Anemia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J7327 | MONOVISC | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9203 | MYLOTARG | gemtuzumab ozogamicin | 5/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0587 | MYOBLOC | rimabotulinumtoxinb | 6/1/2022 | Neurotoxins | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1458 | Naglazyme | galsulfase | 1/1/2023 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2506 | NEULASTA | pegfilgrastim, excludes biosimilar | 8/1/2022 | Neutropenia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1442 | NEUPOGEN | filgrastim (g-csf), excludes biosimilars | 8/1/2022 | Neutropenia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0219 | NEXVIAZYME | Avalglucosidase alfa- ngpt | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2796 | Nplate | romiplostim | 1/1/2023 | Thrombocytopenia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | |
|----------|--|-----------------------------|---|---------------------------------|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J2182 | NUCALA | mepolizumab | 8/1/2022 | Asthma | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0485 | Nulojix | belatacept | 1/1/2023 | Immunosuppressive Agents | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J2350 | OCREVUS | Ocrelizumab | 10/1/2022 | Multiple Sclerosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0222 | ONPATTRO | patisiran | 5/1/2023 | Amyloidosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9299 | OPDIVO | nivolumab | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9298 | Opdualag | nivolumab/relatlimab | 11/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0129 | Orencia | abatacept | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J7324 | ORTHOVISC | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0224 | OXLUMO | Lumasiran | Precertification Notification 8/1/22 - 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Primary Hyperoxaluria | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | |
|----------|---|---|---|-------------------|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | | | | |
| J9177 | PADCEV | Enfortumab vedotin- ejfv | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9306 | PERJETA | Pertuzumab | 10/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9316 | PHESGO | pertuzumab / trastuzumab / hyaluronidase-zzxf | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| 19309 | POLIVY | polatuzumab vedotin- piiq | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1203 | POMBILITI | Cipaglucosidase alfa- atga | Not covered until 9/1/24 with prior authorization. | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9204 | Poteligeo | mogamulizumab-kpkc | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1459 | PRIVIGEN | immune globulin | Requires Precertification Notification 1/1/21- 4/30/24. Requires Prior Authorization as of 5/1/2024. | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| Q4081 | PROCRIT | epoetin alfa | 8/1/2022 | Anemia (Dialysis) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0885 | PROCRIT | epoetin alfa | 8/1/2022 | Anemia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | | | |
|----------|--|------------------------------------|--|--|---|------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | | | | |
| J0897 | PROLIA | denosumab | 6/1/2022 | Osteoporosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1304 | QALSODY | Tofersen | Not covered until 9/1/24 with prior authorization. | Amyotrophic Lateral Sclerosis (ALS) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1301 | Radicava | edaravone | 1/1/2023 | Amyotrophic Lateral Sclerosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J0896 | Reblozyl | luspatercept-aamt | 1/1/2023 | Myelodysplastic Syndrome | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1745 | REMICADE | infliximab, excludes biosimilar | 8/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9312 | RITUXAN | rituximab | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9311 | RITUXAN HYCELA | rituximab / hyaluronidase | 8/1/2022 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J1449 | Rolvedon | eflapegrastim-xnst | Not Covered until 1/1/2024, Then covered with Prior Authorization | Anemia | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9061 | Rybrevant | amivantamab-vmjw | 11/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |
| J9021 | Rylaze | asparaginase | Not Covered until 1/1/2024, Then covered with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | |
|----------|---|----------------------|--|---|---|------|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | |
| J9333 | RYSTIGGO | Rozanolixizumab-noli | Not covered until 9/1/24 with prior authorization. | Myasthenia Gravis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2353 | SandoSTATIN LAR Depot | octreotide depot | 1/1/2023 | Endocrine Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J0491 | Saphnelo | anifrolumab-fnia | Not Covered until 1/1/2024, Then covered with Prior Authorization | Systemic Lupus Erythematosus (SLE or Lupus) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9227 | SARCLISA | isatuximab-irfc | 5/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1602 | Simponi Aria | golimumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2327 | Skyrizi | risankizumab | 11/1/2023 | Anti-Inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1300 | SOLIRIS | eculizumab | 1/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1930 | Somatuline Depot | lanreotide | 1/1/2023 | Endocrine Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1747 | Spevigo | spesolimab-sbzo | Not Covered until 1/1/2024, Then covered with Prior Authorization | Anti-Inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2326 | SPINRAZA | Nusinersen | 10/1/2022 | Spinal Muscular Atrophy | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | |
|----------|---|-----------------------------------|--|---------------------------------|--|--|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | | |
| J3490 | Spravato | esketamine nasal spray | Authorization requirements for this drug retired effective 11/1/23; after this date it is covered without prior authorization. | Antidepressants | S0013 also used for this medication, does not and has never required prior authorization | J3490 is an unclassified drug code and it does require prior authorization if used for any other medication other than Spravato and will be billed for more than \$7500. Please use this form and fax number only. | | |
| J3358 | STELARA IV | Ustekinumab | 10/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J3357 | STELARA SC | Ustekinumab | 10/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J1627 | SUSTOL | granisetron, extended- release | 8/1/2022 | Antiemetics | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J2781 | SYFOVRE | pegcetacoplan (intravitreal) | Precertification Notification 1/1/24- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Ophthalmic Disorders | Previously code C1951. Permanent code J2781 assigned 10/1/23 | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2860 | SYLVANT | Siltuximab | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9262 | SYNRIBO | Omacetaxine mepesuccinate | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | |
|----------|--|-----------------------------|--|---------------------------------|---|------|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | |
| J3055 | TALVEY | Talquetamab-tgvs | Not covered until 9/1/24 with prior authorization. | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9022 | Tecentriq | atezolizumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9380 | Tecvayli | teclistamab cqyv | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J3241 | TEPEZZA | teprotumumab-trbw | 8/1/2022 | Thyroid Eye Disease | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2356 | Tezspire | tezepelumab-ekko | 1/1/2023 | Asthma | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9273 | Tivdak | tisotumab vedotin-tftv | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9033 | Treanda | bendamustine hcl | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J3315 | Trelstar | triptorelin pamoate | 1/1/2023-8/31/24. Authorization requirement removed as of 9/1/24 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1628 | Tremfya | guselkumab | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J7332 | TRILURON | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | |
|----------|---|--------------------------------|--|---------------------------------|---|------|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | |
| J3316 | Triptodur | triptorelin | 1/1/2023-8/31/24. Authorization requirement removed as of 9/1/24. | Endocrine Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J7329 | TRIVISC | Hyaluronan or derivative | 10/1/2022 | Osteoarthritis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9317 | Trodelvy | sacituzumab govitecan- hziy | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1746 | TROGARZO | ibalizumab-uiyk | 5/1/2023 | HIV/AIDS | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2323 | TYSABRI | Natalizumab | 10/1/2022 | Multiple Sclerosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1303 | ULTOMIRIS | Ravulizumab | 10/1/2022 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1823 | Uplizna | inebilizumab-cdon | 1/1/2023 | Auto-inflammatory Conditions | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2777 | Vabysmo | faricimab-svoa | Not Covered until 1/1/2024, Then covered with Prior Authorization | Macular Degeneration | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9357 | VALSTAR | Valrubicin | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9303 | Vectibix | panitumumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |

| Code | Medical Specialty Drugs | | Effective Date | Clinical Category | Note | Note | | |
|----------|---|------------------------|---|--------------------------------------|---|------|--|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the | | | | | | | |
| J9041 | Velcade | bortezomib | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9025 | VIDAZA | Azacitidine | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J1427 | Viltepso | viltolarsen | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Duchenne Muscular Dystrophy (DMD) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J1322 | VIMIZIM | Elosulfase alfa | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J3396 | Visudyne | verteporfin | 1/1/2023 | Ophthalmic Disorders | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J3385 | VPRIV | Velaglucerase Alfa | 10/1/2022 | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J3032 | VYEPTI | Eptinezumab | 10/1/2022 | Migraine | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J1429 | Vyondys 53 | golodirsen | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Duchenne Muscular Dystrophy (DMD) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |
| J9332 | Vyvgart | efgartigimod alfa-fcab | Not Covered until 1/1/2024, Then covered with Prior Authorization | Myasthenia Gravis (MG) | Requires Prior Authorization Form be faxed to 512-831- 5499 | | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note | |
|----------|--|---|---|-------------------|---|------|--|
| To see a | To see a product list of physician-administered specialty medications or infusion therapies along with coverage and notification information please visit the_ | | | | | | |
| J9334 | VYVGART HYTRULO | Efgartigimod alfa, 2 mg and Hyaluronidase-qvfc | Not covered until 9/1/24 with prior authorization. | Myasthenia Gravis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J1558 | XEMBIFY | immune globulin | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Immunodeficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J0218 | Xenpozyme | olipudase alfa-rpcp | Not Covered until 1/1/2024, Then covered with Prior Authorization | Enzyme Deficiency | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J0588 | XEOMIN | incobotulinumtoxin a | 6/1/2022 | Neurotoxins | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J0897 | XGEVA | denosumab | 8/1/2022 | Osteoporosis | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J0775 | Xiaflex | collagenase, clostridium histolyticum | 1/1/2023 | Enzyme | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J2357 | XOLAIR | omalizumab | 8/1/2022 | Asthma | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9228 | Yervoy | ipilimumab | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |
| J9352 | YONDELIS | Trabectedin | Precertification Notification 1/1/21- 8/31/2024, Then covered 9/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | | |

| Code | Medical Sp | ecialty Drugs | Effective Date | Clinical Category | Note | Note |
|----------|--|---------------------------------------|---|---|---|-------------|
| To see a | product list of phys | ician-administered sp notification | ecialty medications information please | • | es along with c | overage and |
| J9223 | Zepzelca | lurbinectedin | 1/1/2023 | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J0565 | ZINPLAVA | bezlotoxumab | 8/1/2022 | Passive Immunizing and Treatment Agents | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9202 | Zoladex | goserelin acetate | Precertification Notification 1/1/21- 12/31/2023, Then covered 1/1/2024 with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9359 | Zynlonta | loncastuximab tesirine- lpyl | Not Covered until 1/1/2024, Then covered with Prior Authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| J9345 | ZYNYZ | Retifanlimab-dlwr | Not covered until 9/1/24 with authorization | Oncology | Requires Prior Authorization Form be faxed to 512-831- 5499 | |
| ** Codes | ** Codes in Orange require authorization if billing > \$7500. Different drugs using these unlisted codes go to different fax numbers. Please follow notes. | | | | | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| 0042T | Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time | |
| 0054T | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image- guidance based on fluoroscopic images | |
| 0055T | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image- guidance | |
| 0071T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue | |
| 0072T | Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue | |
| 0075T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel | |
| 0076T | Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel | |
| 0095T | Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical | |
| 0098T | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical | |
| 0100T | Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intraocular retinal electrode array, with vitrectomy | |
| 0101T | Extracorporeal shock wave involving musculoskeletal system, not otherwise specified | |
| 0102T | Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle | |
| 0106T | Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation | |
| 0107T | Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation | |
| 0108T | Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia | |
| 0109T | Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia | |
| 0110T | Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation | |
| 0164T | Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar | |
| 0165T | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar | |
| 0174T | Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation | |
| 0175T | Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation | |
| 0184T | Excision of rectal tumor, transanal endoscopic microsurgical approach (i.e., TEMS), including muscularis propria (i.e., full thickness) | |
| 0198T | Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0200T | Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed | |
| 0201T | Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed | |
| 0202T | Posterior vertebral joint(s) arthroplasty (e.g., facet joint[s] replacement) including facetectomy, laminectomy, foraminotomy and vertebral column fixation, with or without injection of bone cement, including fluoroscopy, single level, lumbar spine | |
| 0207T | Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral | |
| 0208T | Pure tone audiometry (threshold), automated, air only | |
| 0209T | Pure tone audiometry (threshold), automated; air and bone | |
| | Speech audiometry threshold, automated | |
| 0210T | | |
| 0211T | Speech audiometry threshold, automated; with speech recognition | |
| 0212T | Comprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated | |
| 0213T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or | |
| | nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level | |
| 0214T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or | |
| | nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level | |
| 0215T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure) | |
| 0216T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level | |
| 0217T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level | |
| 0218T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) | |
| 0219T | Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical | |
| 0220T | Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic | |
| 0221T | Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar | |
| 0222T | Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment | |
| 0232T | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed | |
| 0234T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; renal artery | |
| 0235T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; visceral artery (except renal), each vessel | |
| 0236T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; abdominal aorta | |
| 0237T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; brachiocephalic trunk and branches, each vessel | |
| 0238T | Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; iliac artery, each vessel | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0253T | Insertion of anterior segment aqueous drainage device, without extraocular reservoir, | |
| 02551 | internal approach, into the suprachoroidal space | |
| | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, | |
| 0263T | multiple injections, one leg, including ultrasound guidance, if performed; complete | |
| | procedure including unilateral or bilateral bone marrow harvest | |
| 0264T | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, | |
| 02641 | multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest | |
| | Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, | |
| 0265T | multiple injections, one leg, including ultrasound guidance, if performed; unilateral or | |
| 02031 | bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy | |
| | Implantation or replacement of carotid sinus baroreflex activation device; total system | |
| 0266T | (includes generator placement, unilateral or bilateral lead placement, Intraoperative | |
| 01001 | interrogation, programming, and repositioning, when performed) | |
| | Implantation or replacement of carotid sinus baroreflex activation device; lead only, | |
| 0267T | unilateral (includes Intraoperative interrogation, programming, and repositioning, when | |
| | performed) | |
| | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator | |
| 0268T | only (includes Intraoperative interrogation, programming, and repositioning, when | |
| | performed) | |
| | Revision or removal of carotid sinus baroreflex activation device; total system (includes | |
| 0269T | generator placement, unilateral or bilateral lead placement, Intraoperative interrogation, | |
| | programming, and repositioning, when performed) | |
| 0270T | Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral | |
| 02701 | (includes Intraoperative interrogation, programming, and repositioning, when performed) | |
| 0271T | Revision or removal of carotid sinus baroreflex activation device; pulse generator only | |
| 02/11 | (includes Intraoperative interrogation, programming, and repositioning, when performed) | |
| | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, | |
| | including telemetric iterative communication with the implantable device to monitor device | |
| 0272T | diagnostics and programmed therapy values, with interpretation and report (e.g., battery | |
| | status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, | |
| | burst mode, therapy start/stop times each day) | |
| | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device | |
| 0273T | diagnostics and programmed therapy values, with interpretation and report (e.g., battery | |
| 02/01 | status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, | |
| | burst mode, therapy start/stop times each day); with programming | |
| | Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of | |
| 0274T | neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or | |
| 02741 | foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or | |
| | multiple levels, unilateral or bilateral; cervical or thoracic | |
| 0275T | Percutaneous laminotomy/laminectomy | |
| 02707 | Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each | |
| 0278T | treatment session (includes placement of electrodes) | |
| 02097 | Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular | |
| 0308T | lens prosthesis | |
| 02207 | Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with | |
| 0329T | interpretation and report | |
| 0330T | Tear film imaging, unilateral or bilateral, with interpretation and report | |
| 0331T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|--|
| 0332T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT | |
| 0333T | Visual evoked potential, screening of visual acuity, automated, with report | |
| 0335T | Extra-osseous subtalar joint implant | |
| 0338T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral | |
| 0339T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral | |
| 0342T | Therapeutic apheresis with selective HDL delipidation and plasma reinfusion | |
| 0345T | Transcatheter mitral valve repair percutaneous approach via the coronary sinus | |
| 0347T | Placement of interstitial device(s) in bone for radiostereometric analysis (RSA) | |
| 0348T | Radiologic examination, radiostereometric analysis (RSA); spine, (includes, cervical, thoracic and lumbosacral, when performed) | |
| 0349T | Radiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes shoulder, elbow and wrist, when performed) | |
| 0350T | Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee and ankle, when performed) | |
| 0351T | Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real time intraoperative | |
| 0352T | Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred | |
| 0353T | Optical coherence tomography of breast, surgical cavity; real time intraoperative | |
| 0354T | Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred | |
| 0358T | Bioelectrical impedance analysis whole body composition assessment, with interpretation and report | |
| 0362T | Behavior identification supporting assessment, each 15 minutes of technicians' time face-to face with a patient, | Effective 1/1/24. Please use <u>ABA form from the Prior</u> <u>Authorization Page of the</u> <u>mysmarthealth.org website</u> <u>for this request.</u> |
| 0373T | Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time face-to-face with a patient, requiring the following components: | Effective 1/1/24. Please use ABA form from the Prior Authorization Page of the mysmarthealth.org website for this request. |
| 0378T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified healthcare professional | |
| 0379Т | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified healthcare professional | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0394T | High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed | |
| 0395T | High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed | |
| 0397T | Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy | |
| 0398T | Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed | |
| 0402T | Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed) | |
| 0404T | Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency | Code retired 1/1/24 |
| 0408T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes | |
| 0409T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only | |
| 0410T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only | |
| 0411T | Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only | |
| 0412T | Removal of permanent cardiac contractility modulation system; pulse generator only | |
| 0413T | Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular) | |
| 0414T | Removal and replacement of permanent cardiac contractility modulation system pulse generator only | |
| 0415T | Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead) | |
| 0416T | Relocation of skin pocket for implanted cardiac contractility modulation pulse generator | |
| 0417T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system | |
| 0418T | Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system | |
| 0419T | Destruction of neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibromas | |
| 0420T | Destruction of neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofibromas | |
| 0421T | Transurethral waterjet ablation of prostate, including control of postoperative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed) | |
| 0422T | Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral | |
| 0424T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator) | Code retired 1/1/24 |
| 0425T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only | Code retired 1/1/24 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0426T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Code retired 1/1/24 |
| 0427T | Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only | Code retired 1/1/24 |
| 0428T | Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only | Code retired 1/1/24 |
| 0429T | Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only | Code retired 1/1/24 |
| 0430T | Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Code retired 1/1/24 |
| 0431T | Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only | Code retired 1/1/24 |
| 0432T | Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only | Code retired 1/1/24 |
| 0433T | Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only | Code retired 1/1/24 |
| 0434T | Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea | Code retired 1/1/24 |
| 0435T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session | Code retired 1/1/24 |
| 0436T | Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study | Code retired 1/1/24 |
| 0437T | Implantation of non-biologic or synthetic implant (e.g., polypropylene) for fascial reinforcement of the abdominal wall | |
| 0439T | Myocardial contrast perfusion echocardiography; at rest or with stress, for assessment of myocardial ischemia or viability | |
| 0440T | Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve | |
| 0441T | Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve | |
| 0442T | Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (e.g., brachial plexus, pudendal nerve) | |
| 0443T | Real time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance | |
| 0444T | Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral | |
| 0445T | Subsequent placement of a drug-eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral | |
| 0446T | Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training | |
| 0447T | Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision | |
| 0448T | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation | |
| 0449T | Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device | |
| 0450T | Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device | |
| 0464T | Visual evoked potential, testing for glaucoma, with interpretation and report | |
| 0465T | Suprachoroidal injection of a pharmacologic agent (does not include supply of medication) | Code retired 1/1/24 |
| 0469T | Retinal polarization scan, ocular screening with on-site automated results, bilateral | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0472T | Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified healthcare professional | |
| 0473T | Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified healthcare professional | |
| 0474T | Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space | |
| 0479T | Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children | |
| 0480T | Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children | |
| 0481T | Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed | |
| 0483T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous approach, including transseptal puncture, when performed | |
| 0484T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic exposure (eg, thoracotomy, transapical) | |
| 0485T | Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral | |
| 0486T | Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral | |
| 0489T | Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells | |
| 0490T | Autologous adipose-derived regenerative cell therapy for scleroderma in the hands;multiple injections in one or both hands | |
| 0494T | Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed | |
| 0495T | Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified healthcare professional, including physiological and LABoratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field | |
| 0496T | each additional hour (List separately in addition to code for primary procedure) | |
| 0499T | Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed | Code retired 1/1/24 |
| 0501T | Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data | Code retired 1/1/24 |
| 0502T | Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery; data preparation and transmission | Code retired 1/1/24 |

| CPT, HCPCS | | |
|------------|--|-----------------------|
| or Revenue | Category III Description | Comments/ Limitations |
| Code | | |
| | Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic | Code retired 1/1/24 |
| 0503T | simulation software analysis of functional data to assess the severity of coronary artery | |
| 05051 | disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and | |
| | generation of estimated FFR model | |
| | Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary | Code retired 1/1/24 |
| | computed tomography angiography data using computation fluid dynamics physiologic | |
| 0504T | simulation software analysis of functional data to assess the severity of coronary artery | |
| | disease; anatomical data review in comparison with estimated FFR model to reconcile | |
| | discordant data, interpretation and report | |
| 0505T | Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of | |
| | intravascular stent graft(s) and closure by any method, | |
| 0506T | Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report | |
| | Near infrared dual imaging (ie, simultaneous reflective and transilluminated light) of | |
| 0507T | meibomian glands, unilateral or bilateral, with interpretation and report | |
| | Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral | Code retired 1/1/24 |
| 0508T | density, tibia | |
| 0509T | Electroretinography (ERG) with interpretation and report, pattern (PERG) | |
| 0510T | Removal of sinus tarsi implant | |
| 0511T | Removal and reinsertion of sinus tarsi implant | |
| | Extracorporeal shock wave for integumentary wound healing, including topical application | |
| 0512T | and dressing care; initial wound | |
| | Extracorporeal shock wave for integumentary wound healing, including topical application | |
| 0513T | and dressing care; each additional wound (List separately in addition to code for primary | |
| | procedure) | |
| | Insertion of wireless cardiac stimulator for left ventricular pacing, including device | |
| 0515T | interrogation and programming, and imaging supervision and interpretation, when | |
| | performed; complete system (includes electrode and generator [transmitter and battery]) | |
| | Insertion of wireless cardiac stimulator for left ventricular pacing, including device | |
| 0516T | interrogation and programming, and imaging supervision and interpretation, when | |
| | performed; pulse generator component(s) (battery and/or transmitter) only Insertion of wireless cardiac stimulator for left ventricular pacing, including device | |
| 0517T | interrogation and programming, and imaging supervision and interpretation, when | |
| 03171 | performed; both components of pulse generator (battery and transmitter) only | |
| | Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; battery | |
| 0518T | component only | |
| | Removal and replacement of pulse generator for wireless cardiac stimulator for left | |
| 0519T | ventricular pacing, including device interrogation and programming; both components | |
| | (battery and transmitter) | |
| 0520T | Removal and replacement of pulse generator for wireless cardiac stimulator for left | |
| | ventricular pacing, including device interrogation and programming; battery component only | |
| | Interrogation device evaluation (in person) with analysis, review and report, includes | |
| 0521T | connection, recording, and disconnection per patient encounter, wireless cardiac stimulator | |
| | for left ventricular pacing | |
| 0527 | Programming device evaluation (in person) with iterative adjustment of the implantable | |
| 0522T | device to test the function of the device and select optimal permanent programmed values | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| 0523T | Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color- coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure) | |
| 0524T | Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring | |
| 0525T | Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor) | |
| 0526T | electrode only | |
| 0527T | implantable monitor only | |
| 0528T | Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report | |
| 0529T | Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report | |
| 0530T | Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor) | |
| 0531T | electrode only | |
| 0532T | implantable monitor only | |
| 0533T | Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report | Code retired 1/1/24 |
| 0534T | set-up, patient training, configuration of monitor | Code retired 1/1/24 |
| 0535T | data upload, analysis and initial report configuration | Code retired 1/1/24 |
| 0536T | download review, interpretation and report | Code retired 1/1/24 |
| 0537T | Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day | |
| 0538T | preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage) | |
| 0539T | receipt and preparation of CAR-T cells for administration | |
| 0540T | CAR-T cell administration, autologous | |
| 0541T | Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; | |
| 0542T | interpretation and report | |
| 0543T | Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae | |
| 0544T | Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture | |
| 0545T | Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach | |
| 0546T | Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report | |
| 0547T | Bone material quality testing by microindentation(s) of the tibia(s), with results reported as a score | |
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified healthcare professional | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0553T | Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention | |
| 0554T | Bone strength and fracture risk using finite element analysis of functional data and bone- mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report | |
| 0555T | retrieval and transmission of the scan data | |
| 0556T | assessment of bone strength and fracture risk and bone mineral density | |
| 0557T | interpretation and report | |
| 0558T | Computed tomography scan taken for the purpose of biomechanical computed tomography analysis | |
| 0559T | Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure | |
| 0560T | each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure) | |
| 0561T | Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide | |
| 0562T | each additional anatomic guide (List separately in addition to code for primary procedure) | |
| 0563T | Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral | |
| 0564T | Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations | |
| 0565T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation | |
| 0566T | Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral | |
| 0567T | Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound | |
| 0568T | Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound | |
| 0569T | Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis | |
| 0570T | Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure) | |
| 0571T | Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed | |
| 0572T | Insertion of substernal implantable defibrillator electrode | |
| 0573T | Removal of substernal implantable defibrillator electrode | |
| 0574T | Repositioning of previously implanted substernal implantable defibrillator-pacing electrode | |
| 0575T | Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified healthcare professional | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0576T | Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified healthcare professional, includes connection, recording and disconnection per patient encounter | |
| 0577T | Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters) | |
| 0578T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified healthcare professional | |
| 0579T | Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | |
| 0580T | Removal of substernal implantable defibrillator pulse generator only | |
| 0581T | Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral | |
| 0582T | Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance | |
| 0583T | Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia | |
| 0584T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous | |
| 0585T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic | |
| 0586T | Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open | |
| 0587T | Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve | |
| 0588T | Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve | |
| 0589T | Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters | |
| 0590T | Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0594T | Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device | |
| 0596T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement | |
| 0597T | Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement | |
| 0598T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity) | |
| 0599T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure) | |
| 0600T | Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous | |
| 0601T | Ablation, irreversible electroporation; 1 or more tumors per organ, including fluoroscopic and ultrasound guidance, when performed, open | |
| 0602T | Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent | |
| 0603T | Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours | |
| 0604T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; initial device provision, set-up and patient education on use of equipment | |
| 0605T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days | |
| 0606T | Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified Healthcare professional of remote surveillance center data analyses, each 30 days | |
| 0607T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment | |
| 0608T | Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified healthcare professional | |
| 0609T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs | |
| 0610T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis | |
| 0611T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs | |
| 0612T | Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | Percutaneous transcatheter implantation of interatrial septal shunt device, including right | |
| 0613T | and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed | |
| 0614T | Removal and replacement of substernal implantable defibrillator pulse generator | |
| 0615T | Eye-movement analysis without spatial calibration, with interpretation and report | |
| 0616T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens | |
| 0617T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens | |
| 0618T | Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange | |
| 0619T | Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed | |
| 0620T | Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization (s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed | |
| 0621T | Trabeculostomy ab interno by laser; | |
| 0622T | Trabeculostomy ab interno by laser; with use of ophthalmic endoscope | |
| 0623T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report | |
| 0624T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission | |
| 0625T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography | |
| 0626T | Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report | |
| 0627T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level | |
| 0628T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure) | |
| 0629T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level | |
| 0630T | Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure) | |
| 0631T | Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity | |
| 0632T | Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|--|
| 0633T | Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material | |
| 0634T | Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s) | |
| 0635T | Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s) | |
| 0636T | Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s) | |
| 0637T | Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s) | |
| 0638T | Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s) | |
| 0639T | Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed | |
| 0640T | Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; first anatomic site | Effective 7/1/21 |
| 0641T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition only, each flap or wound | Effective 7/1/21. Code Retired 1/1/24 |
| 0642T | Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound | Effective 7/1/21. Code Retired 1/1/24 |
| 0643T | Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach | Effective 7/1/21 |
| 0644T | Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed | Effective 7/1/21 |
| 0645T | Transcatheter implantation of coronary sinus reduction device including vascular access and closure, right heart catheterization, venous angiography, coronary sinus angiography, imaging guidance, and supervision and interpretation, when performed | Effective 7/1/21 |
| 0646T | Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed | Effective 7/1/21 |
| 0647T | Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report | Effective 7/1/21 |
| 0648T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; single organ | Effective 7/1/21 |
| 0649T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); single organ (List separately in addition to code for primary procedure) | Effective 7/1/21 |
| 0650T | Programming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment of the implantable device to test the function of the device and select optimal permanently programmed values with analysis, review and report by a physician or other qualified healthcare professional | Effective 7/1/21 |
| 0651T | Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report | Effective 7/1/21 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 00527 | Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of | Effective 7/1/21 |
| 0652T | specimen(s) by brushing or washing, when performed (separate procedure) | |
| 0653T | Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple | Effective 7/1/21 |
| 0654T | Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter | Effective 7/1/21 |
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging | Effective 7/1/21 |
| 0656T | Anterior lumbar or thoracolumbar vertebral body tethering; up to 7 vertebral segments | Effective 7/1/21 |
| 0657T | Anterior lumbar or thoracolumbar vertebral body tethering; 8 or more vertebral segments | Effective 7/1/21 |
| 0658T | Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score | Effective 7/1/21 |
| 0659T | Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation | Effective 7/1/21 |
| 0660T | Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach | Effective 7/1/21 |
| 0661T | Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant | Effective 7/1/21 |
| 0662T | Scalp cooling, mechanical; initial measurement and calibration of cap | Effective 7/1/21 |
| 0663T | Scalp cooling, mechanical; placement of device, monitoring, and removal of device (List separately in addition to code for primary procedure) | Effective 7/1/21 |
| 0664T | Donor hysterectomy (including cold preservation); open, from cadaver donor | Effective 7/1/21 |
| 0665T | Donor hysterectomy (including cold preservation); open, from living donor | Effective 7/1/21 |
| 0666T | Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor | Effective 7/1/21 |
| 0667T | Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor | Effective 7/1/21 |
| 0668T | Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary | Effective 7/1/21 |
| 0669T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each | Effective 7/1/21 |
| 0670T | Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each | Effective 7/1/21 |
| 0671T | Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more | Effective 1/1/2022 |
| 0672T | Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence | Effective 1/1/2022 |
| 0673T | Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance | Effective 1/1/2022 |
| 0674T | Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s) | Effective 1/1/2022 |
| 0675T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead | Effective 1/1/2022 |
| 0676T | Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure) | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| 0677T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead | Effective 1/1/2022 |
| 0678T | Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure) | Effective 1/1/2022 |
| 0679T | Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Effective 1/1/2022 |
| 0680T | Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s) | Effective 1/1/2022 |
| 0681T | Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads | Effective 1/1/2022 |
| 0682T | Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Effective 1/1/2022 |
| 0683T | Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified healthcare professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Effective 1/1/2022 |
| 0684T | Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified healthcare professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Effective 1/1/2022 |
| 0685T | Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified healthcare professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function | Effective 1/1/2022 |
| 0686T | Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance | Effective 1/1/2022 |
| 0687T | Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session | Effective 1/1/2022 |
| 0688T | Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified healthcare professional, with report, per calendar month | Effective 1/1/2022 |
| 0689T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) | Effective 1/1/2022 |
| 0690T | Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure) | Effective 1/1/2022 |
| 0691T | Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report | Effective 1/1/2022 |
| 0692T | Therapeutic ultrafiltration | Effective 1/1/2022 |
| 0693T | Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0694T | 3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative | Effective 1/1/2022 |
| 0695T | Body surface–activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement | Effective 1/1/2022 |
| 0696T | Body surface–activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation | Effective 1/1/2022 |
| 0697T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs | Effective 1/1/2022 |
| 0698T | Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure) | Effective 1/1/2022 |
| 0699T | Injection, posterior chamber of eye, medication | Effective 1/1/2022 |
| 0700T | Molecular fluorescent imaging of suspicious nevus; first lesion | Effective 1/1/2022 |
| 0701T | Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure) | Effective 1/1/2022 |
| 0704T | Remote treatment of amblyopia using an eye tracking device; device supply with initial set- up and patient education on use of equipment | Effective 1/1/2022 |
| 0705T | Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days | Effective 1/1/2022 |
| 0706T | Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified healthcare professional, per calendar month | Effective 1/1/2022 |
| 0707T | Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization | Effective 1/1/2022 |
| 0708T | Intradermal cancer immunotherapy; preparation and initial injection | Effective 1/1/2022 |
| 0709T | Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure) | Effective 1/1/2022 |
| 0710T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report | Effective 1/1/2022 |
| 0711T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission | Effective 1/1/2022 |
| 0712T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability | Effective 1/1/2022 |
| 0713T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report | Effective 1/1/2022 |
| 0714T | Transperineal Laser Ablation Of Benign Prostatic Hyperplasia, Including Imaging Guidance | Effective 7/1/2022 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|--|
| 0715T | Percutaneous Transluminal Coronary Lithotripsy (List Separately In Addition To Code For Primary Procedure) | Effective 7/1/21. Code Retired 1/1/24 |
| 0716T | Cardiac Acoustic Waveform Recording With Automated Analysis And Generation Of Coronary Artery Disease Risk Score | Effective 7/1/2022 |
| 0717T | Autologous Adipose-Derived Regenerative Cell (Adrc) Therapy For Partial Thickness Rotator Cuff Tear; Adipose Tissue Harvesting, Isolation And Preparation Of Harvested Cells, Including Incubation With Cell Dissociation Enzymes, Filtration, Washing And Concentration Of Adrcs | Effective 7/1/2022 |
| 0718T | Autologous Adipose-Derived Regenerative Cell (Adrc) Therapy For Partial Thickness Rotator Cuff Tear; Injection Into Supraspinatus Tendon Including Ultrasound Guidance, Unilateral | Effective 7/1/2022 |
| 0719T | Posterior Vertebral Joint Replacement, Including Bilateral Facetectomy, Laminectomy, And Radical Discectomy, Including Imaging Guidance, Lumbar Spine, Single Segment | Effective 7/1/2022 |
| 0720T | Percutaneous Electrical Nerve Field Stimulation, Cranial Nerves, Without Implantation | Effective 7/1/2022 |
| 0721T | Quantitative Computed Tomography (Ct) Tissue Characterization, Including Interpretation And Report, Obtained Without Concurrent Ct Examination Of Any Structure Contained In Previously Acquired Diagnostic Imaging | Effective 7/1/2022 |
| 0722T | Quantitative Computed Tomography (Ct) Tissue Characterization, Including Interpretation And Report, Obtained With Concurrent Ct Examination Of Anystructure Contained In The Concurrently Acquired Diagnostic Imaging Dataset (List Separately In Addition To Code For Primary Procedure) | Effective 7/1/2022 |
| 0723T | Quantitative Magnetic Resonance Cholangiopancreatography (Qmrcp) Including Data Preparation And Transmission, Interpretation And Report, Obtained Without Diagnostic Magnetic Resonance Imaging (Mri) Examination Of The Same Anatomy (Eg, Organ, Gland, Tissue, Target Structure) During The Same Session | Effective 7/1/2022 |
| 0724T | Quantitative Magnetic Resonance Cholangiopancreatography (Qmrcp) Including Data Preparation And Transmission, Interpretation And Report, Obtained With Diagnostic Magnetic Resonance Imaging (Mri) Examination Of The Same Anatomy (Eg, Organ, Gland, Tissue, Target Structure) (List Separately In Addition To Code For Primary Procedure) | Effective 7/1/2022 |
| 0725T | Vestibular Device Implantation, Unilateral | Effective 7/1/2022 |
| 0726T | Removal Of Implanted Vestibular Device, Unilateral | Effective 7/1/2022 |
| 0727T | Removal And Replacement Of Implanted Vestibular Device, Unilateral | Effective 7/1/2022 |
| 0728T | Diagnostic Analysis Of Vestibular Implant, Unilateral; With Initial Programming | Effective 7/1/2022 |
| 0729T | Diagnostic Analysis Of Vestibular Implant, Unilateral; With Subsequent Programming | Effective 7/1/2022 |
| 0730T | Trabeculotomy By Laser, Including Optical Coherence Tomography (Oct) Guidance | Effective 7/1/2022 |
| 0731T | Augmentative Ai-Based Facial Phenotype Analysis With Report | Effective 7/1/2022 |
| 0732T | Immunotherapy Administration With Electroporation, Intramuscular | Effective 7/1/2022 |
| 0733T | Remote Body And Limb Kinematic Measurement-Based Therapy Ordered By A Physician Or Other Qualified Health Care Professional; Supply And Technical Support, Per 30 Days | Effective 7/1/2022 |
| 0734T | Remote Body And Limb Kinematic Measurement-Based Therapy Ordered By A Physician Or Other Qualified Health Care Professional; Treatment Management Services By A Physician Or Other Qualified Health Care Professional, Per Calendar Month | Effective 7/1/2022 |
| 0735T | Preparation Of Tumor Cavity, With Placement Of A Radiation Therapy Applicator For Intraoperative Radiation Therapy (Iort) Concurrent With Primary Craniotomy (List Separately In Addition To Code For Primary Procedure) | Effective 7/1/2022 |
| 0736T | Colonic Lavage, 35 Or More Liters Of Water, Gravity-Fed, With Induced Defecation, Including Insertion Of Rectal Catheter | Effective 7/1/2022 |
| 0737T | Xenograft Implantation Into The Articular Surface | Effective 7/1/2022 |
| 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination | Effective 1/1/2023 |

| CPT, HCPCS | | |
|--------------------|---|-------------------------------|
| or Revenue Code | Category III Description | Comments/ Limitations |
| couc | Ablation of malignant prostate tissue by magnetic field induction, including all | Effective 1/1/2023 |
| 0739T | intraprocedural, transperineal needle/catheter placement for nanoparticle installation and | |
| | intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation | |
| 0740T | Remote autonomous algorithm-based recommendation system for insulin dose calculation | Effective 1/1/2023 |
| 07447 | and titration; initial set-up and patient education Remote autonomous algorithm-based recommendation system for insulin dose calculation | Effective 1/1/2023 |
| 0741T | and titration; provision of software, data collection, transmission, and storage, each 30 days | |
| 0742T | Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed | Effective 1/1/2023 |
| 07421 | (List separately in addition to code for primary procedure) | |
| | Bone strength and fracture risk using finite element analysis of functional data and bone- | Effective 1/1/2023 |
| 0743T | mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of | |
| 07431 | bone strength and bone mineral density and classification of any vertebral fractures, with | |
| | overall fracture risk assessment, interpretation and report | |
| 07447 | Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging | Effective 1/1/2023 |
| 0744T | guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed | |
| | Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia | Effective 1/1/2023 |
| 0745T | localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, | |
| | CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance | |
| | Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia | Effective 1/1/2023 |
| 0746T | localization and mapping of arrhythmia site (nidus) into a multidimensional radiation | |
| | treatment plan Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, | Effective 1/1/2023 |
| 0747T | arrhythmia | |
| 0748T | Injections of stem cell product into perianal perifistular soft tissue, including fistula | Effective 1/1/2023 |
| 07461 | preparation (eg, removal of setons, fistula curettage, closure of internal openings) | E7 1 1 1 1 1 1 1 1 1 1 |
| | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, | Effective 1/1/2023 |
| 0749T | retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk | |
| | and BMD, interpretation and report; | |
| | Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral | Effective 1/1/2023 |
| 0750T | density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk | |
| | and BMD, interpretation and report; with single-view digital X-ray examination of the hand | |
| | taken for the purpose of DXR-BMD | F((, .)) |
| 0751T | Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 07507 | Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic | Effective 1/1/2023 |
| 0752T | examination (List separately in addition to code for primary procedure) | |
| 0753T | Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic | Effective 1/1/2023 |
| | examination (List separately in addition to code for primary procedure) Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic | Effective 1/1/2023 |
| 0754T | examination (List separately in addition to code for primary procedure) | |
| 0755T | Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic | Effective 1/1/2023 |
| 0,001 | examination (List separately in addition to code for primary procedure) | Effective 1/1/2002 |
| 0756T | Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to | Effective 1/1/2023 |
| | code for primary procedure) | |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|--|
| 0757T | Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0758T | Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0759T | Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0760T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0761T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0762T | Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0763T | Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0764T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0765T | Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram | Effective 1/1/2023 |
| 0766T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve | Effective 1/1/2023 |
| 0767T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0768T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve | Effective 1/1/2023. Code Retired 1/1/24 |
| 0769T | Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure) | Effective 1/1/2023. Code Retired 1/1/24 |
| 0770T | Virtual reality technology to assist therapy (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0771T | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | Effective 1/1/2023 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|--|
| 0772Т | Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | Effective 1/1/2023 |
| 0773T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older | Effective 1/1/2023 |
| 0774T | Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service) | Effective 1/1/2023 |
| 0775T | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra- articular implant(s) (eg, bone allograft[s], synthetic device[s]) | Effective 1/1/2023. Code Retired 1/1/24 |
| 0776T | Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment | Effective 1/1/2023 |
| 0777T | Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 0778T | Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function | Effective 1/1/2023 |
| 0779T | Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report | Effective 1/1/2023 |
| 0780T | Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract | Effective 1/1/2023 |
| 0781T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi | Effective 1/1/2023 |
| 0782T | Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus | Effective 1/1/2023 |
| 0783T | Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment | Effective 1/1/2023 |
| 0784T | Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed | Effective 1/1/24 |
| 0785T | Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator | Effective 1/1/24 |
| 0786T | Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed | Effective 1/1/24 |
| 0787T | Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator | Effective 1/1/24 |
| 0788T | Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 1-3 parameters | Effective 1/1/24 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0789T | Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 4 or more parameters | Effective 1/1/24 |
| 0790T | Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed | Effective 1/1/24 |
| 0791T | Motor-cognitive, semi-immersive virtual reality–facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure) | Effective 10/1/2023 |
| 0793T | Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance | Effective 10/1/2023 |
| 0794T | Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately | Effective 10/1/2023 |
| 0795T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components) | Effective 10/1/2023 |
| 0796T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system) | Effective 10/1/2023 |
| 0797T | Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | Effective 10/1/2023 |
| 0798T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components) | Effective 10/1/2023 |
| 0799T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component | Effective 10/1/2023 |
| 0800T | Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system) | Effective 10/1/2023 |
| 0801T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components) | Effective 10/1/2023 |
| 0802T | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component | Effective 10/1/2023 |

| CPT, HCPCS or Revenue | Category III Description | Comments/ Limitations |
|--------------------------|---|---|
| Code | Category in Description | Comments/ Limitations |
| | Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, | Effective 10/1/2023 |
| 0803T | including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a | |
| | dual-chamber leadless pacemaker system) Programming device evaluation (in person) with iterative adjustment of implantable device | Effective 10/1/2023 |
| 0804T | to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, | |
| | leadless pacemaker system in dual cardiac chambers | F.(|
| 0805T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach | Effective 10/1/2023 |
| 0806T | Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach | Effective 10/1/2023 |
| 0807T | Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, | Effective 10/1/2023 |
| | quantification of pulmonary tissue ventilation, data review, interpretation and report | |
| | Pulmonary tissue ventilation analysis using software-based processing of data from | Effective 10/1/2023 |
| | separately captured cinefluorograph images; in combination with computed tomography | |
| 0808T | (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data | |
| | preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report | |
| 0809T | Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, placement of transfixing device(s) and intra-articular implant(s), including allograft or synthetic device(s) | Effective 10/1/2023. Code Retired 1/1/24 |
| 0810T | Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies | Effective 10/1/2023 |
| 0811T | Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); set-up and patient education on use of equipment | Effective 1/1/24 |
| 0812T | Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days | Effective 1/1/24 |
| 0813T | Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon | Effective 1/1/24 |
| 0814T | Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral | Effective 1/1/24 |
| 0815T | Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine | Effective 1/1/24 |
| | Open insertion or replacement of integrated neurostimulation system for bladder | Effective 1/1/24 |
| 0816T | dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous | |
| 0817T | Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial | Effective 1/1/24 |
| 0818T | Revision or removal of integrated neurostimulation system for bladder dysfunction, including | Effective 1/1/24 |
| 0819T | analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous Revision or removal of integrated neurostimulation system for bladder dysfunction, including | Effective 1/1/24 |
| 0820T | analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour | Effective 1/1/24 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0821T | Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0822T | Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0823T | Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed | Effective 1/1/24 |
| 0824T | Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed | Effective 1/1/24 |
| 0825T | Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed | Effective 1/1/24 |
| 0826T | Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless pacemaker system in single-cardiac chamber | Effective 1/1/24 |
| 0827T | Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0828T | Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0829T | Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0830T | Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0831T | Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0832T | Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0833T | Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0834T | Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0835T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure) | Effective 1/1/24 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| 0836T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0837T | Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0838T | Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0839T | Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0840T | Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0841T | Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0842T | Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0843T | Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0844T | Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0845T | Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0846T | Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0847T | Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0848T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0849T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0850T | Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0851T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0852T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0853T | Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0854T | Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure) | Effective 1/1/24 |

| CPT, HCPCS or Revenue Code | Category III Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| 0855T | Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0856T | Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0857T | Opto-acoustic imaging, breast, unilateral, including axilla when performed, real-time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0858T | Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report | Effective 1/1/24 |
| 0859T | Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure) | Effective 1/1/24 |
| 0860T | Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities | Effective 1/1/24 |
| 0861T | Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter) | Effective 1/1/24 |
| 0862T | Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only | Effective 1/1/24 |
| 0863T | Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only | Effective 1/1/24 |
| 0864T | Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy | Effective 1/1/24 |
| 0865T | Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session | Effective 1/1/24 |
| 0866T | Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure) | Effective 1/1/24 |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|--|
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the cc | de is not listed here. |
| 00170 | Anesthesia for intraoral treatments, including biopsy; not otherwise specified | Pre-certification of Anesthesia is only applicable when dental services are performed in a hospital/medical facility setting. |
| 01999 | dental procedure | |
| 11950 | Subcutaneous injection of filling material (eg, collagen); 1 cc or less | |
| 11951 | 1.1 to 5.0 cc | |
| 11952 | 5.1 to 10.0 cc | |
| 11954 | over 10.0 cc | |
| 14000 | Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less | |
| 14001 | defect 10.1 sq cm to 30.0 sq cm | |
| 14020 | Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10 sq cm or less | |
| 14021 | defect 10.1 sq cm to 30.0 sq cm | |
| 14040 | Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10 sq cm or less | |
| 14041 | defect 10.1 sq cm to 30.0 sq cm | |
| 14060 | Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less | |
| 14061 | defect 10.1 sq cm to 30.0 sq cm | |
| 14301 | Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm | |
| 15002 | Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; first 100 sq cm or 1% of body area of infants and children Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; first 100 sq cm or 1% of body area of infants and children Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; first 100 sq cm or 1% of body area of infants and children | |
| 15003 | each additional 100 sq cm, or part thereof, or each additional 1% of body area of infants and children (List separately in addition to code for primary procedure) | |
| 15004 | Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet and/or multiple digits; first 100 sq cm or 1% of body area of infants and children | |
| 15005 | each additional 100 sq cm, or part thereof, or each additional 1% of body area of infants and children (List separately in addition to code for primary procedure) | |
| 15040 | Harvest of skin for tissue cultured skin autograft, 100 sq cm or less | |
| 15050 | Pinch graft, single or multiple, to cover small ulcer, tip of digit, or other minimal open area (except on face), up to defect size 2 cm diameter | |
| 15100 | Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less, or 1%of body area of infants and children (except 15050) | |
| 15101 | Split-thickness autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof(List separately in addition to code for primary procedure) | |
| 15110 | Epidermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children | |
| 15111 | Epidermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure) | |

| CPT, HCPCS | Dress dure Description | Common to (Linuito tions |
|--------------------|---|---------------------------|
| or Revenue Code | Procedure Description | Comments/ Limitations |
| | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is pet listed here |
| FI | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, | de is not listed here. |
| 15115 | and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children | |
| | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, | |
| | and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of | |
| 15116 | infants and children, or part thereof(List separately in addition to code for primary | |
| | procedure) | |
| | Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, | |
| 15120 | and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children | |
| | (except 15050) | |
| | Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits,genitalia, hands, feet, | |
| 15121 | and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of | |
| 10121 | infants and children, or part thereof(List separately in addition to code for primary | |
| | procedure) | |
| 15130 | Dermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and | |
| | children | |
| 15101 | Dermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body | |
| 15131 | area of infants and children, or part thereof (List separately in addition to code for primary procedure) | |
| | Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or | |
| 15135 | multiple digits; first 100 sq cm or less, or 1% of body area of infants and children | |
| | Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or | |
| 15136 | multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and | |
| 10100 | children, or part thereof (List separately in addition to code for primary procedure) | |
| 15150 | Tissue cultured skin autograft, trunk, arms, legs; first 25 sq cm or less | |
| 15151 | Tissue cultured skin autograft, trunk, arms, legs; additional 1 sq cm to 75 sq cm | |
| 45452 | Tissue cultured skin autograft, trunk, arms, legs; each additional 100 sqcm, or each additional | |
| 15152 | 1% of body area of infants and children, or part thereof | |
| 15155 | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, | |
| 13133 | feet, and/or multiple digits; first 25 sq cm or less | |
| 15156 | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, | |
| 15150 | feet, and/or multiple digits; additional 1 sq cm to 75 sq cm | |
| | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, | |
| 15157 | feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of | |
| | infants and children, or part thereof | |
| 15200 | Full thickness graft, free, including direct closure of donor site, trunk; 20 sq cm or less | |
| 15201 | Full thickness graft, free, including direct closure of donor site, trunk; each additional 20 sq | |
| | cm, or part thereof (List separately in addition to code for primary procedure) | |
| 15220 | Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; 20 sq | |
| | cm or less | |
| 15221 | Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; each | |
| 15221 | additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure) | |
| | Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, | |
| 15240 | mouth, neck, axillae, genitalia, hands, and/or feet; 20 sq cm or less | |
| | Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, | |
| 15241 | mouth, neck, axillae, genitalia, hands, and/or feet; each additional 20 sq cm, or part thereof | |
| | (List separately in addition to code for primary procedure) | |
| 15260 | Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or | |
| | | |

| CPT, HCPCS or Revenue | Procedure Description | Comments/ Limitations |
|--------------------------|--|------------------------|
| Code | Procedure Description | comments/ Limitations |
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 15261 | Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure) | |
| 15271 | Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area | |
| 15272 | Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof | |
| 15273 | Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface | |
| 15274 | Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof | |
| 15275 | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area | |
| 15276 | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof | |
| 15277 | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children | |
| 15278 | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof | |
| 15570 | Formation of direct or tubed pedicle, with or without transfer; trunk | |
| 15572 | scalp, arms, or legs | |
| 15574 | forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands or feet | |
| 15576 | eyelids, nose, ears, lips, or intraoral | |
| 15600 | Delay of flap or sectioning of flap (division and inset); at trunk | |
| 15610 | at scalp, arms, or legs | |
| 15620 | at forehead, cheeks, chin, neck, axillae, genitalia, hands, or feet | |
| 15630 | at eyelids, nose, ears, or lips | |
| 15650 | Transfer, intermediate, of any pedicle flap (eg, abdomen to wrist, Walking tube), any location | |
| 15730 | Midface flap (ie, zygomaticofacial flap) with preservation of vascular pedicle(s) | |
| 15731 | Forehead flap with preservation of vascular pedicle (eg, axial pattern flap, paramedian forehead flap) | |
| 15733 | Muscle, myocutaneous, or fasciocutaneous flap; head and neck with named vascular pedicle (ie, buccinators, genioglossus, temporalis, masseter, sternocleidomastoid, levator scapulae) | |
| 15734 | trunk | |
| 15736 | upper extremity | |
| 15738 | lower extremity | |
| 15740 | Flap; island pedicle requiring identification and dissection of an anatomically named axial vessel | |
| 15750 | neurovascular pedicle | |
| 15756 | Free muscle or myocutaneous flap with microvascular anastomosis | |
| 15757 | Free skin flap with microvascular anastomosis | |

| CPT, HCPCS or Revenue | Procedure Description | Comments/ Limitations |
|--------------------------|--|-----------------------------|
| Code | | |
| | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 15758 | Free fascial flap with microvascular anastomosis | |
| 15760 | Graft; composite (eg, full thickness of external ear or nasal ala), including primary closure, donor area | |
| 15769 | Grafting of autologous soft tissue, other, harvested by direct excision (e.g., fat, dermis, fascia) | Effective June 1, 2021 |
| 15770 | dermal-fat-fascia | , |
| | Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, | |
| 15771 | and/or legs; 50cc or less injectate: | Effective June 1, 2021 |
| 15772 | autologous fat grafting to the trunk, breasts, extremities, or scalp for each additional 50cc of injectate | Effective June 1, 2021 |
| 15773 | Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet | Effective September 1, 2021 |
| 15777 | Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (eg, breast, trunk) (List separately in addition to code for primary procedure) | |
| 15780 | Dermabrasion; total face (eg, for acne scarring, fine wrinkling, rhytids, general keratosis) | |
| 15781 | segmental, face | |
| 15782 | regional, other than face | |
| 15786 | Abrasion (e.g. keratosis, scar) - single & multiple | |
| 15787 | Abrasion (e.g. keratosis, scar) - single & multiple | |
| 15792 | Chemical peel, non facial; epidermal | |
| 15793 | dermal | |
| 15819 | Cervicoplasty | |
| 15820 | Blepharoplasty – lower eyelid | |
| 15821 | Blepharoplasty – lower eyelid | |
| 15822 | Blepharoplasty – upper eyelid | |
| 15823 | Blepharoplasty – upper eyelid | |
| 15824 | Rhytidectomy; forehead | |
| 15825 | neck with platysmal tightening (platysmal flap, P-flap) | |
| 15826 | gLABellar frown lines | |
| 15828 | cheek, chin, and neck | |
| 15829 | superficial musculoaponeurotic system (SMAS) flap | |
| 15830 | Panniculectomy | |
| 15832 | thigh | |
| 15833 | leg | |
| 15834 | hip | |
| 15835 | buttock | |
| 15836 | arm | |
| 15837 | forearm or hand | |
| 15838 | submental fat pad | |
| 15839 | other area | |
| 15840 | Graft for facial nerve paralysis; free fascia graft (including obtaining fascia) | |
| 15841 | free muscle graft (including obtaining graft) | |
| 15842 | free muscle flap by microsurgical technique | |
| 15845 | regional muscle transfer | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|---|------------------------|
| Pl | ease note any elective procedure done as an inpatient also requires authorization even if the co | le is not listed here. |
| 15847 | Abdominoplasty | |
| 15877 | Lipectomy – suction assisted | |
| 15879 | Lipectomy - lower extremity | Effective June 1, 2021 |
| 17106 | Destruction of cutaneous vascular proliferative lesions, less than 10 sq cm | |
| 17107 | Destruction of cutaneous vascular proliferative lesions, 10.0 to 50.0 sq cm | |
| 17108 | Destruction of cutaneous vascular proliferative lesions, over 50.0 sq cm | |
| 17999 | Unlisted procedure – skin, mucous membrane & subcutaneous tissue | |
| 19300 | Mastectomy for gynecomastia | |
| 19303 | Mastectomy, simple, complete | |
| 19305 | Mastectomy, radical, including pectoral muscles, axillary lymph nodes | |
| 19306 | Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) | |
| 19307 | Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle | |
| 19316 | Mastopexy | |
| 19318 | Reduction mammaplasty | |
| 19325 | Mammaplasty, augmentation w/ or w/o implant | |
| 19328 | Removal of mammary implant material | |
| 19330 | Removal of mammary implant material | |
| 19340 | Immediate or delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction | |
| 19342 | Immediate or delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction | |
| 19350 | Nipple/areola reconstruction | |
| 19355 | Correction of inverted nipples | |
| 19357 | Breast reconstruction, immediate or delayed, with tissue expander, including subsequent expansion | |
| 19361 | Breast reconstruction with latissimus dorsi flap, without prosthetic implant | |
| 19364 | Breast reconstruction with free flap | |
| 19367 | Breast reconstruction with transverse rectus abdominis myocutaneous flap (TRAM), single pedicle, including closure of donor site | |
| 19368 | with microvascular anastomosis (supercharing) | |
| 19369 | Breast reconstruction with transverse rectus abdominis myocutaneous flap (TRAM), double pedicle, including closure of donor site | |
| 19370 | Periprosthetic capsulectomy | |
| 19371 | Periprosthetic capsulectomy | |
| 19380 | Revision of reconstructed breast | |
| 19396 | Moulage preparation for custom implant | |
| 19499 | Unlisted procedure – breast | |
| 20912 | Nasal cartilage graft | Effective 1/1/2021 |
| 20932 | Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone | |
| 20933 | hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure) | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| | ا ease note any elective procedure done as an inpatient also requires authorization even if the cod | de is not listed here. |
| 20934 | intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure) | |
| 21110 | Interdental fixation device for conditions other than fracture or dislocation | |
| 21120 | Genioplasty; augmentation - all types | |
| 21121 | sliding osteotomy, single piece | |
| 21122 | Genioplasty; augmentation - all types | |
| 21123 | Genioplasty; augmentation - all types | |
| 21125 | Augmentation, mandibular angle; prosthetic material or bone graft | |
| 21127 | Augmentation, mandibular angle; prosthetic material or bone graft | |
| 21137 | Forehead reduction | |
| 21138 | Forehead reduction | |
| 21139 | Forehead reduction | |
| 21141 | Midface reconstruction | |
| 21142 | Midface reconstruction | |
| 21143 | Midface reconstruction | |
| 21145 | Midface reconstruction | |
| 21146 | Midface reconstruction | |
| 21147 | Midface reconstruction | |
| 21150 | Midface reconstruction | |
| 21151 | Midface reconstruction | |
| 21154 | Midface reconstruction | |
| 21155 | Midface reconstruction | |
| 21159 | Midface reconstruction | |
| 21160 | Midface reconstruction | |
| 21172 | Forehead reconstruction | |
| 21175 | Forehead reconstruction | |
| 21179 | Forehead reconstruction | |
| 21180 | Forehead reconstruction | |
| 21210 | Graft, bone, nasal,maxillary or malar areas | Effective 1/1/2021 |
| 21280 | Canthopexy | |
| 21282 | Canthopexy | |
| 22100 | Partial excision of posterior vertebral component (eg, spinous process, lamina or facet) for intrinsic bony lesion, single vertebral segment; cervical | |
| 22101 | thoracic | |
| 22102 | lumbar | |
| 22103 | each additional segment (List separately in addition to code for primary procedure) | |
| 22110 | Partial excision of vertebral body, for intrinsic bony lesion, without decompression of spinal cord or nerve root(s), single vertebral segment; cervical | |
| 22112 | thoracic | |
| 22114 | lumbar | |
| 22116 | each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 22206 | Osteotomy of spine, posterior or posterolateral approach, 3 columns, 1 vertebral segment (eg, pedicle/vertebral body subtraction); thoracic | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|---|------------------------|
| PI | ا ease note any elective procedure done as an inpatient also requires authorization even if the cod | de is not listed here. |
| 22207 | lumbar | |
| 22208 | each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 22210 | Osteotomy of spine, posterior or posterolateral approach, 1 vertebral segment; cervical | |
| 22212 | thoracic | |
| 22214 | lumbar | |
| 22216 | each additional vertebral segment (List separately in addition to primary procedure) | |
| 22220 | Osteotomy of spine, including discectomy, anterior approach, single vertebral segment; cervical | |
| 22222 | thoracic | |
| 22224 | lumbar | |
| 22226 | each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 22318 | Open treatment and/or reduction of odontoid fracture(s) and or dislocation(s) (including os odontoideum), anterior approach, including placement of internal fixation; without grafting | |
| 22319 | with grafting | |
| 22325 | Open treatment and/or reduction of vertebral fracture(s) and/or dislocation(s), posterior approach, 1 fractured vertebra or dislocated segment; lumbar | |
| 22326 | cervical | |
| 22327 | thoracic | |
| 22328 | each additional fractured vertebra or dislocated segment (List separately in addition to code for primary procedure) | |
| 22505 | Manipulation of spine requiring anesthesia, any region | |
| 22510 | Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic | |
| 22511 | lumbosacral | |
| 22512 | each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure) | |
| 22513 | Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic | |
| 22514 | lumbar | |
| 22515 | each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure) | |
| 22526 | Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level | |
| 22527 | 1 or more additional levels (List separately in addition to code for primary procedure) | |
| 22532 | Arthrodesis, lateral extracavitary technique, including minimal discectomy to prepare interspace (other than for decompression); thoracic | |
| 22533 | lumbar | |
| 22534 | thoracic or lumbar, each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 22548 | Arthrodesis, anterior transoral or extraoral technique, clivus-C1-C2 (atlas-axis), with or without excision of odontoid process | |
| 22551 | Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below C2 | |
| 22552 | cervical below C2, each additional interspace (List separately in addition to code for primary procedure) | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|---|------------------------|
| | l ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 22554 | Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below C2 | |
| 22556 | thoracic | |
| 22558 | lumbar | |
| 22585 | each additional interspace (List separately in addition to code for primary procedure) | |
| 22586 | Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace | |
| 22590 | Arthrodesis, posterior technique, craniocervical (occiput-C2) | |
| 22595 | Arthrodesis, posterior technique, atlas-axis (C1-C2) | |
| 22600 | Arthrodesis, posterior or posterolateral technique, single level; cervical below C2 segment | |
| 22610 | thoracic (with lateral transverse technique, when performed) | |
| 22612 | lumbar (with lateral transverse technique, when performed) | |
| 22614 | each additional vertebral segment (List separately in addition to code for primary procedure) | |
| 22630 | Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace; lumbar | |
| 22632 | each additional interspace (List separately in addition to code for primary procedure) | |
| 22633 | Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace (other than for decompression), single interspace and segment; lumbar | |
| 22634 | each additional interspace and segment (List separately in addition to code for primary procedure) | |
| 22800 | Arthrodesis, posterior, for spinal deformity, with or without cast; up to 6 vertebral segments | |
| 22802 | 7 to 12 vertebral segments | |
| 22804 | 13 or more vertebral segments | |
| 22818 | Kyphectomy, circumferential exposure of spine and resection of vertebral segment(s) (including body and posterior elements); single or 2 segments | |
| 22819 | 3 or more segments | |
| 22830 | Exploration of spinal fusion | |
| 22840 | Posterior non-segmental instrumentation (eg, Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure) | |
| 22841 | Internal spinal fixation by wiring of spinous processes (List separately in addition to code for primary procedure) | |
| 22842 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure) | |
| 22843 | 7 to 12 vertebral segments (List separately in addition to code for primary procedure) | |
| 22844 | 13 or more vertebral segments (List separately in addition to code for primary procedure) | |
| 22845 | Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for primary procedure) | |
| 22846 | 4 to 7 vertebral segments (List separately in addition to code for primary procedure) | |
| 22847 | 8 or more vertebral segments (List separately in addition to code for primary procedure) | |
| 22848 | Pelvic fixation (attachment of caudal end of instrumentation to pelvic bony structures) other than sacrum (List separately in addition to code for primary procedure) | |
| 22849 | Reinsertion of spinal fixation device | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|---|
| | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here |
| 22850 | Removal of posterior non segmental instrumentation (eg, Harrington rod) | |
| 22852 | Removal of posterior segmental instrumentation | |
| 22052 | Insertion of interbody biomechanical device(s) (eg, synthetic cage, mesh) with integral | |
| 22853 | anterior instrumentation for device anchoring (eg, synthetic edge, mesh) when performed, to intervertebral disc space in conjunction with interbody arthrodesis, each interspace (List separately in addition to code for primary procedure) | |
| 22854 | Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in conjunction with interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure) | |
| 22855 | Removal of anterior instrumentation | |
| 22856 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); single interspace, cervical | |
| 22857 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar | |
| 22858 | second level, cervical (List separately in addition to code for primary procedure) | |
| 22859 | Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh, methylmethacrylate) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure) | |
| 22860 | Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure) | Effective 1/1/2023 |
| 22861 | Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical | |
| 22862 | lumbar | |
| 22864 | Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical | |
| 22865 | lumbar | |
| 22899 | Unlisted procedure, spine | |
| 23921 | Shoulder-secondary closure or scar revision | |
| 24925 | Arm through humerus-secondary closure or scar revision | |
| 25907 | forearm, through radius and ulna - secondary closure or scar revision | |
| 25922 | Wrist- secondary closure or scar revision | |
| 27278 | Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device | Effective 1/1/24 (added on 5/1/24 list) |
| 27412 | Autologous chondrocyte implantation, knee | |
| 27415 | Osteochondral allograft, knee, open | |
| 27416 | Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft [s]) | |
| 29867 | osteochondral allograft (eg, mosaicplasty) | |
| 30120 | Excision or surgical planning of skin for rhinophyma | |
| 30400 | Rhinoplasty | |
| 30410 | Rhinoplasty | |

| CPT, HCPCS or Revenue | Procedure Description | Comments/ Limitations |
|--------------------------|---|---|
| Code | ease note any elective procedure done as an inpatient also requires authorization even if the co | is not listed here |
| 30420 | Rhinoplasty | |
| 30420 | Rhinoplasty | |
| 30435 | Rhinoplasty | |
| 30450 | Rhinoplasty | |
| | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including | |
| 30460 | columellar lengthening; tip only | |
| 30462 | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies | |
| 30520 | Septoplasty or submucous resection | |
| 30999 | Unlisted procedure – nose | |
| 31660 | Bronchial Thermoplasty | |
| 31661 | with bronchial thermoplasty, 2 or more lobes | |
| 32851 | Transplant – lung | |
| 32852 | Transplant – lung | |
| 32853 | Transplant – lung | |
| 32854 | Transplant – lung | |
| 33267 | Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) | Effective 9/1/22 |
| 33268 | Exclusion of left atrial appendage, open, performed at the time of other sternotomy or thoracotomy procedure(s), any method | Effective 9/1/22 |
| 33269 | Exclusion of left atrial appendage, thoracoscopic, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) | Effective 9/1/22 |
| 33276 | Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed | Effective 1/1/24 (added on 5/1/24 list) |
| 33277 | Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure) | Effective 1/1/24 (added on 5/1/24 list) |
| 33287 | Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator | Effective 1/1/24 (added on 5/1/24 list) |
| 33288 | Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) | Effective 1/1/24 (added on 5/1/24 list) |
| 33370 | Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous | Effective 9/1/22, removed PA requirement effective 8/1/24 |
| 33927 | Implantation of a total replacement heart system(artificial heart) with recipient cardiectomy | |
| 33928 | Removal and replacement of total replacement heart system. (artificial heart) | |
| 33929 | Removal of total replacement heart system (artificial heart) for heart | |
| 33935 | Transplant – heart/lung | |
| 33945 | Transplant – heart | |
| 36260 | Insertion of implantable intra-arterial infusion pump (eg, for chemotherapy of liver) | |
| 36465 | multiple incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg | Effective June 1, 2021 |
| 36466 | Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein). | Effective June 1, 2021 |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 36470 | Injection of sclerosing solution | |
| 36471 | Injection of sclerosing solution | |
| 36473 | Endovenous mechanochemical destruction - 1st vein- imaging guidance | Effective 1/1/2021 |
| 36474 | Endovenous mechanochemical destruction - 1st vein- imaging guidance | Effective 1/1/2021 |
| 36475 | Endovenous ablation therapy - radiofrequency | |
| 36476 | Endovenous ablation therapy - radiofrequency | |
| 36478 | Endovenous ablation therapy - laser | |
| 36479 | Endovenous ablation therapy - laser | |
| 36482 | Endovenous chemical destruction vein arm or leg, 1st | Effective 1/1/2021 |
| 36483 | Endovenous chemical destruction vein arm or leg, subsequent | Effective 1/1/2021 |
| 37500 | Vascular endoscopy, surgical, with ligation of perforator veins subfascial (SEPS) | |
| 37700 | Ligation/division/stripping/stab phlebectomy | |
| 37718 | Ligation/division/stripping/stab phlebectomy | |
| 37722 | Ligation/division/stripping/stab phlebectomy | |
| 37735 | Ligation/division/stripping/stab phlebectomy | |
| 37760 | Ligation/division/stripping/stab phlebectomy | |
| 37761 | Ligation/division/stripping/stab phlebectomy | |
| 37765 | Ligation/division/stripping/stab phlebectomy | |
| 37766 | Ligation/division/stripping/stab phlebectomy | |
| 37780 | Ligation/division/stripping/stab phlebectomy | |
| 37785 | Ligation/division/stripping/stab phlebectomy | |
| 38240 | Transplant – bone marrow | |
| 38241 | Transplant – bone marrow | |
| 38242 | Transplant – bone marrow | |
| 41899 | dental procedure | |
| 42145 | Palatopharyngoplasty | |
| 43284 | Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed | Effective 5/1/2020 |
| 43285 | Removal of esophageal sphincter augmentation device | Effective 5/1/2020 |
| 43289 | Unlisted laparoscopy, surgical, esophageal sphincter augmentation | Effective 5/1/2020 |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon | Effective 1/1/2023 |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with of intragastric bariatric balloon(s) | Effective 1/1/2023 |
| 43497 | Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM]) | Effective 9/1/22 |
| 43633 | Gastrectomy, partial, distal; with Roux-en-Y reconstruction | Effective 7/1/2020 |
| 43644 | Lap Gastric Bypass w/Roux-en-Y | |
| 43645 | Gastric Bypass w/small intestine reconstruction to limit absorption | |
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, | Effective 7/1/2020 |
| 43659 | Unlisted lap procedure, stomach | |
| 43770 | Lap Band | |
| 43771 | Revision of adjustable gastric restrictive device component only | |
| 43772 | Laparoscopy, surgical, gastric restrictive procedure, of adjustable gastric restrictive device component only. | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| Pl | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 43773 | & replacement of Lap Band | |
| 43774 | Laparoscopy, surgical, gastric restrictive procedure, of adjustable gastric restrictive device and subcutaneous port components | |
| 43775 | Sleeve Gastrectomy | |
| 43842 | Gastric restrictive procedure, without gastric bypass, for morbid obesity: vertical-banded gastroplasty | |
| 43843 | Gastric restrictive procedure, w/o gastric bypass, other than vertical- banded gastroplasty | |
| 43845 | Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch) | |
| 43846 | Gastric Bypass w/Roux-en-Y | |
| 43847 | Gastric Bypass w/small intestine reconstruction to limit absorption | |
| 43848 | Revision of gastric restrictive procedure, other than adjustable gastric restrictive device | |
| 43860 | Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy | |
| 43865 | Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy | |
| 43881 | Implantation or replacement of gastric neurostimulator electrodes, antrum, open | Effective 7/1/2020 |
| 43886 | Gastric restrictive procedure; open; revision of subcutaneous port component only | |
| 43887 | Gastric restrictive procedure, open; of subcutaneous port component only | |
| 43888 | Gastric restrictive procedure, open; and replacement of subcutaneous port component only | |
| 43999 | Gastric Outlet Repair Unlisted procedure, stomach | |
| 44135 | Transplant – small intestine | |
| 44136 | Transplant – small intestine | |
| 44799 | Unlisted procedure, small intestine | Effective 7/1/2020 |
| 47135 | Transplant-Liver | |
| 48160 | Transplant – pancreas | |
| 48554 | Transplant – pancreas | |
| 50360 | Transplant – kidney | |
| 50365 | Transplant – kidney | |
| 50380 | Transplant – kidney | |
| 50436 | Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with post procedure tube placement, when performed; | |
| 50437 | Including new access into the renal collecting system | |
| 55867 | Laparoscopy, surgical prostatectomy, simple subtotal (including control of postoperative bleeding, vasectomy, meatotomy, urethral calibration and/or dilation, and internal urethrotomy), includes robotic assistance, when performed | Effective 1/1/2023 |
| 58720 | Salpingo-oophorectomy, complete or partial, unilateral or bilateral (separate procedure) | |
| 58940 | Oophorectomy, partial or total, unilateral or bilateral. | |
| 60512 | Parathyroid autotransplantation (List separately in addition to code for primary procedure) | |
| 61736 | Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion | Effective 9/1/22 |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|---|--|
| Pl | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 61737 | Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s) | Effective 9/1/22 |
| 61889 | Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s) | Effective 1/1/2024 (added on 5/1/24 list |
| 62380 | Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar | |
| 63001 | Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; cervical | |
| 63003 | thoracic | |
| 63005 | lumbar, except for spondylolisthesis | |
| 63011 | sacral | |
| 63012 | Laminectomy with of abnormal facets and/or pars interarticularis with decompression of cauda equina and nerve roots for spondylolisthesis, lumbar (Gill type procedure) | |
| 63015 | Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), more than 2 vertebral segments; cervical | |
| 63016 | thoracic | |
| 63017 | lumbar | |
| 63020 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical | |
| 63030 | 1 interspace, lumbar | |
| 63035 | each additional interspace, cervical or lumbar (List separately in addition to code for primary procedure) | |
| 63040 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; cervical | |
| 63042 | lumbar | |
| 63043 | each additional cervical interspace (List separately in addition to code for primary procedure) | |
| 63044 | each additional lumbar interspace (List separately in addition to code for primary procedure) | |
| 63045 | Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; cervical | |
| 63046 | thoracic | |
| 63047 | lumbar | |
| 63048 | each additional segment, cervical, thoracic, or lumbar (List separately in addition to code for primary procedure) | |
| 63050 | Laminoplasty, cervical, with decompression of the spinal cord, 2 or more vertebral segments; | |
| 63051 | with reconstruction of the posterior bony elements (including the application of bridging bone graft and non-segmental fixation devices [eg, wire, suture, mini-plates], when performed) | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 63052 | Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis]), during posterior interbody arthrodesis, lumbar; single vertebral segment (List separately in addition to code for primary procedure) | Effective 9/1/22 |
| 63053 | Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis]), during posterior interbody arthrodesis, lumbar; each additional segment (List separately in addition to code for primary procedure) | Effective 9/1/22 |
| 63055 | Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; thoracic | |
| 63056 | lumbar (including transfacet, or lateral extraforaminal approach) (eg, far lateral herniated intervertebral disc) | |
| 63057 | each additional segment, thoracic or lumbar (List separately in addition to code for primary procedure) | |
| 63064 | Costovertebral approach with decompression of spinal cord or nerve root(s) (eg, herniated intervertebral disc), thoracic; single segment | |
| 63066 | each additional segment (List separately in addition to code for primary procedure) | |
| 63075 | Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; cervical, single interspace | |
| 63076 | cervical, each additional interspace (List separately in addition to code for primary procedure) | |
| 63077 | thoracic, single interspace | |
| 63078 | thoracic, each additional interspace (List separately in addition to code for primary procedure) | |
| 63081 | Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach with decompression of spinal cord and/or nerve root(s); cervical, single segment | |
| 63082 | cervical, each additional segment (List separately in addition to code for primary procedure) | |
| 63085 | Vertebral corpectomy (vertebral body resection), partial or complete, transthoracic approach with decompression of spinal cord and/or nerve root(s); thoracic, single segment | |
| 63086 | thoracic, each additional segment (List separately in addition to code for primary procedure) | |
| 63087 | Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic or lumbar; single segment | |
| 63088 | each additional segment (List separately in addition to code for primary procedure) | |
| 63090 | Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic, lumbar, or sacral; single segment | |
| 63091 | each additional segment (List separately in addition to code for primary procedure) | |
| 63101 | Vertebral corpectomy (vertebral body resection), partial or complete, lateral extracavitary approach with decompression of spinal cord and/or nerve root(s) (eg, for tumor or retropulsed bone fragments); thoracic, single segment | |
| 63102 | lumbar, single segment | |
| 63103 | thoracic or lumbar, each additional segment (List separately in addition to code for primary procedure) | |
| 63170 | Laminectomy with myelotomy (eg, Bischof or DREZ type), cervical, thoracic, or thoracolumbar | |
| 63172 | Laminectomy with drainage of intramedullary cyst/syrinx; to subarachnoid space | |
| 63173 | to peritoneal or pleural space | |
| 63185 | Laminectomy with rhizotomy; 1 or 2 segments | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 63190 | more than 2 segments | |
| 63191 | Laminectomy with section of spinal accessory nerve | |
| 63197 | thoracic | |
| 63200 | Laminectomy, with release of tethered spinal cord, lumbar | |
| 63250 | Laminectomy for excision or occlusion of arteriovenous malformation of spinal cord; cervical | |
| 63251 | thoracic | |
| 63252 | thoracolumbar | |
| 63265 | Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; cervical | |
| 63266 | thoracic | |
| 63267 | lumbar | |
| 63268 | sacral | |
| 63270 | Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; cervical | |
| 63271 | thoracic | |
| 63272 | lumbar | |
| 63273 | sacral | |
| 63275 | Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, cervical | |
| 63276 | extradural, thoracic | |
| 63277 | extradural, lumbar | |
| 63278 | extradural, sacral | |
| 63280 | intradural, extramedullary, cervical | |
| 63281 | intradural, extramedullary, thoracic | |
| 63282 | intradural, extramedullary, lumbar | |
| 63283 | intradural, sacral | |
| 63285 | intradural, intramedullary, cervical | |
| 63286 | intradural, intramedullary, thoracic | |
| 63287 | intradural, intramedullary, thoracolumbar | |
| 63290 | combined extradural-intradural lesion, any level | |
| 63295 | Osteoplastic reconstruction of dorsal spinal elements, following primary intraspinal procedure (List separately in addition to code for primary procedure) | |
| 63300 | Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; extradural, cervical | |
| 63301 | extradural, thoracic by transthoracic approach | |
| 63302 | extradural, thoracic by thoracolumbar approach | |
| 63303 | extradural, lumbar or sacral by transperitoneal or retroperitoneal approach | |
| 63304 | intradural, cervical | |
| 63305 | intradural, thoracic by transthoracic approach | |
| 63306 | intradural, thoracic by thoracolumbar approach | |
| 63307 | intradural, lumbar or sacral by transperitoneal or retroperitoneal approach | |
| 63308 | each additional segment (List separately in addition to codes for single segment) | |
| 63600 | Creation of lesion of spinal cord by stereotactic method, percutaneous, any modality (including stimulation and/or recording) | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|----------------------------------|
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 63610 | Stereotactic stimulation of spinal cord, percutaneous, separate procedure not followed by other surgery | |
| 63620 | Stereotactic radiosurgery | |
| 63621 | each additional spinal lesion (List separately in addition to code for primary procedure) | |
| 63650 | Percutaneous implantation of neurostimulator electrode array, epidural | |
| 63655 | Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural | |
| 63661 | of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed | Removed PA requirement 8/1/24 |
| 63662 | of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed | · · · |
| 63663 | Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed | |
| 63664 | Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed | |
| 63685 | Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver | |
| 63688 | Revision or of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array | |
| 63700 | Repair of meningocele; less than 5 cm diameter | |
| 63702 | larger than 5 cm diameter | |
| 63704 | Repair of myelomeningocele; less than 5 cm diameter | |
| 63706 | larger than 5 cm diameter | |
| 63707 | Repair of dural/cerebrospinal fluid leak, not requiring laminectomy | |
| 63709 | Repair of dural/cerebrospinal fluid leak or pseudomeningocele, with laminectomy | |
| 63710 | Dural graft, spinal | |
| 63740 | Creation of shunt, lumbar, subarachnoid-peritoneal, -pleural, or other; including laminectomy | |
| 63741 | percutaneous, not requiring laminectomy | |
| 64561 | Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed | |
| 64568 | Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | Effective 6/1/2021 |
| 64582 | Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array | Effective 9/1/22 |
| 64583 | Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator | Effective 9/1/22 |
| 64584 | of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array | Effective 9/1/22 |
| 64590 | Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver | Effective 7/1/2020 |
| 64628 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral | Effective 9/1/22 |
| 64629 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure) | Effective 9/1/22 |
| 65781 | limbal stem cell allograft (eg, cadaveric or living donor) | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 67715 | Canthotomy | |
| 67900 | Repair of brow ptosis, blepharoptosis | |
| 67901 | Repair of blepharoptosis; frontalis muscle technique with suture or other material (eg, banked fascia) | |
| 67902 | Repair of blepharoptosis; frontalis muscle technique with autologous fascial sling (includes obtaining fascia) | |
| 67903 | Repair of blepharoptosis; (tarso) levator resection or advancement, internal approach | |
| 67904 | Repair of blepharoptosis; (tarso) levator resection or advancement, external approach | |
| 67906 | Repair of blepharoptosis; superior rectus technique with fascial sling (includes obtaining fascia) | |
| 67908 | Repair of blepharoptosis; conjunctivo-tarso-Muller's muscle-levator resection (eg, Fasanella- Servat type) | |
| 67911 | Correction of lid retraction | |
| 67914 | Repair of ectropion | |
| 67915 | Repair of ectropion; thermocauterization | |
| 67916 | Repair of ectropion; excision tarsal wedge | |
| 67917 | Repair of ectropion; extensive (eg, tarsal strip operations) | |
| 67921 | Repair of entropion, suture | |
| 67922 | Repair of entropion; thermocauterization | |
| 67923 | Repair of entropion; excision tarsal wedge | |
| 67924 | Repair of entropion; extensive (eg, tarsal strip or capsulopalpebral fascia repairs operation) | |
| 67950 | Canthoplasty | |
| 67999 | Unlisted procedure, eyelids | |
| 69300 | Otoplasty - protruding ear | |
| 69716 | Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor | Effective 9/1/22 |
| 69719 | , osseointegrated implant, skull; with percutaneous attachment to external speech processor | Effective 9/1/22 |
| 69726 | , osseointegrated implant, skull; with percutaneous attachment to external speech processor | Effective 9/1/22 |
| 69727 | , osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor | Effective 9/1/22 |
| 69728 | , entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex | |
| 69729 | Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex | |
| 69730 | Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex | Effective 1/1/23 |
| 90867 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management | |
| 90868 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, subsequent delivery and management, per session | |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| Pl | ا ease note any elective procedure done as an inpatient also requires authorization even if the coc | de is not listed here. |
| 90869 | Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, subsequent motor threshold re- determination with delivery and management | |
| 95782 | younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | |
| 95783 | younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist | |
| 95801 | minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone) | |
| 95805 | Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness | |
| 95808 | Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist | |
| 95810 | age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | |
| 95811 | age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | |
| 96116 | Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report | |
| 96121 | each additional hour (List separately in addition to code for primary procedure) | |
| 96130 | Psychological testing evaluation services by physician or other qualified healthcare professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour | |
| 96131 | each additional hour (List separately in addition to code for primary procedure) | |
| 96132 | Neuropsychological testing evaluation services by physician or other qualified healthcare professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour | |
| 96133 | each additional hour (List separately in addition to code for primary procedure) | |
| 96136 | Psychological or neuropsychological test administration and scoring by physician or other qualified healthcare professional, two or more tests, any method; first 30 minutes | |
| 96137 | each additional 30 minutes (List separately in addition to code for primary procedure) | |
| 96138 | Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes | |
| 96139 | each additional 30 minutes (List separately in addition to code for primary procedure) | |
| 96146 | Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only | |
| ** 96365 if >\$7500 | Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Co. | Effective 10.1.23 |
| ** 96366 if >\$7500 | Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug | Effective 10.1.23 |
| 96920 | Excimer laser treatment for psoriasis; total area less than 250 sq cm | Effective 1/1/2022 |
| 96921 | Excimer laser treatment for psoriasis; 250 sq cm to 500 sq cm | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | Procedure Description | Comments/ Limitations | | |
|----------------------------------|--|---|--|--|
| | Please note any elective procedure done as an inpatient also requires authorization even if the code is not listed here. | | | |
| 96922 | Excimer laser treatment for psoriasis; over 500 sq cm | Effective 1/1/2022 | | |
| | ABA assessment | Effective 1/1/24. Please use | | |
| 07454 | | ABA form located on the | | |
| 97151 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org website for this request. | | |
| | ADA accomment | Effective 1/1/24. Please use | | |
| | ABA assessment | ABA form located on the | | |
| 97152 | | Prior Authorization Page of | | |
| 57152 | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | Adaptive Behavior Treatment | Effective 1/1/24. Please use | | |
| | | ABA form located on the | | |
| 97153 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | Adaptive behavior treatment with protocol modification | Effective 1/1/24. Please use | | |
| | | ABA form located on the | | |
| 97154 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | Adaptive behavior treatment by protocol | Effective 1/1/24. Please use | | |
| | | ABA form located on the | | |
| 97155 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | Family adaptive behavior treatment guidance | Effective 1/1/24. Please use ABA form located on the | | |
| 97156 | | Prior Authorization Page of | | |
| 37130 | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | multiple patients' adaptive behavior treatment face-to-face with a group of guardians or | Effective 1/1/24. Please use | | |
| | caregivers | ABA form located on the | | |
| 97157 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org | | |
| | | website for this request. | | |
| | Group adaptive behavior treatment with protocol modification, | Effective 1/1/24. Please use | | |
| | | ABA form located on the | | |
| 97158 | | Prior Authorization Page of | | |
| | | the mysmarthealth.org | | |
| | | website for this request. | | |
| 99183 | Hyperbaric Oxygen Therapy (HBO Therapy) | Effective 1/1/2021 | | |
| 99499 | Transplant evaluations (general code used for all types). | | | |
| ** S2066, S2067, S2068 ** | These are non-covered codes. Please use the proper procedure codes instead: 19361, 19364, 19366, 19367, 19368, or 19369. | Effective 1/1/2020 | | |

| СРТ, НСРСЅ | De d'al seu Davastation | | |
|--------------------|--|-----------------------|--|
| or Revenue Code | Radiology Description | Comments/ Limitations | |
| | Please note any elective procedure done as an inpatient also requires authorization even if the code is not listed here. | | |
| 70336 | MRI temporomandibular joint(s) | | |
| 70540 | MRI orbit, face and /or neck; w/o contrast | | |
| 70542 | MRI orbit, face and /or neck; w/o contrast | | |
| 70543 | MRI orbit, face and /or neck; w/o contrast followed by contrast | | |
| 70544 | Magnetic resonance angiography, head; without contrast material(s) | | |
| 70545 | with contrast material(s) | | |
| 70546 | without contrast material(s), followed by contrast material(s) and further sequences | | |
| 70547 | MRA neck; w/o contrast | | |
| 70548 | MRA neck; with contrast | | |
| 70549 | MRA neck; w/o contrast followed by contrast | | |
| 70551 | MRI brain; w/o contrast | | |
| 70552 | MRI brain; with contrast | | |
| 70553 | MRI brain; w/o contrast followed by contrast | | |
| 70554 | Functional MRI; not requiring physician or psychologist administration | | |
| 70555 | Functional MRI; requiring physician or psychologist administration of entire | | |
| 70557 | Magnetic resonance (eg, proton) imaging, brain (including brain stem and skull base), during open intracranial procedure (eg, to assess for residual tumor or residual vascular malformation); without contrast material | | |
| 70558 | with contrast material(s) | | |
| 70559 | without contrast material(s), followed by contrast material(s) and further sequences | | |
| 71550 | MRI chest; w/o contrast | | |
| 71551 | MRI chest; with contrast | | |
| 71552 | MRI chest; w/o contrast followed by contrast | | |
| 71555 | MRA chest; with or w/o contrast | | |
| 72141 | MRI cervical spine; w/o contrast | | |
| 72142 | MRI cervical spine; with contrast | | |
| 72146 | MRI thoracic spine, w/o contrast | | |
| 72147 | MRI thoracic spine; with contrast | | |
| 72148 | MRI lumbar spine; w/o contrast | | |
| 72149 | MRI lumbar spine; with contrast | | |
| 72156 | MRI cervical spine; w/o contrast followed by contrast | | |
| 72157 | MRI thoracic spine; w/o contrast followed by contrast | | |
| 72158 | MRI lumbar spine; w/o contrast followed by contrast | | |
| 72159 | MRA spinal canal and contents; with or w/o contrast | | |
| 72195 | MRI pelvis; w/o contrast | | |
| 72196 | MRI pelvis; with contrast | | |
| 72197 | MRI pelvis; w/o contrast followed by contrast | | |
| 72198 | MRA pelvis; with or w/o contrast | | |
| 73218 | MRI upper extremity; other than joint w/o contrast | | |
| 73219 | MRI upper extremity; other than joint with contrast | | |
| 73220 | MRI upper extremity; other than joint w/o contrast followed by contrast | | |
| 73221 | MRI upper extremity; any joint w/o contrast | | |

| CPT, HCPCS or Revenue | Radiology Description | Comments/ Limitations | |
|--------------------------|---|-----------------------|--|
| Code | | | |
| Pl | Please note any elective procedure done as an inpatient also requires authorization even if the code is not listed here. | | |
| 73222 | MRI upper extremity; any joint with contrast | | |
| 73223 | MRI upper extremity; any joint w/o contrast followed by contrast | | |
| 73225 | MRA upper extremity; with or w/o contrast | | |
| 73718 | MRI lower extremity, other than joint w/o contrast | | |
| 73719 | MRI lower extremity, other than joint with contrast | | |
| 73720 | MRI lower extremity, other than joint, without contrast followed by contrast | | |
| 73721 | MRI lower extremity, any joint, w/o contrast | | |
| 73722 | MRI lower extremity, any joint with contrast | | |
| 73723 | MRI lower extremity, any joint w/o contrast followed by contrast | | |
| 73725 | MRA lower extremity; with or w/o contrast | | |
| 74181 | MRI abdomen; w/o contrast | | |
| 74182 | MRI abdomen; with contrast | | |
| 74183 | MRI abdomen; w/o contrast followed by contrast | | |
| 74185 | MRA abdomen; with or w/o contrast | | |
| 74712 | Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation | | |
| 74713 | each additional gestation (List separately in addition to code for primary procedure) | | |
| 75557 | MRI cardiac; morphology and function w/o contrast | | |
| 75559 | MRI cardiac; morphology and function w/o contrast material; with stress | | |
| 75561 | MRI cardiac; morphology and function w/o contrast followed by contrast and | | |
| 75563 | MRI cardiac; morphology and function w/o contrast followed by contrast and | | |
| 75565 | Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure) | | |
| 76390 | Magnetic resonance spectroscopy | | |
| 76391 | MRI Elastography | | |
| 76498 | Unlisted magnetic resonance procedure (eg, diagnostic, interventional) | | |
| 77021 | Magnetic resonance imaging guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation | | |
| 77022 | Magnetic resonance imaging guidance for, and monitoring of, parenchymal tissue ablation | | |
| 77046 | MRI breast; without contrast; unilateral | | |
| 77047 | MRI breast; with contrast; bilateral | | |
| 77048 | MRI breast; without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral | | |
| 77049 | MRI breast; without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral | | |
| 77084 | MRI bone marrow blood supply | | |
| 77520 | Proton treatment delivery; simple, without compensation | | |
| 77522 | simple, with compensation | | |
| 77523 | intermediate | | |
| 77525 | complex | | |
| 78102 | Bone marrow imaging; limited area | | |

| CPT, HCPCS or Revenue Code | Radiology Description | Comments/ Limitations |
|----------------------------------|--|------------------------|
| PI | ease note any elective procedure done as an inpatient also requires authorization even if the co | de is not listed here. |
| 78103 | multiple areas | |
| 78104 | whole body | |
| 78429 | Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan | Effective 9/1/2020 |
| 78430 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan | Effective 9/1/2020 |
| 78431 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan | Effective 9/1/2020 |
| 78432 | Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability) | Effective 9/1/2020 |
| 78433 | Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan | Effective 9/1/2020 |
| 78434 | Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure) | Effective 9/1/2020 |
| 78451 | Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic) | |
| 78452 | multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | |
| 78453 | Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic) | |
| 78454 | multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | |
| 78459 | Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study | |
| 78466 | Myocardial imaging, infarct avid, planar; qualitative or quantitative | |
| 78468 | with ejection fraction by first pass technique | |
| 78469 | tomographic SPECT with or without quantification | |
| 78472 | Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without additional quantitative processing | |
| 78473 | multiple studies, wall motion study plus ejection fraction, at rest and stress (exercise and/or pharmacologic), with or without additional quantification | |
| 78481 | Cardiac blood pool imaging (planar), first pass technique; single study, at rest or with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification | |
| 78483 | multiple studies, at rest and with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification | |

| CPT, HCPCS or Revenue Code | Radiology Description | Comments/ Limitations | | |
|----------------------------------|---|-----------------------|--|--|
| PI | Please note any elective procedure done as an inpatient also requires authorization even if the code is not listed here. | | | |
| 78491 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic) | | | |
| 78492 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic) | | | |
| 78494 | Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study plus ejection fraction, with or without quantitative processing | | | |
| 78496 | Cardiac blood pool imaging, gated equilibrium, single study, at rest, with right ventricular ejection fraction by first pass technique (List separately in addition to code for primary procedure) | | | |
| 78499 | Unlisted cardiovascular procedure, diagnostic nuclear medicine | | | |
| 78608 | PET of brain for metabolic evaluation | | | |
| 78609 | PET of brain for perfusion evaluation | | | |
| 78811 | PET IMAGING LIMITED AREA CHEST HEAD/NECK | | | |
| 78812 | PET imaging of skull base to mid-thigh | | | |
| 78813 | PET imaging of entire body | | | |
| 78814 | PET IMAGING CT FOR ATTENUATION LIMITED AREA | | | |
| 78815 | PET IMAGING CT ATTENUATION SKULL BASE MID-THIGH | | | |
| 78816 | PET IMAGING FOR CT ATTENUATION WHOLE BODY | | | |
| 91113 | Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report | Effective 9.1.2022 | | |
| A9599 | Radiopharmaceutical, diagnostic for beta-amyloid PET imaging | | | |
| C030BZ | PET IMAGING, BRAIN, C-11 | | | |
| C030KZ | PET IMAGING, BRAIN, F-18 | | | |
| C030MZ | PET IMAGING, BRAIN, O-15 | | | |
| C030YZ | PET IMAGING, BRAIN, OTHER RADIONUCLIDE | | | |
| C03YYZ | PET IMAGING, CNS, OTHER RADIONUCLIDE | | | |
| C23GKZ | PET IMAGING, MYOCARDIUM, F-18 | | | |
| C23GM | HEART, PET IMAGING, MYOCARDIUM, O-15 | | | |
| C23GMZ | PET IMAGING, MYOCARDIUM, O-15 | | | |
| C23GQZ | PET IMAGING, MYOCARDIUM, RB-82 | | | |
| C23GRZ | PET IMAGING, MYOCARDIUM, N-13 | | | |
| C23GYZ | PET IMAGING, MYOCARDIUM, OTHER RADIONUCLIDE | | | |
| C23YYZ | PET IMAGING, HEART, OTHER RADIONUCLIDE | | | |
| CB32KZ | PET IMAGING, LUNGS & BRONCHI, F-18 | | | |
| CB32YZ | PET IMAGING, LUNG & BRONCHI, OTH RADIONUCLIDE | | | |
| CB3YYZ | PET IMAGING, RESP SYST, OTHER RADIONUCLIDE | | | |
| CW3NYZ | PET IMAGING, WHOLE BODY, OTHER RADIONUCLIDE | | | |
| G0219 | PET imaging whole body; melanoma | | | |
| G0235 | PET not otherwise specified | | | |
| G0252 | PET imaging initial dx | | | |

| CPT, HCPCS or Revenue | LAB Description | Comments/ Limitations |
|--------------------------|---|--|
| Code | | |
| | All genetic testing codes require review and preauthorization. | |
| 81105 | Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P) | |
| 81106 | Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein lb [platelet], alpha polypeptide [GPIba]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M) | |
| 81107 | Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA- 3a/b (I843S) | |
| 81108 | Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q) | |
| 81109 | Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant (eg, HPA-5a/b (K505E)) | |
| 81110 | Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post- transfusion purpura), gene analysis, common variant, HPA-6a/b (R489Q) | |
| 81111 | Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M) | |
| 81112 | Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y) | |
| 81120 | IDH1 (ISOCITRATE DEHYDROGENASE 1 [NADP+], SOLUBLE) (EG, GLIOMA), COMMON VARIANTS (EG, R132H, R132C) | |
| 81121 | IDH2 (ISOCITRATE DEHYDROGENASE 2 [NADP+], MITOCHONDRIAL) (EG, GLIOMA), COMMON VARIANTS (EG, R140W, R172M) | |
| 81161 | DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed | |
| 81162 | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements) | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81163 | BRCA full sequence analysis | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81164 | BRCA full duplication/deletion analysis (ie, detection of large gene rearrangements) | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|--|
| | All genetic testing codes require review and preauthorization. | |
| 81165 | BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81166 | BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements) | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81167 | BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements) | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81170 | ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain | |
| 81171 | AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | |
| 81172 | AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status) | |
| 81173 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status), full gene sequence | |
| 81174 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status), known familial variant | |
| 81175 | ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence | |
| 81176 | ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12) | |
| 81177 | ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81178 | ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81179 | ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81180 | ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81181 | ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81182 | ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81183 | ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|--|
| | All genetic testing codes require review and preauthorization. | |
| 81184 | CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | |
| 81185 | full gene sequence | |
| 81186 | CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant | |
| 81187 | CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81188 | CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | |
| 81189 | MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) (EG, GLIOBLASTOMA MULTIFORME) PROMOTER METHYLATION ANALYSIS | |
| 81190 | CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s) | |
| 81200 | ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X) | |
| 81201 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence | |
| 81202 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants | |
| 81203 | APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants | |
| 81204 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status) | |
| 81205 | BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease) gene analysis, common variants (eg, R183P, G278S, E422X) | |
| 81206 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative | |
| 81207 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative | |
| 81208 | BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative | |
| 81209 | BLM (Bloom syndrome, RecQ helicase-like) (eg, Bloom syndrome) gene analysis, 2281del6ins7 variant | |
| 81210 | BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s) | |
| 81212 | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |
| 81215 | BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations | | |
|----------------------------------|--|--|--|--|
| | All genetic testing codes require review and preauthorization. | | | |
| 81216 | BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 | | |
| 81217 | known familial variant | Effective 1.1.23 Prior Authorization requirements are waived when billed with any of the following diagnosis codes: Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44 | | |
| 81218 | CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence | | | |
| 81219 | CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9 | | | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines) | | | |
| 81221 | known familial variants | | | |
| 81222 | duplication/deletion variants | | | |
| 81223 | full gene sequence | | | |
| 81224 | CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility) | | | |
| 81225 | CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17) | | | |
| 81226 | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN) | | | |
| 81227 | CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6) | | | |
| 81228 | Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis) | | | |
| 81229 | Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities | | | |
| 81230 | CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22) | | | |
| 81231 | CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7) | | | |
| 81232 | DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6) | | | |
| 81233 | BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F) | | | |
| 81234 | DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles | | | |
| 81235 | EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q) | | | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81236 | EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence | |
| 81237 | EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646) | |
| 81238 | F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence | |
| 81239 | DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size) | |
| 81240 | F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoaguLABility) gene analysis, 20210G>A variant | |
| 81241 | F5(Coagulation Factor V) (eg; hereditary hypercoagulability) gene analysis, 20120G>A variant | |
| 81242 | FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis, common variant (eg, IVS4+4A>T) | |
| 81243 | FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | |
| 81244 | FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status) | |
| 81245 | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis | |
| 81246 | FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836) | |
| 81247 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-) | |
| 81248 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s) | |
| 81249 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence | |
| 81250 | G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X) | |
| 81251 | GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A) | |
| 81252 | GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence | |
| 81253 | GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants | |
| 81254 | GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6- D13S1854)]) | |
| 81255 | HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S) | |
| 81256 | HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C282Y, H63D) | |
| 81257 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; common deletions or variant (eg, Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha 20.5, Constant Spring) | |
| 81258 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant | |

| CPT, HCPCS or Revenue | LAB Description | Comments/ Limitations |
|--------------------------|--|-----------------------|
| Code | All genetic testing codes require review and preauthorization. | |
| 81259 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence | |
| 81260 | IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex- associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P) | |
| 81261 | IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction) | |
| 81262 | IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot) | |
| 81263 | IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysis | |
| 81264 | IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) | |
| 81265 | Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells) | |
| 81266 | Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (eg, additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure) | |
| 81267 | Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection | |
| 81268 | with cell selection (eg, CD3, CD33), each cell type | |
| 81269 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants | |
| 81270 | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant | |
| 81271 | HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles | |
| 81272 | KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18) | |
| 81273 | KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s) | |
| 81274 | characterization of alleles (eg, expanded size) | |
| 81275 | KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13) | |
| 81276 | KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146) | |
| 81277 | Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities | |
| 81279 | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13) | Effective 1/1/2021 |
| 81283 | IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant | |
| 81284 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81285 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles; characterization of alleles (eg, expanded size) | |
| 81286 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles; full gene sequence | |
| 81287 | MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) (EG, GLIOBLASTOMA MULTIFORME) PROMOTER METHYLATION ANALYSIS | |
| 81288 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis | |
| 81289 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles: known familial variant(s) | |
| 81290 | MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis, common variants (eg, IVS3- 2A>G, del6.4kb) | |
| 81291 | MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoaguLABility) gene analysis, common variants (eg, 677T, 1298C) | |
| 81292 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | |
| 81293 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | |
| 81294 | MLH1(mutl homolog 1, Colon cancer, nonpolyposis type 2) eg; hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis, full sequence analysis or known familial variants or duplication/deletion variants | |
| 81295 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | |
| 81296 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | |
| 81297 | MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | |
| 81298 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | |
| 81299 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | |
| 81300 | MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | |
| 81301 | Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed | |
| 81302 | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis | |
| 81303 | known familial variant | |
| 81304 | duplication/deletion variants | |
| 81305 | MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant | |
| 81306 | NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant (s) (eg, *2, *3, *4, *5, *6) | |
| 81307 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence | |

| CPT, HCPCS or Revenue | LAB Description | Comments/ Limitations |
|--------------------------|--|-----------------------|
| Code | | commentsy Emitations |
| | All genetic testing codes require review and preauthorization. | |
| 81308 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant | |
| 81309 | PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20) | |
| 81310 | NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants | |
| 81311 | NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61) | |
| 81312 | PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81313 | PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer) | |
| 81314 | PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18) | |
| 81315 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative | |
| 81316 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or quantitative | |
| 81317 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis | |
| 81318 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | |
| 81319 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | |
| 81320 | PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F) | |
| 81321 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis | |
| 81322 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant | |
| 81323 | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant | |
| 81324 | RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy) gene analysis, targeted sequence analysis (eg, exons 3-8) | |
| 81325 | PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis | |
| 81326 | PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant | |
| 81328 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants | |
| 81329 | PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants | |
| 81330 | SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis, common variants (eg, R496L, L302P, fsP330) | |
| 81331 | SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81332 | SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *S and *Z) | |
| 81333 | TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q) | |
| 81334 | RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy) gene analysis, targeted sequence analysis (eg, exons 3-8) | |
| 81335 | TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3) | |
| 81336 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence | |
| 81337 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s) | |
| 81338 | MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; common variants (eg, W515A, W515K, W515L, W515R) | Effective 1/1/2021 |
| 81339 | MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene analysis; sequence analysis, exon 10 | Effective 1/1/2021 |
| 81340 | TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction) | |
| 81341 | TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot) | |
| 81342 | TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) | |
| 81343 | PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81344 | TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles | |
| 81345 | TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region) | |
| 81346 | TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant) | |
| 81347 | SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L) | Effective 1/1/2021 |
| 81348 | SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L) | Effective 1/1/2021 |
| 81349 | Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low- pass sequencing analysis | Effective 1/1/2021 |
| 81350 | UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37) | |
| 81351 | TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence | Effective 1/1/2021 |
| 81352 | TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis (eg, 4 oncology) | Effective 1/1/2021 |
| 81353 | TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant | Effective 1/1/2021 |
| 81355 | VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T) | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81357 | U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P) | Effective 1/1/2021 |
| 81360 | ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs) | Effective 1/1/2021 |
| 81361 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE) | |
| 81362 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s) | |
| 81363 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s) | |
| 81364 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequence | |
| 81370 | HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 | |
| 81371 | HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, and -DRB1 (eg, verification typing) | |
| 81372 | HLA Class I typing, low resolution (eg, antigen equivalents); complete (ie, HLA-A, -B, and -C) | |
| 81373 | HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each | |
| 81374 | HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each | |
| 81375 | HLA Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and -DQB1 | |
| 81376 | HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, - DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each | |
| 81377 | HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each | |
| 81378 | HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and -DRB1 | |
| 81379 | HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and - C) | |
| 81380 | HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each | |
| 81381 | HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each | |
| 81382 | HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, - DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each | |
| 81383 | HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each | |
| 81400 | Molecular pathology procedure, Level 1 | |
| 81401 | Molecular pathology procedure level 2 | |
| 81402 | Molecular pathology procedure level 3 | |
| 81403 | Molecular pathology procedure, Level 4 | |
| 81404 | Molecular pathology procedure, Level 5 | |
| 81405 | Molecular pathology procedure, Level 6 | |
| 81406 | Molecular pathology procedure, Level 7 | |
| 81407 | Molecular pathology procedure, Level 8 | |
| 81408 | Molecular pathology procedure, Level 9 | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81410 | Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK | |
| 81411 | Duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1 | |
| 81412 | Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1 | |
| 81413 | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A | |
| 81414 | Duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1 | |
| 81415 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis | |
| 81416 | sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure) | |
| 81417 | re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome) | |
| 81419 | Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2 | Effective 1/1/2021 |
| 81422 | Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri- du-chat syndrome), circulating cell-free fetal DNA in maternal blood | |
| 81425 | Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis | |
| 81426 | sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure) | |
| 81427 | re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome) | |
| 81430 | Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1 | |
| 81431 | duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes | |
| 81432 | Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53 | |
| 81433 | Duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11 | |
| 81434 | Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 81435 | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11 | |
| 81436 | duplication/deletion analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, and STK11 | |
| 81437 | Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL | |
| 81438 | Duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL | |
| 81439 | Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7, PKP2, TTN) | |
| 81440 | Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP | |
| 81441 | Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2 | Effective 1/1/2023 |
| 81442 | Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1 | |
| 81443 | Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish- associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH) | |
| 81445 | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis | |
| 81448 | Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1) | |
| 81449 | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis | Effective 1/1/2023 |
| 81450 | Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|---|
| | All genetic testing codes require review and preauthorization. | |
| 81451 | Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis | Effective 1/1/2023 |
| 81455 | Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis | Effective 9/1/2020 |
| 81456 | Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis | Effective 1/1/2023 |
| 81457 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability | Effective 1/1/2024 (added on 5/1/24 list |
| 81458 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability | Effective 1/1/2024 (added on 5/1/24 list |
| 81459 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements | Effective 1/1/2024 (added on 5/1/24 list |
| 81460 | Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection | |
| 81462 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements | Effective 1/1/2024 (added on 5/1/24 list |
| 81463 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability | Effective 1/1/2024 (added on 5/1/24 list |
| 81464 | Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements | Effective 1/1/2024 (added on 5/1/24 list |
| 81465 | Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed | |
| 81470 | X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2 | |
| 81471 | duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2 | |
| 81479 | Unlisted molecular pathology procedure | |
| 81490 | Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score | |
| 81493 | Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score | |
| 81500 | Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score | |

| CPT, HCPCS or Revenue | LAB Description | Comments/ Limitations |
|--------------------------|---|--|
| Code | | |
| | All genetic testing codes require review and preauthorization. | |
| | Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 | |
| 81503 | microglobulin, transferrin, and prealbumin), utilizing serum, algorithm reported as a risk score | |
| 81504 | Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores | |
| 81506 | Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score | |
| 81508 | Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score | |
| 81509 | Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score | |
| 81510 | Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score | |
| 81511 | Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing) | |
| 81512 | Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score | |
| 81517 | Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years | Effective 1/1/2024 (added on 5/1/24 list |
| 81518 | Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy | |
| 81520 | Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score | |
| 81522 | Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score | |
| 81523 | Oncology (breast), mRNA, next-generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk to distant metastasis | Effective 1/1/2021 |
| 81525 | Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score | |
| 81529 | Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis | Effective 1/1/2021 |
| 81535 | Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination | |
| 81536 | each additional single drug or drug combination (List separately in addition to code for primary procedure) | |
| 81538 | Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|--|
| | All genetic testing codes require review and preauthorization. | |
| 81539 | Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score | |
| 81540 | Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype | |
| 81541 | Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score | |
| 81542 | Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score | Effective 9/1/2020 |
| 81551 | Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy | |
| 81552 | Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis | |
| 81554 | Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP]) | Effective 1/1/2021 |
| 81595 | Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score | |
| 81596 | Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2- macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver | |
| 81599 | Multianalyte Assays with Algorithmic Analyses | Effective 6/1/2021 |
| 82232 | Beta 2 microglobulin | |
| 83080 | b-hyphenHexosamindase, each assay | |
| 88237 | Cytogenetic Studies | |
| 88271 | Cytogenetic Studies | |
| 88275 | Cytogenetic Studies | |
| 93150 | Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming | Effective 1/1/2024 (added on 5/1/24 list |
| 0012U | Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s) | |
| 0014U | Hematology (hematolymphoid neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood or bone marrow, report of specific gene rearrangement(s) | |
| 0017U | Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12- 14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected | |
| 0018U | Oncology (thyroid) microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as positive or negative result for moderate to high risk of malignancy. (ThyGenx formerly Mirinform Thyroid) | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|------------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0022U | Targeted genomic sequence analysis panele, non-small cell lung neoplasia, DNA & RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants associated | |
| 0023U | Oncology (Acute myelogenous leukemia) DNA, genotyping of internal tandem duplication | |
| 0026U | Oncology (thyroid) DNA & mRNA of 112 genes, next hyphengeneration sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as categorical result (Positive, high probability of malignancy or negative, low probability of malignancy | |
| 0027U | JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15 | |
| 0033U | Proprietary Laboratory Analyses | Effective 1/1/2021 |
| 0037U | FoundationOne Proprietary Lab Analyses | Effective 8/1/21 |
| 0049U | NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative | |
| 0050U | Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements | |
| 0056U | Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s) | |
| 0060U | Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell- free fetal DNA in maternal blood | |
| 0070U | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN) | |
| 0090U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant) | Effective June 1, 2021 |
| 0111U | Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue | |
| 0113U | Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score | |
| 0120U | Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter | |
| 0129U | Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53) | |
| 0130U | Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure) | |
| 0131U | Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) | |
| 0132U | Hereditary ovarian cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure) | |

| CPT, HCPCS or Revenue | LAB Description | Comments/ Limitations |
|--------------------------|--|-----------------------|
| Code | | |
| | All genetic testing codes require review and preauthorization. | |
| 0133U | Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure) | |
| 0134U | Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure) | |
| 0135U | Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) | |
| 0136U | ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0137U | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0138U | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0154U | FGFR3 (fibroblast growth factor receptor 3) gene analysis | |
| 0155U | PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis | |
| 0156U | Copy number (eg, intellectual disability, dysmorphology), sequence analysis | |
| 0157U | APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0158U | MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0159U | MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0160U | MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0161U | PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) | |
| 0162U | Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure) | |
| 0173U | Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes | |
| 0174U | Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin- embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents | |
| 0175U | Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes | |
| 0177U | Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status | |
| 0179U | Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s) | |
| 0180U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N- acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons | |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0181U | Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1 | |
| 0182U | Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10 | |
| 0183U | Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19 | |
| 0184U | Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP- ribosyltransferase 4 [Dombrock blood group]) exon 2 | |
| 0185U | Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4 | |
| 0186U | Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2 | |
| 0187U | Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2 | |
| 0188U | Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4 | |
| 0189U | Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2 | |
| 0190U | Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3 | |
| 0191U | Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6 | |
| 0192U | Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9 | |
| 0193U | Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26 | |
| 0194U | Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo- endopeptidase [Kell blood group]) exon 8 | |
| 0195U | KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13) | |
| 0196U | Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3 | |
| 0197U | Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1 | |
| 0198U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5 | |
| 0199U | Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12 | |
| 0200U | Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3 | |
| 0201U | Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 | |
| 0203U | Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness | Effective 1/1/2021 |
| 0204U | Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected | Effective 1/1/2021 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0205U | Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements | Effective 1/1/2021 |
| 0206U | Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease | Effective 1/1/2021 |
| 0207U | quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) | Effective 1/1/2021 |
| 0208U | Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma | Effective 1/1/2021 |
| 0209U | Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities | Effective 1/1/2021 |
| 0211U | Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association | Effective 1/1/2021 |
| 0212U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband | Effective 1/1/2021 |
| 0213U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling) | Effective 1/1/2021 |
| 0214U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband | Effective 1/1/2021 |
| 0215U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling) | Effective 1/1/2021 |
| 0216U | Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Effective 1/1/2021 |
| 0217U | Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants | Effective 1/1/2021 |
| 0218U | Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants | Effective 1/1/2021 |
| 0219U | Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility | Effective 1/1/2021 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0220U | Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score | Effective 1/1/2021 |
| 0221U | Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene | Effective 1/1/2021 |
| 0222U | Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next- generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3 | Effective 1/1/2021 |
| 0242U | Targeted Genomic Sequence Analysis Panel, Solid Organ Neoplasm, Cell-Free Circulating Dna Analysis Of 55-74 Genes, Interrogation For Sequence Variants, Gene Copy Number Amplifications, And Gene Rearrangements | Effective 4/1/2021 |
| 0244U | Oncology (Solid Organ), Dna, Comprehensive Genomic Profiling, 257 Genes, Interrogation For Single-Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, Gene Rearrangements, Tumor-Mutational Burden And Microsatellite Instability, Utilizing Formalin- Fixed Paraffin-Embedded Tumor Tissue | Effective 4/1/2021 |
| 0245U | Oncology (Thyroid), Mutation Analysis Of 10 Genes And 37 Rna Fusions And Expression Of 4 Mrna Markers Using Next-Generation Sequencing, Fine Needle Aspirate, Report Includes Associated Risk Of Malignancy Expressed As A Percentage | Effective 4/1/2021 |
| 0246U | Red Blood Cell Antigen Typing, Dna, Genotyping Of At Least 16 Blood Groups With Phenotype Prediction Of At Least 51 Red Blood Cell Antigens | Effective 4/1/2021 |
| 0250U | Oncology (Solid Organ Neoplasm), Targeted Genomic Sequence Dna Analysis Of 505 Genes, Interrogation For Somatic Alterations (Snvs [Single Nucleotide Variant], Small Insertions And Deletions, One Amplification, And Four Translocations), Microsatellite Instability And Tumor- Mutation Burden | Effective 9/1/21 |
| 0257U | Very long chain acyl-coenzyme A (CoA) dehydrogenase (VLCAD), leukocyte enzyme activity, whole blood | Effective 1/1/2022 |
| 0258U | Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50- 100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics | Effective 1/1/2022 |
| 0260U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping | Effective 1/1/2022 |
| 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score | Effective 1/1/2022 |
| 0264U | Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping | Effective 1/1/2022 |
| 0265U | Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants | Effective 1/1/2022 |
| 0266U | Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes | Effective 1/1/2022 |
| 0267U | Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing | Effective 1/1/2022 |
| 0268U | Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0269U | Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0270U | Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0271U | Hematology (congenital neutropenia), genomic sequence analysis of 24 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0272U | Hematology (genetic bleeding disorders), genomic sequence analysis of 60 genes, blood, buccal swab, or amniotic fluid, comprehensive | Effective 1/1/2022 |
| 0273U | Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAU), blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0274U | Hematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0275U | Hematology (heparin-induced thrombocytopenia), platelet antibody reactivity by flow cytometry, serum | Effective 1/1/2022 |
| 0276U | Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0277U | Hematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0278U | Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid | Effective 1/1/2022 |
| 0282U | Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes | Effective 1/1/2022 |
| 0285U | Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score | Effective 1/1/2022 |
| 0286U | CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S- methyltransferase) (eg, drug metabolism) gene analysis, common variants | Effective 1/1/2022 |
| 0287U | Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) | Effective 1/1/2022 |
| 0288U | Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score | Effective 1/1/2022 |
| 0289U | Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |
| 0290U | Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |
| 0291U | Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |
| 0292U | Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |
| 0293U | Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |
| 0294U | Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0295U | Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score | Effective 1/1/2022 |
| 0296U | Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy | Effective 1/1/2022 |
| 0297U | Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification | Effective 1/1/2022 |
| 0298U | Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification | Effective 1/1/2022 |
| 0299U | Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification | Effective 1/1/2022 |
| 0300U | Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification | Effective 1/1/2022 |
| 0301U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); | Effective 1/1/2022 |
| 0302U | Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enrichment | Effective 1/1/2022 |
| 0303U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic | Effective 1/1/2022 |
| 0304U | Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic | Effective 1/1/2022 |
| 0305U | Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index | Effective 1/1/2022 |
| 0306U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD | Effective 1/1/2022 |
| 0307U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD | Effective 1/1/2022 |
| 0308U | Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD | Effective 1/1/2022 |
| 0309U | Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event | Effective 1/1/2022 |
| 0310U | Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NTproBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD | Effective 1/1/2022 |
| 0311U | Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified | Effective 1/1/2022 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0312U | Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment | Effective 1/1/2022 |
| 0313U | Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia) | Effective 1/1/2022 |
| 0314U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) | Effective 1/1/2022 |
| 0315U | Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B) | Effective 1/1/2022 |
| 0316U | Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine | Effective 1/1/2022 |
| 0317U | Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithmgenerated evaluation reported as decreased or increased risk for lung cancer | Effective 1/1/2022 |
| 0318U | Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood | Effective 1/1/2022 |
| 0319U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection | Effective 1/1/2022 |
| 0320U | Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection | Effective 1/1/2022 |
| 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique | Effective 1/1/2022 |
| 0322U | Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD | Effective 1/1/2022 |
| 0323U | Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi | Effective 7/1/2022 |
| 0326U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | Effective 7/1/2022 |
| 0328U | Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service | Effective 7/1/2022 |
| 0329U | Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations | Effective 7/1/2022 |
| 0330U | Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab | Effective 7/1/2022 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| | All genetic testing codes require review and preauthorization. | |
| 0331U | Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations | Effective 7/1/2022 |
| 0332U | Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint–inhibitor therapy | Effective 10/1/2022 |
| 0333U | Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result | Effective 10/1/2022 |
| 0334U | Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin- embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden | Effective 10/1/2022 |
| 0335U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants | Effective 10/1/2022 |
| 0336U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent) | Effective 10/1/2022 |
| 0337U | Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood | Effective 10/1/2022 |
| 0338U | Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker– expressing cells, peripheral blood | Effective 10/1/2022 |
| 0339U | Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer | Effective 10/1/2022 |
| 0340U | Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate | Effective 10/1/2022 |
| 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline | Effective 10/1/2022 |
| 0343U | Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer | Effective 10/1/2022 |
| 0344U | Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH | Effective 10/1/2022 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|--|---|
| | All genetic testing codes require review and preauthorization. | |
| 0346U | Beta amyloid, A?40 and A?42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma | Effective 10/1/2022 |
| 0364U | Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate | Effective 10/1/2023 |
| 0387U | Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression | Effective 10/1/2023 |
| 0388U | Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection | Effective 10/1/2023 |
| 0389U | Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD | Effective 10/1/2023 |
| 0397U | Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations | Effective 10/1/2023. Retired code as of 10/1/23 |
| 0399U | Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG- binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected | Effective 10/1/2023 |
| 0401U | Cardiology (coronary heart disease [CAD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event | Effective 10/1/2023 |
| 0404U | Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression | Effective 1/1/2024 |
| 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected | Effective 1/1/2024 |
| 0406U | Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer | Effective 1/1/2024 |
| 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function | Effective 1/1/2024 |
| 0409U | Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability | Effective 1/1/2024 |
| 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected | Effective 1/1/2024 |
| 0412U | Beta amyloid, A β 42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology | Effective 1/1/2024 |
| 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations | Effective 1/1/2024 |

| CPT, HCPCS or Revenue Code | LAB Description | Comments/ Limitations |
|----------------------------------|---|---|
| | All genetic testing codes require review and preauthorization. | |
| 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker | Effective 1/1/2024 |
| 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants | Effective 1/1/2024 |
| 0418U | Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score | Effective 1/1/2024 |
| 0439U | Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms | Effective 4/1/2024 (added on 5/1/24 list |
| 0440U | Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms | Effective 4/1/2024 (added on 5/1/24 list |
| 0444U | Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes | Effective 4/1/2024 (added on 5/1/24 list |
| 0448U | Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions | Effective 4/1/2024 (added on 5/1/24 list |
| 0449U | Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia) | Effective 4/1/2024 (added on 5/1/24 list |
| S3840 | DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2 | |
| S3841 | Genetic testing for retinoblastoma | |
| S3842 | Genetic testing for von Hippel-Lindau disease | |
| S3844 | DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness | |
| S3845 | Genetic testing for alpha-thalassemia | |
| S3846 | Genetic testing for hemoglobin E beta-thalassemia | |
| S3849 | Genetic testing for Niemann-Pick Disease | |
| S3850 | Genetic testing for sickle cell anemia | |
| S3853 | Genetic testing for myotonic muscular dystrophy | |
| S3866 | Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|--|
| A6521 | Gradient compression garment, glove, padded, for nighttime use, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6523 | Gradient compression garment, arm, padded, for nighttime use, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6525 | Gradient compression garment, lower leg and foot, padded, for nighttime use, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6527 | Gradient compression garment, full leg and foot, padded, for nighttime use, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6529 | Gradient compression garment, bra, for nighttime use, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6555 | Gradient compression stocking, below knee, 40 mmhg or greater, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6556 | Gradient compression stocking, thigh length, 18-30 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6557 | Gradient compression stocking, thigh length, 30-40 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6558 | Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6559 | Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6560 | Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6561 | Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6562 | Gradient compression stocking, waist length, 18-30 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6563 | Gradient compression stocking, waist length, 30-40 mmhg, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6564 | Gradient compression stocking, waist length, 40 mmhg or greater, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6565 | Gradient compression gauntlet, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6567 | Gradient compression garment, neck/head, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6569 | Gradient compression garment, torso/shoulder, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6571 | Gradient compression garment, genital region, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6573 | Gradient compression garment, toe caps, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6574 | Gradient compression arm sleeve and glove combination, custom, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6576 | Gradient compression arm sleeve, custom, medium weight, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6577 | Gradient compression arm sleeve, custom, heavy weight, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6579 | Gradient compression glove, custom, medium weight, each | Effective 1/1/24 (Added on 5/1/24 list) |
| A6580 | Gradient compression glove, custom, heavy weight, each | 5/1/24 list) Effective 1/1/24 (Added on 5/1/24 list) |
| B4105 | Digestive enzyme cartridge | Effective 9/1/2022 |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|---|
| C1831 | Custom cage for spine | Effective 1/1/2022 |
| C1832 | Autograft suspension, including cell processing and application, and all system components | Effective 9/1/2022 |
| C1833 | Monitor, cardiac, including intracardiac lead and all system components (implantable) | Effective 9/1/2022 |
| C9781 | Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed | Effective 9/1/2022 |
| E0194 | Air fluidized bed | |
| E0277 | Powered -pressure reducing air mattress | Effective 9/1/2020 |
| E0465 | Home ventilator, any type, used with invasive interface, (e.g., tracheostomy tube) | |
| E0466 | Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell) | |
| E0467 | Home ventilator, multi-function respiratory device | Effective 8/1/24 |
| E0468 | Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions | Effective 4/1/24 (added on 5/1/24 list) |
| E0482 | Cough stimulating device, alternating positive and negative airway pressure E0482. | Effective 8/1/24 |
| E0483 | High frequency chest wall oscillation system, includes all accessories and supplies, each | |
| E0486 | Oral device used to reduce upper airway | Effective 9/1/2020 |
| E0630 | Patient Lift - Hydraulic | Effective 9/1/2020 |
| E0638 | Standing frame/table system one position | Effective 9/1/2020 |
| E0652 | Pneumatic compressor, segmental home model with calibrated gradient pressure | |
| E0670 | Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk | |
| E0747 | Osteogenesis stimulator, electrical, non-invasive, other than spinal applications | |
| E0748 | Osteogenesis stimulator, electrical, non-invasive, spinal applications | |
| E0760 | osteogenesis stimulator, low intensity ultrasound, non-invasive | |
| E0764 | Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program | |
| E0766 | electrical stimulation device for cancer treatment | Effective 5/19/2020 |
| E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | |
| E0986 | Manual wheelchair accessory, push activated power assist | Effective 9/1/2020 |
| E1002 | Wheelchair accessory, power seating system | Effective 9/1/2020 |
| E1007 | Wheelchair accessory, power seating system | Effective 9/1/2020 |
| E1220 | Wheelchair, special size or construction | Effective 9/1/2020 |
| E1230 | Power operated vehicle (three or four wheel non highway) specify brand name and model number | |
| E1232 | Wheelchair, pediatric size, tilt in space, folding | Effective 9/1/2020 |
| E1234 | Wheelchair, pediatric size, | Effective 9/1/2020 |
| E1235 | Wheelchair, pediatric size | Effective 9/1/2020 |
| E1236 | Wheelchair pediatric size | Effective 9/1/2020 |
| E2102 | Adjunctive, non-implanted continuous glucose monitor or receiver | Effective 10/1/2023 |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| E2103 | Non-adjunctive, non-implanted continuous glucose monitor or receiver as maintained by CMS falls under Miscellaneous Pumps and Monitors . | Effective 10/1/2023 |
| E2311 | Power wheelchair accessory | Effective 9/1/2020 |
| E2368 | Power wheelchair component, motor, replacement only | |
| E2369 | Power wheelchair component, gearbox, replacement only | |
| E2370 | Power wheelchair component, motor and gearbox combination, replacement only | |
| E2502 | Speech generating device, digitized speech, using pre-recorded messages, greater than 8 minutes but less than or equal to 20 minutes recording time | |
| E2504 | Speech generating device, digitized speech, using pre-recorded messages, greater than 20 minutes but less than or equal to 40 minutes recording time | |
| E2506 | Speech generating device, digitized speech, using pre-recorded messages, greater than 40 minutes recording time | |
| E2508 | Speech generating device, synthesized speech, requiring message formulation by spelling and access by physical contact with the device | |
| E2510 | Speech generating device, synthesized speech, permitting multiple methods of message formulation and multiple methods of device access | |
| E2609 | Custom fabricated wheelchair seat cushion | Effective 9/1/2020 |
| E2627 | Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable rancho type | |
| E2629 | Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, friction arm support (friction dampening to proximal and distal joints) | |
| K0005 | Ultra Lightweight wheelchair | |
| K0006 | Heavy-duty wheelchair | |
| K0009 | Other manual wheelchair/base | Effective 9/1/2020 |
| K0606 | Automatic external defibrillator, with integrated electrocardiogram analysis, garment type | |
| K0609 | Replacement electrodes for use with automated external defibrillator, garment type only, each | |
| K0800 | Power operated vehicle, group 1 standard, patient weight capacity up to and including 300 pounds | |
| K0801 | Power operated vehicle, group 1 heavy duty, patient weight capacity, 301 to 450 pounds | |
| K0802 | Power operated vehicle, group 1 heavy duty, patient weight capacity 451 to 600 pounds | |
| K0806 | Powered operated vehicle, group 2 standard, patient weight capacity up to and including 300 pounds | |
| K0807 | K0807: Power operated vehicle, group 2 heavy duty, patient weight capacity 301 to 450 pounds | |
| K0808 | K0808: Power operated vehicle, group 2 very heavy duty, patient weight capacity 451 to 600 pounds | |
| K0812 | Power operated vehicle, not otherwise classified | |
| K0813 | Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds | |
| K0814 | Power wheelchair, group 1 standard, portable, captain's chair, patient weight capacity up to and including 300 pounds | |
| K0815 | Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds | |
| K0816 | Power wheelchair, group 1 standard, captain's chair, patient weight capacity up to and including 300 pounds | |
| K0820 | Power wheelchair, group 2 standard, portable, sling/solid seat/back, patient weight capacity up to and including 300 pounds | |

| CPT, HCPCS | | |
|--------------------|--|-----------------------|
| or Revenue Code | DME Description | Comments/ Limitations |
| K0821 | Power wheelchair, group 2 standard, portable, captain's chair, patient weight capacity up to | |
| ROOLI | and including 300 pounds | |
| K0822 | Power wheelchair, group 2 standard, sling/solid seat/back, patient weight capacity up to and | |
| | including 300 pounds | |
| K0823 | Power wheelchair, group 2 standard, captain's chair, patient weight capacity up to and | |
| | including 300 pounds | |
| K0824 | Power wheelchair, group 2 heavy duty, sling/solid seat and back, patient weight capacity 301 | |
| 100005 | to 450 pounds | |
| K0825 | Power wheelchair, group 2 heavy duty, captain's chair, patient weight capacity 301 to 450 pounds | |
| K0826 | Power wheelchair, group 2 very heavy duty, sling/solid seat/back, patient weight capacity | |
| 10020 | 451 to 600 pounds | |
| K0827 | Power wheelchair, group 2 very heavy duty, captain's chair, patient weight capacity 451 to | |
| | 600 pounds | |
| K0828 | Power wheelchair, group 2 extra very heavy duty, sling/solid seat/back, patient weight | |
| | capacity 601 pounds or more | |
| K0829 | Power wheelchair, group 2 extra heavy duty, captain's chair, patient weight capacity 601 | |
| | pounds or more | |
| K0835 | Power wheelchair, group 2 standard, single power option, sling/solid seat/back, patient | |
| K0836 | weight capacity up to and including 300 pounds Power wheelchair, group 2 standard, single power option, captain's chair, patient weight | |
| 10050 | capacity up to and including 300 pounds | |
| K0837 | Power wheelchair, group 2 heavy duty, single power option, sling/solid seat/back, patient | |
| | weight capacity 301 to 450 pounds | |
| K0838 | Power wheelchair, group 2 heavy duty, single power option, captain's chair, patient weight | |
| | capacity 301 to 450 pounds | |
| K0839 | Power wheelchair, group 2 very heavy duty, single power option, sling/solid seat/back, | |
| | patient weight capacity 451 to 600 pounds | |
| K0840 | Power wheelchair, group 2 very heavy duty, single power option, sling/solid seat/back, | |
| K0841 | patient weight capacity 601 pounds or more Power wheelchair, group 2 standard, multiple power option, sling/solid seat/back, patient | |
| 10041 | weight capacity up to and including 300 pounds | |
| K0842 | Power wheelchair, group 2 standard, multiple power option, captain's chair, patient weight | |
| | capacity up to and including 300 pounds | |
| K0843 | Power wheelchair, group 2 heavy duty, multiple power option, sling/solid seat/back, patient | |
| - | weight capacity 301 to 450 pounds | |
| K0848 | Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and | |
| K0040 | including 300 pounds | |
| K0849 | Power wheelchair, group 3 standard, captain's chair, patient weight capacity up to and including 300 pounds | |
| K0850 | Power wheelchair, group 3 heavy duty, sling/solid seat/back, patient weight capacity 301 to | |
| 1.0050 | 450 pounds | |
| K0851 | Power wheelchair, group 3 heavy duty, captain's chair, patient weight capacity 301 to 450 | |
| | pounds | |
| K0852 | Power wheelchair, group 3 very heavy duty, sling/solid seat/back, patient weight capacity | |
| | 451 to 600 pounds | |
| K0853 | Power wheelchair, group 3 very heavy duty, captains chair, patient weight capacity 451 to | |
| K0054 | 600 pounds | |
| K0854 | Power wheelchair, group 3 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more | |
| | out bounds of more | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|--|
| K0855 | Power wheelchair, group 3 extra heavy duty, captains chair, patient weight capacity 601 | |
| K0033 | pounds or more | |
| K0856 | Power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient | |
| | weight capacity up to and including 300 pounds | |
| K0857 | Power wheelchair, group 3 standard, single power option, captain's chair, patient weight | |
| | capacity up to and including 300 pounds | |
| K0858 | Power wheelchair, group 3 heavy duty, single power option, sling/solid seat/back, patient | |
| | weight 301 to 450 pounds | |
| K0859 | Power wheelchair, group 3 heavy duty, single power option, captain's chair, patient weight | |
| | capacity 301 to 450 pounds | |
| K0860 | Power wheelchair, group 3 very heavy duty, single power option, sling/solid seat/back, | |
| | patient weight capacity 451 to 600 pounds | |
| K0861 | Power wheelchair, group 3 standard, multiple power option, sling/solid seat/back, patient | |
| | weight capacity up to and including 300 pounds | |
| K0862 | Power wheelchair, group 3 heavy duty, multiple power option, sling/solid seat/back, patient | |
| | weight capacity 301 to 450 pounds | |
| K0863 | Power wheelchair, group 3 very heavy duty, multiple power option, sling/solid seat/back, | |
| | patient weight capacity 451 to 600 pounds | |
| K0864 | Power wheelchair, group 3 extra heavy duty, multiple power option, sling/solid seat/back, | |
| | patient weight capacity 601 pounds or more | |
| K0868 | Power wheelchair, group 4 standard, sling/solid seat/back, patient weight capacity up to and | |
| | including 300 pounds | |
| K0869 | Power wheelchair, group 4 standard, captain's chair, patient weight capacity up to and | |
| | including 300 pounds | |
| K0870 | Power wheelchair, group 4 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds | |
| K0871 | Power wheelchair, group 4 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds | |
| K0877 | Power wheelchair, group 4 standard, single power option, sling/solid seat/back, patient | |
| 10077 | weight capacity up to and including 300 pounds | |
| K0878 | Power wheelchair, group 4 standard, single power option, captain's chair, patient weight | |
| 10070 | capacity up to and including 300 pounds | |
| K0879 | Power wheelchair, group 4 heavy duty, single power option, sling/solid seat/back, patient | |
| 110070 | weight capacity 301 to 450 pounds | |
| K0880 | Power wheelchair, group 4 very heavy duty, single power option, sling/solid seat/back, | |
| | patient weight capacity 451 to 600 pounds | |
| K0884 | Power wheelchair, group 4 standard, multiple power option, sling/solid seat/back, patient | |
| - | weight capacity up to and including 300 pounds | |
| K0885 | Power wheelchair, group 4 standard, multiple power option, captain's chair, patient weight | |
| | capacity up to and including 300 pounds | |
| K0886 | Power wheelchair, group 4 heavy duty, multiple power option, sling/solid seat/back, patient | |
| | weight capacity 301 to 450 pounds | |
| K0890 | Power wheelchair, group 5 pediatric, single power option, sling/solid seat/back, patient | |
| | weight capacity up to and including 125 pounds | |
| K0891 | Power wheelchair, group 5 pediatric, multiple power option, sling/solid seat/back, patient | |
| | weight capacity up to and including 125 pounds | |
| K0898 | Power wheelchair, not otherwise classified | |
| K0899 | Power mobility device, not coded by DME PDAC or does not meet criteria | |
| K1022 | Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type | Effective 1/1/2022. Retired Code as of 1/1/24 |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L0112 | Cranial cervical orthosis, congenital torticollis type, with or without soft interface material, adjustable range of motion joint, custom fabricated | |
| L0456 | Thoracic-lumbar-sacral orthosis (TLSO), flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L0457 | Thoracic-lumbar-sacral orthosis (TLSO), flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated, off-the-shelf | |
| L0458 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment | |
| L0460 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L0462 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, modular segmented spinal system, three rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment | |
| L0464 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, modular segmented spinal system, four rigid plastic shells, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment | |
| L0480 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, one piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated | |
| L0482 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, one piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L0484 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, two piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD- CAM model, custom fabricated | |
| L0486 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated | |
| L0488 | Thoracic-lumbar-sacral orthosis (TLSO), triplanar control, one piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, prefabricated, includes fitting and adjustment | |
| L0631 | Lumbar-sacral orthosis (LSO), sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to T-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L0635 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, lumbar flexion, rigid posterior frame/panel(s), lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to T-9 vertebra, lateral strength provided by rigid lateral frame/panel (s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, prefabricated, includes fitting and adjustment | |
| L0636 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, lumbar flexion, rigid posterior frame/panels, lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to T-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, custom fabricated | |
| L0637 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to T-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L0638 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to T-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, custom fabricated | |
| L0639 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to T-9 vertebra, anterior extends from symphysis pubis to xiphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| L0640 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, rigid shell(s)/panel(s), posterior | |
| | extends from sacrococcygeal junction to T-9 vertebra, anterior extends from symphysis pubis | |
| | to xiphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall | |
| | strength is provided by overlapping rigid material and stabilizing closures, includes straps, | |
| 10640 | closures, may include soft interface, pendulous abdomen design, custom fabricated | |
| L0648 | Lumbar-sacral orthosis (LSO), sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to T-9 vertebra, produces intracavitary | |
| | pressure to reduce load on the intervertebral discs, includes straps, closures, may include | |
| | padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | |
| L0650 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, with rigid anterior and posterior | |
| | frame/panel(s), posterior extends from sacrococcygeal junction to T-9 vertebra, lateral | |
| | strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce | |
| | load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, | |
| | pendulous abdomen design, prefabricated, off-the-shelf | |
| L0651 | Lumbar-sacral orthosis (LSO), sagittal-coronal control, rigid shell(s)/panel(s), posterior | |
| | extends from sacrococcygeal junction to T-9 vertebra, anterior extends from symphysis pubis | |
| | to xiphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall | |
| | strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf | |
| L0700 | Cervical-thoracic-lumbar-sacral-orthoses (CTLSO), anterior-posterior-lateral control, molded | |
| 20700 | to patient model (Minerva type) | |
| L0710 | Cervical-thoracic-lumbar-sacral-orthoses (CTLSO), anterior-posterior-lateral-control, molded | |
| | to patient model, with interface material (Minerva type) | |
| L1000 | Cervical-thoracic-lumbar-sacral orthosis (CTLSO) (Milwaukee), inclusive of furnishing initial | |
| | orthosis, including model | |
| L1005 | Tension based scoliosis orthosis and accessory pads, includes fitting and adjustment | |
| L1200 | Thoracic-lumbar-sacral-orthosis (TLSO), inclusive of furnishing initial orthosis only | |
| L1300 | Other scoliosis procedure, body jacket molded to patient model | |
| L1310 | Other scoliosis procedure, postoperative body jacket | |
| L1680 | Hip orthosis (HO), abduction control of hip joints, dynamic, pelvic control, adjustable hip | |
| | motion control, thigh cuffs (Rancho hip action type), custom fabricated | |
| L1681 | Hip orthosis (HO), bilateral hip joints and thigh cuffs, adjustable flexion, extension, abduction | Effective 1/1/24 |
| | control of hip joint, postoperative hip abduction type, prefabricated item that has been | |
| | trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L1685 | Hip orthosis (HO), abduction control of hip joint, postoperative hip abduction type, custom | |
| 21005 | fabricated | |
| L1686 | Hip orthosis (HO), abduction control of hip joint, postoperative hip abduction type, | |
| | prefabricated, includes fitting and adjustment | |
| L1690 | Combination, bilateral, lumbo-sacral, hip, femur orthosis providing adduction and internal | |
| 14700 | rotation control, prefabricated, includes fitting and adjustment | |
| L1700 | Legg-perthes orthosis, (Toronto type), custom-fabricated | |
| L1710 | Legg-perthes orthosis, (Newington type), custom fabricated | |
| L1720 | Legg-perthes orthosis, trilateral, (Tachdijan type), custom-fabricated | |
| L1730 | Legg-perthes orthosis, (Scottish Rite type), custom-fabricated | |
| L1755 | Legg-perthes orthosis, (Patten bottom type), custom-fabricated | |
| L1834 | Knee orthosis, without knee joint, rigid, custom-fabricated | |
| L1840 | Knee orthosis (KO), derotation, medial-lateral, anterior cruciate ligament, custom fabricated | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L1843 | Knee orthosis (KO), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L1844 | Knee orthosis (KO), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, custom fabricated | |
| L1845 | Knee orthosis (KO), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | |
| L1846 | Knee orthosis (KO), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, custom fabricated | |
| L1851 | Knee orthosis (ko), single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf | |
| L1852 | Knee orthosis (ko), double upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated, off-the-shelf | |
| L1860 | Knee orthosis (KO), modification of supracondylar prosthetic socket, custom-fabricated (SK) | |
| L1920 | Ankle foot orthosis, single upright with static or adjustable stop (Phelps or Perlstein type), custom-fabricated | |
| L1930 | prefabricated - Ankle foot orthosis, plastic or other material, prefabricated, includes fitting and adjustment | |
| L1932 | Ankle foot orthosis (AFO), rigid anterior tibial section, total carbon fiber or equal material, prefabricated, includes fitting and adjustment | |
| L1940 | Ankle foot orthosis, plastic or other material, custom-fabricated | |
| L1945 | Ankle foot orthosis (AFO), plastic, rigid anterior tibial section (floor reaction), custom- fabricated | |
| L1950 | Ankle foot orthosis, spiral, (institute of rehabilitative medicine type), plastic, custom- fabricated | |
| L1951 | Ankle foot orthosis, spiral, (Institute of Rehabilitative Medicine type), plastic or other material, prefabricated, includes fitting and adjustment | |
| L1960 | Ankle foot orthosis, posterior solid ankle, plastic, custom-fabricated | |
| L1970 | Ankle foot orthosis, plastic with ankle joint, custom-fabricated | |
| L1971 | Ankle foot orthosis, single upright free plantar dorsiflexion, solid stirrup, calf band/cuff (single bar 'BK' orthosis), custom-fabricated | |
| L1980 | Ankle foot orthosis, double upright free plantar dorsiflexion, solid stirrup, calf band/cuff (double bar 'BK' orthosis), custom-fabricated Ankle foot orthosis, double upright free plantar dorsiflexion, solid stirrup, calf band/cuff (double bar 'BK' orthosis), custom-fabricated | |
| L1990 | Knee ankle foot orthosis, single upright, free knee, free ankle, solid stirrup, thigh and calf bands/cuffs (single bar 'AK' orthosis), custom-fabricated | |
| L2000 | Knee ankle foot orthosis (KAFO), single upright, free knee, free ankle, solid stirrup, thigh and calf bands/cuffs (single bar 'AK' orthosis), custom-fabricated | |
| L2005 | Knee ankle foot orthosis (KAFO), any material, single or double upright, stance control, automatic lock and swing phase release, any type activation, includes ankle joint, any type, custom fabricated | |
| L2010 | Knee ankle foot orthosis (KAFO), single upright, free ankle, solid stirrup, thigh and calf bands/cuffs (single bar 'AK' orthosis), without knee joint, custom-fabricated | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| L2020 | Knee ankle foot orthosis (KAFO), double upright, free ankle, solid stirrup, thigh and calf | |
| 12020 | bands/cuffs (double bar 'AK' orthosis), custom-fabricated | |
| L2030 | Knee ankle foot orthosis (KAFO), double upright, free ankle, solid stirrup, thigh and calf | |
| | bands/cuffs, (double bar 'AK' orthosis), without knee joint, custom fabricated | |
| L2034 | Knee ankle foot orthosis (KAFO), full plastic, single upright, with or without free motion knee, | |
| | medial lateral rotation control, with or without free motion ankle, custom fabricated | |
| L2035 | Knee ankle foot orthosis, full plastic, static (pediatric size), without free motion ankle, prefabricated, includes fitting and adjustment | |
| L2036 | Knee ankle foot orthosis, full plastic, double upright, with or without free motion knee, with or without free motion ankle, custom fabricated | |
| L2037 | Knee ankle foot orthosis (KAFO), full plastic, single upright, with or without free motion knee, with or without free motion ankle, custom fabricated | |
| L2038 | Knee ankle foot orthosis (KAFO), full plastic, with or without free motion knee, multi-axis ankle, custom fabricated | |
| L2108 | Ankle foot orthosis (AFO), fracture orthosis, tibial fracture cast orthosis, custom-fabricated | |
| L2126 | Knee ankle foot orthosis (KAFO), fracture orthosis, femoral fracture cast orthosis, thermoplastic type casting material, custom-fabricated | |
| L2128 | Knee ankle foot orthosis(KAFO), fracture orthosis, femoral fracture cast orthosis, custom- fabricated | |
| L2134 | Knee ankle foot orthosis(KAFO), fracture orthosis, femoral fracture cast orthosis, semi-rigid, prefabricated, includes fitting and adjustment | |
| L2136 | Knee ankle foot orthosis(KAFO), fracture orthosis, femoral fracture cast orthosis, rigid, prefabricated, includes fitting and adjustment | |
| L2232 | Addition to lower extremity orthosis, rocker bottom for total contact ankle foot orthosis, for custom fabricated orthosis only | |
| L2320 | Addition to lower extremity, non-molded lacer, for custom fabricated orthosis only | |
| L2330 | Addition to lower extremity, lacer molded to patient model, for custom fabricated orthosis only | |
| L2350 | Addition to lower extremity, prosthetic type, (BK) socket, molded to patient model, (used for 'PTB' 'AFO' orthoses) | |
| L2387 | Addition to lower extremity, polycentric knee joint, for custom fabricated knee ankle foot orthosis, each joint | |
| L2520 | Addition to lower extremity, thigh/weight bearing, quadrilateral brim, custom fitted | |
| L2525 | Addition to lower extremity, thigh/weight bearing, ischial containment/narrow M-L brim molded to patient model | |
| L2627 | Addition to lower extremity, pelvic control, plastic, molded to patient model, reciprocating hip joint and cables | |
| L2628 | Addition to lower extremity, pelvic control, metal frame, reciprocating hip joint and cables | |
| L2800 | Addition to lower extremity orthosis, knee control, knee cap, medial or lateral pull, for use with custom fabricated orthosis only | |
| L3674 | Shoulder orthosis (SO), abduction positioning (airplane design), thoracic component and support bar, with or without nontorsion joint/turnbuckle, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3720 | Elbow orthosis | Effective 7/1/2020 |
| L3730 | Elbow orthosis (EO), double upright with forearm/arm cuffs, extension/ flexion assist, custom-fabricated | |
| L3740 | Elbow orthosis (EO), double upright with forearm/arm cuffs, adjustable position lock with active control, custom-fabricated | |
| L3765 | Elbow wrist hand finger orthosis (EWHFO), rigid, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| L3766 | Elbow wrist hand finger orthosis (EWHFO), includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3891 | Addition to upper extremity joint | Effective 7/1/2020 |
| L3900 | Wrist hand finger orthosis (WHFO), dynamic flexor hinge, reciprocal wrist extension/ flexion, finger flexion/extension, wrist or finger driven, custom-fabricated | |
| L3901 | Wrist hand finger orthosis (WHFO), dynamic flexor hinge, reciprocal wrist extension/ flexion, finger flexion/extension, cable driven, custom-fabricated | |
| L3904 | Wrist hand finger orthosis (WHFO), external powered, electric, custom-fabricated | |
| L3905 | Wrist hand orthosis (WHO), includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3961 | Shoulder elbow wrist hand orthosis (SEWHO), shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3967 | Shoulder elbow wrist hand orthosis (SEWHO), abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3971 | Shoulder elbow wrist hand orthosis (SEWHO), shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3973 | Shoulder elbow wrist hand orthosis (SEWHO), abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3975 | Shoulder elbow wrist hand finger orthosis, shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3976 | Shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3977 | Shoulder elbow wrist hand finger orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3978 | Shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment | |
| L3981 | Upper extremity fracture orthosis, humeral, prefabricated, includes shoulder cap design, with or without joints, forearm section, may include soft interface, straps, includes fitting and adjustments | |
| L4000 | Replace girdle for spinal orthosis (Cervical-thoracic-lumbar-sacral orthosis (CTLSO) or Shoulder orthosis (SO)) | |
| L4020 | Replace quadrilateral socket brim, molded to patient model | |
| L4631 | Ankle foot orthosis (AFO), walking boot type, varus/valgus correction, rocker bottom, anterior tibial shell, soft interface, custom arch support, plastic or other material, includes straps and closures, custom fabricated | |
| L5010 | Partial foot, molded socket, ankle height, with toe filler | |
| L5020 | Partial foot, molded socket, tibial tubercle height, with toe filler | |
| L5050 | Ankle, Symes, molded socket, SACH foot | |
| L5060 | Ankle, Symes, metal frame, molded leather socket, articulated ankle/foot | |
| L5100 | Below knee, molded socket, shin, SACH foot | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L5105 | Below knee, plastic socket, joints and thigh lacer, SACH foot | |
| L5150 | Knee disarticulation (or through knee), molded socket, external knee joints, shin, SACH foot | |
| L5160 | Knee disarticulation (or through knee), molded socket, bent knee configuration, external knee joints, shin, SACH foot | |
| L5200 | Above knee, molded socket, single axis constant friction knee, shin, SACH foot | |
| L5210 | Above knee, short prosthesis, no knee joint ('stubbies'), with foot blocks, no ankle joints, each | |
| L5220 | Above knee, short prosthesis, no knee joint ('stubbies'), with articulated ankle/foot, dynamically aligned, each | |
| L5230 | Above knee, for proximal femoral focal deficiency, constant friction knee, shin, SACH foot | |
| L5250 | Hip disarticulation, Canadian type; molded socket, hip joint, single axis constant friction knee, shin, SACH foot | |
| L5270 | Hip disarticulation, tilt table type; molded socket, locking hip joint, single axis constant friction knee, shin, SACH foot | |
| L5280 | Hemipelvectomy, Canadian type; molded socket, hip joint, single axis constant friction knee, shin, SACH foot | |
| L5301 | Below knee, molded socket, shin, SACH foot, endoskeletal system | |
| L5312 | Knee disarticulation (or through knee), molded socket, single axis knee, pylon, SACH foot, endoskeletal system | |
| L5321 | Above knee, molded socket, open end, SACH foot, endoskeletal system, single axis knee | |
| L5331 | Hip disarticulation, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot | |
| L5341 | Hemipelvectomy, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot | |
| L5400 | Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, and one cast change, below knee | |
| L5420 | Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment and suspension and one cast change 'AK' or knee disarticulation | |
| L5500 | Initial, below knee 'PTB' type socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, direct formed | |
| L5505 | Initial, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, direct formed | |
| L5510 | Preparatory, below knee 'PTB' type socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, molded to model | |
| L5520 | Preparatory, below knee 'PTB' type socket, non-alignable system, pylon, no cover, SACH foot, thermoplastic or equal, direct formed | |
| L5530 | Preparatory, below knee 'PTB' type socket, non-alignable system, pylon, no cover, SACH foot, thermoplastic or equal, molded to model | |
| L5535 | Preparatory, below knee 'PTB' type socket, non-alignable system, no cover, SACH foot, prefabricated, adjustable open end socket | |
| L5540 | Preparatory, below knee 'PTB' type socket, non-alignable system, pylon, no cover, SACH foot, laminated socket, molded to model | |
| L5560 | Preparatory, above knee- knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, molded to model | |
| L5570 | Preparatory, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, SACH foot, thermoplastic or equal, direct formed | |
| L5580 | Preparatory, above knee - knee disarticulation ischial level socket, non-alignable system, pylon, no cover, SACH foot, thermoplastic or equal, molded to model | |
| L5585 | Preparatory, above knee - knee disarticulation, ischial level socket, non-alignable system, pylon, no cover, SACH foot, prefabricated adjustable open end socket | |

| CPT, HCPCS or Revenue | DME Description | Comments/ Limitations |
|--------------------------|---|----------------------------|
| Code | | |
| L5590 | Preparatory, above knee - knee disarticulation ischial level socket, non-alignable system, pylon no cover, SACH foot, laminated socket, molded to model | |
| L5595 | Preparatory, hip disarticulation-hemipelvectomy, pylon, no cover, SACH foot, thermoplastic | |
| 23333 | or equal, molded to patient model | |
| L5600 | Preparatory, hip disarticulation-hemipelvectomy, pylon, no cover, SACH foot, laminated | |
| | socket, molded to patient model | |
| L5610 | Addition to lower extremity, endoskeletal system, above knee, hydracadence system | |
| L5611 | Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control | |
| L5613 | Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar | |
| | linkage, with hydraulic swing phase control | |
| L5614 | Addition to lower extremity, exoskeletal system, above knee-knee disarticulation, 4 bar | |
| L5615 | linkage, with pneumatic swing phase control Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance | Effective 1/1/24 (Added on |
| 25015 | phase control | 5/1/24 list) |
| L5616 | Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, | |
| | friction swing phase control | |
| L5639 | Addition to lower extremity, below knee, wood socket | |
| L5643 | Addition to lower extremity, hip disarticulation, flexible inner socket, external frame | |
| L5645 | Addition to lower extremity, below knee, flexible inner socket, external frame | |
| L5647 | Addition to lower extremity, below knee suction socket | |
| L5649 | Addition to lower extremity, ischial containment/narrow M-L socket | |
| L5651 | Addition to lower extremity, above knee, flexible inner socket, external frame | |
| L5681 | Addition to lower extremity, below knee/above knee, custom fabricated socket insert for congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without looking machanism initial only. | |
| L5683 | without locking mechanism, initial only Addition to lower extremity, below knee/above knee, custom fabricated socket insert for other than congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only | |
| L5700 | Replacement, socket, below knee, molded to patient model | |
| L5701 | Replacement, socket, above knee/knee disarticulation, including attachment plate, molded to patient model | |
| L5702 | Replacement, socket, hip disarticulation, including hip joint, molded to patient model | |
| L5703 | Ankle, Symes, molded to patient model, socket without solid ankle cushion heel (SACH) foot, replacement only | |
| L5705 | Custom shaped protective cover, above knee | |
| L5706 | Custom shaped protective cover, knee disarticulation | |
| L5707 | Custom shaped protective cover, hip disarticulation | |
| L5718 | Addition, exoskeletal knee-shin system, polycentric, friction swing and stance phase control | |
| L5722 | Addition, exoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase | |
| | control | |
| L5724 | Addition, exoskeletal knee-shin system, single axis, fluid swing phase control | |
| L5726 | Addition, exoskeletal knee-shin system, single axis, external joints fluid swing phase control | |
| L5728 | Addition, exoskeletal knee-shin system, single axis, fluid swing and stance phase control | |
| L5780 | Addition, exoskeletal knee-shin system, single axis, pneumatic/hydra pneumatic swing phase control | |
| L5781 | Addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|---|
| L5782 | Addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system, heavy duty | |
| L5795 | Addition, exoskeletal system, hip disarticulation, ultra-light material (titanium, carbon fiber or equal) | |
| L5814 | Addition, endoskeletal knee-shin system, polycentric, hydraulic swing phase control, mechanical stance phase lock | |
| L5816 | Addition, endoskeletal knee-shin system, polycentric, mechanical stance phase lock | |
| L5818 | Addition, endoskeletal knee-shin system, polycentric, friction swing, and stance phase control | |
| L5822 | Addition, endoskeletal knee-shin system, single axis, pneumatic swing, friction stance phase control | |
| L5824 | Addition, endoskeletal knee-shin system, single axis, fluid swing phase control | |
| L5826 | Addition, endoskeletal knee-shin system, single axis, hydraulic swing phase control, with miniature high activity frame | |
| L5828 | Addition, endoskeletal knee-shin system, single axis, fluid swing and stance phase control | |
| L5830 | Addition, endoskeletal knee-shin system, single axis, pneumatic/ swing phase control | |
| L5840 | Addition, endoskeletal knee/shin system, 4-bar linkage or multiaxial, pneumatic swing phase control | |
| L5845 | Addition, endoskeletal, knee-shin system, stance flexion feature, adjustable | |
| L5848 | Addition to endoskeletal knee-shin system, fluidstance extension, dampening feature, with or without adjustability | |
| L5856 | Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing and stance phase, includes electronic sensor(s), any type | |
| L5857 | Addition to lower extremity prosthesis, endoskeletal knee-shin system, microprocessor control feature, swing phase only, includes electronic sensor(s), any type | |
| L5858 | Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only, includes electronic sensor(s), any type | |
| L5859 | Addition to lower extremity prosthesis, endoskeletal knee-shin system, powered and programmable flexion/extension assist control, includes any type motor(s) | |
| L5926 | Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type | Effective 1/1/24 (Added on 5/1/24 list) |
| L5930 | Addition, endoskeletal system, high activity knee control frame | |
| L5950 | Addition, endoskeletal system, above knee, ultra-light material (titanium, carbon fiber or equal) | |
| L5960 | Addition, endoskeletal system, hip disarticulation, ultra-light material (titanium, carbon fiber or equal) | |
| L5961 | Addition, endoskeletal system, polycentric hip joint, pneumatic or hydraulic control, rotation control, with or without flexion and/or extension control | |
| L5964 | Addition, endoskeletal system, above knee, flexible protective outer surface covering system | |
| L5966 | Addition, endoskeletal system, hip disarticulation, flexible protective outer surface covering system | |
| L5968 | Addition to lower limb prosthesis, multiaxial ankle with swing phase active dorsiflexion feature | |
| L5973 | Endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, includes power source | |
| L5979 | All lower extremity prosthesis, multiaxial ankle, dynamic response foot, one piece system | |
| L5980 | All lower extremity prostheses, flex foot system | |
| L5981 | All lower extremity prostheses, flex-walk system or equal | |
| L5987 | All lower extremity prosthesis, shank foot system with vertical loading pylon | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L5988 | Addition to lower limb prosthesis, vertical shock reducing pylon feature | |
| L5990 | Addition to lower extremity prosthesis, user adjustable heel height | |
| L6000 | Partial hand, thumb remaining | |
| L6010 | Partial hand, little and/or ring finger remaining | |
| L6020 | Partial hand, no finger remaining | |
| L6026 | Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self- suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device, excludes terminal device(s) | |
| L6050 | Wrist disarticulation, molded socket, flexible elbow hinges, triceps pad | |
| L6055 | Wrist disarticulation, molded socket with expandable interface, flexible elbow hinges, triceps pad | |
| L6100 | Below elbow, molded socket, flexible elbow hinge, triceps pad | |
| L6110 | Below elbow, molded socket, (Muenster or Northwestern suspension types) | |
| L6120 | Below elbow, molded double wall split socket, step-up hinges, half cuff | |
| L6130 | Below elbow, molded double wall split socket, stump activated locking hinge, half cuff | |
| L6200 | Elbow disarticulation, molded socket, outside locking hinge, forearm | |
| L6205 | Elbow disarticulation, molded socket with expandable interface, outside locking hinges, forearm | |
| L6250 | Above elbow, molded double wall socket, internal locking elbow, forearm | |
| L6300 | Shoulder disarticulation, molded socket, shoulder bulkhead, humeral section, internal locking elbow, forearm | |
| L6310 | Shoulder disarticulation, passive restoration (complete prosthesis) | |
| L6320 | Shoulder disarticulation, passive restoration (shoulder cap only) | |
| L6350 | Interscapular thoracic, molded socket, shoulder bulkhead, humeral section, internal locking elbow, forearm | |
| L6360 | Interscapular thoracic, passive restoration (complete prosthesis) | |
| L6370 | Interscapular thoracic, passive restoration (shoulder cap only) | |
| L6380 | Immediate post surgical or early fitting, application of initial rigid dressing, including fitting alignment and suspension of components, and one cast change, wrist disarticulation or below elbow | |
| L6382 | Immediate post surgical or early fitting, application of initial rigid dressing including fitting alignment and suspension of components, and one cast change, elbow disarticulation or above elbow | |
| L6384 | Immediate post surgical or early fitting, application of initial rigid dressing including fitting alignment and suspension of components, and one cast change, shoulder disarticulation or interscapular thoracic | |
| L6400 | Below elbow, molded socket, endoskeletal system, including soft prosthetic tissue shaping | |
| L6450 | Elbow disarticulation, molded socket, endoskeletal system, including soft prosthetic tissue shaping | |
| L6500 | Above elbow, molded socket, endoskeletal system, including soft prosthetic tissue shaping | |
| L6550 | Shoulder disarticulation, molded socket, endoskeletal system, including soft prosthetic tissue shaping | |
| L6570 | Interscapular thoracic, molded socket, endoskeletal system, including soft prosthetic tissue shaping | |
| L6580 | Preparatory, wrist disarticulation or below elbow, single wall plastic socket, friction wrist, flexible elbow hinges, figure of eight harness, humeral cuff, Bowden cable control, USMC or equal pylon, no cover, molded to patient model | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L6582 | Preparatory, wrist disarticulation or below elbow, single wall socket, friction wrist, flexible elbow hinges, figure of eight harness, humeral cuff, Bowden cable control, USMC or equal pylon, no cover, direct formed | |
| L6584 | Preparatory, elbow disarticulation or above elbow, single wall plastic socket, friction wrist, locking elbow, figure of eight harness, fairlead cable control, USMC or equal pylon, no cover, molded to patient model | |
| L6586 | Preparatory, elbow disarticulation or above elbow, single wall socket, friction wrist, locking elbow, figure of eight harness, fairlead cable control, USMC or equal pylon, no cover, direct formed | |
| L6588 | Preparatory, shoulder disarticulation or interscapular thoracic, single wall plastic socket, shoulder joint, locking elbow, friction wrist, chest strap, fairlead cable control, USMC or equal pylon, no cover, molded to patient model | |
| L6590 | Preparatory, shoulder disarticulation or interscapular thoracic, single wall socket, shoulder joint, locking elbow, friction wrist, chest strap, fairlead cable control, USMC or equal pylon, no cover, direct formed | |
| L6621 | Upper extremity prosthesis addition, flexion/extension wrist with or without friction, for use with external powered terminal device | |
| L6624 | Upper extremity addition, flexion/extension and rotation wrist unit | |
| L6638 | Upper extremity addition to prosthesis, electric locking feature, only for use with manually powered elbow | |
| L6646 | Upper extremity addition, shoulder joint, multipositional locking, flexion, adjustable abduction friction control, for use with body powered or external powered system | |
| L6648 | Upper extremity addition, shoulder lock mechanism, external powered actuator | |
| L6693 | Upper extremity addition, locking elbow, forearm counterbalance | |
| L6696 | Addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated socket insert for congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only | |
| L6697 | Addition to upper extremity prosthesis, below elbow/above elbow, custom fabricated socket insert for other than congenital or atypical traumatic amputee, silicone gel, elastomeric or equal, for use with or without locking mechanism, initial only | |
| L6707 | Terminal device, hook, mechanical, voluntary closing, any material, any size, lined or unlined | |
| L6708 | Terminal device, hand, mechanical, voluntary opening, any material, any size | |
| L6709 | Terminal device, hand, mechanical, voluntary closing, any material, any size | |
| L6712 | Terminal device, hook, mechanical, voluntary closing, any material, any size, lined or unlined, pediatric | |
| L6713 | Terminal device, hand, mechanical, voluntary opening, any material, any size, pediatric | |
| L6714 | Terminal device, hand, mechanical, voluntary closing, any material, any size, pediatric | |
| L6715 | Terminal device, multiple articulating digit, includes motor(s), initial issue or replacement | |
| L6721 | Terminal device, hook or hand, heavy duty, mechanical, voluntary opening, any material, any size, lined or unlined | |
| L6722 | Terminal device, hook or hand, heavy duty, mechanical, voluntary closing, any material, any size, lined or unlined | |
| L6880 | Electric hand, switch or myoelectric controlled, independently articulating digits, any grasp pattern or combination of grasp patterns, includes motor(s) | |
| L6881 | Automatic grasp feature, addition to upper limb electric prosthetic terminal device | |
| L6882 | Microprocessor control feature, addition to upper limb prosthetic terminal device | |
| L6883 | Replacement socket, below elbow/wrist disarticulation, molded to patient model, for use with or without external power | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L6884 | Replacement socket, above elbow/elbow disarticulation, molded to patient model, for use | |
| LOÕÕ4 | with or without external power | |
| L6885 | Replacement socket, shoulder disarticulation/interscapular thoracic, molded to patient | |
| | model, for use with or without external power | |
| L6900 | Hand restoration (casts, shading and measurements included), partial hand, with glove, | |
| | thumb or one finger remaining | |
| L6905 | Hand restoration (casts, shading and measurements included), partial hand, with glove, | |
| | multiple fingers remaining | |
| L6910 | Hand restoration (casts, shading and measurements included), partial hand, with glove, no | |
| | fingers remaining | |
| L6920 | Wrist disarticulation, external power, self-suspended inner socket, removable forearm shell, | |
| | Otto Bock or equal, switch, cables, two batteries and one charger, switch control of terminal | |
| 10025 | device | |
| L6925 | Wrist disarticulation, external power, self-suspended inner socket, removable forearm shell, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectronic control | |
| | of terminal device | |
| L6930 | Below elbow, external power, self-suspended inner socket, removable forearm shell, Otto | |
| 20000 | Bock or equal switch, cables, two batteries and one charger, switch control of terminal device | |
| L6935 | Below elbow, external power, self-suspended inner socket, removable forearm shell, Otto | |
| 10000 | Bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of | |
| | terminal device | |
| L6940 | Elbow disarticulation, external power, molded inner socket, removable humeral shell, | |
| | outside locking hinges, forearm, Otto Bock or equal switch, cables, two batteries and one | |
| | charger, switch control of terminal device | |
| L6945 | Elbow disarticulation, external power, molded inner socket, removable humeral shell, | |
| | outside locking hinges, forearm, Otto Bock or equal electrodes, cables, two batteries and one | |
| | charger, myoelectronic control of terminal device | |
| L6950 | above elbow, external power, molded inner socket, removable humeral shell, internal locking | |
| | elbow, forearm, Otto Bock or equal switch, cables, two batteries and one charger, switch | |
| 10055 | control of terminal device | |
| L6955 | Above elbow, external power, molded inner socket, removable humeral shell, internal | |
| | locking elbow, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of terminal device | |
| L6960 | Shoulder disarticulation, external power, molded inner socket, removable shoulder shell, | |
| L0900 | shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal switch, | |
| | cables, two batteries and one charger, switch control of terminal device | |
| L6965 | Shoulder disarticulation, external power, molded inner socket, removable shoulder shell, | |
| | shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal | |
| | electrodes, cables, two batteries and one charger, myoelectronic control of terminal device | |
| L6970 | interscapular-thoracic, external power, molded inner socket, removable shoulder shell, | |
| | shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal switch, | |
| | cables, two batteries and one charger, switch control of terminal device | |
| L6975 | Interscapular-thoracic, external power, molded inner socket, removable shoulder shell, | |
| | shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal | |
| | electrodes, cables, two batteries and one charger, myoelectronic control of terminal device | |
| L7007 | Electric hand, switch or myoelectric controlled, adult | |
| L7008 | Electric hand, switch or myoelectric, controlled, pediatric | |
| L7009 | Electric hook, switch or myoelectric controlled, adult | |
| L7040 | Prehensile actuator, switch controlled | |
| L7045 | Electric hook, switch or myoelectric controlled, pediatric | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|--|-----------------------|
| L7170 | Electronic elbow, Hosmer or equal, switch controlled | |
| L7180 | Electronic elbow, microprocessor sequential control of elbow and terminal device | |
| L7181 | Electronic elbow, microprocessor simultaneous control of elbow and terminal device | |
| L7185 | Electronic elbow, adolescent, Variety Village or equal, switch controlled | |
| L7186 | Electronic elbow, child, Variety Village or equal, switch controlled | |
| L7190 | Electronic elbow, adolescent, Variety Village or equal, myoelectronically controlled | |
| L7191 | Electronic elbow, child, Variety Village or equal, myoelectronically controlled | |
| L7259 | Electronic wrist rotator, any type | |
| L8035 | Custom breast prosthesis, post mastectomy, molded to patient model | |
| L8040 | Nasal prosthesis, provided by a non-physician | |
| L8041 | Midfacial prosthesis, provided by a non-physician | |
| L8042 | Orbital prosthesis, provided by a non-physician | |
| L8043 | Upper facial prosthesis, provided by a non-physician | |
| L8043 | Hemi-facial prosthesis, provided by a non-physician | |
| L8044 | Auricular prosthesis, provided by a non-physician | |
| L8045 | | |
| | Partial facial prosthesis, provided by a non-physician | |
| L8047 | Nasal septal prosthesis, provided by a non-physician | |
| L8609 | Artificial cornea | |
| L8614 | Cochlear device, includes all internal and external components | |
| L8615 | Headset/headpiece for use with cochlear implant device, replacement | |
| L8616 | Microphone for use with cochlear implant device, replacement | |
| L8617 | Transmitting coil for use with cochlear implant device, replacement | |
| L8618 | Transmitter cable for use with cochlear implant device, replacement | |
| L8619 | Cochlear implant, external speech processor and controller, integrated system, replacement | |
| L8627 | Cochlear implant, external speech processor, component, replacement | |
| L8628 | Cochlear implant, external controller component, replacement | |
| L8629 | Transmitting coil and cable, integrated, for use with cochlear implant device, replacement | |
| L8631 | Metacarpal phalangeal joint replacement, two or more pieces, metal (e.g., stainless steel or cobalt chrome), ceramic-like material (e.g., pyrocarbon), for surgical implantation (all sizes, includes entire system) | |
| L8659 | Interphalangeal finger joint replacement, 2 or more pieces, metal (e.g., stainless steel or cobalt chrome), ceramic-like material (e.g., pyrocarbon) for surgical implantation, any size | |
| L8679 | Implantable neurostimulator, pulse generator, any type | |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only | |
| L8682 | Implantable neurostimulator radio frequency receiver | |
| L8683 | Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver | |
| L8689 | external recharging system for battery (internal) for use with implantable neurostimulator, replacement only | |
| L8690 | Auditory osseointegrated device, includes all internal and external components | |
| L8691 | Auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each | |
| L8692 | Auditory osseointegrated device, external sound processor, used without osseointegration, body worn | |

| CPT, HCPCS or Revenue Code | DME Description | Comments/ Limitations |
|----------------------------------|---|-----------------------|
| L8693 | Auditory osseointegrated device abutment, any length, replacement only | |
| L8694 | Auditory osseointegrated device, transducer/actuator, replacement only, each | |
| Q0479 | Power module for use with electric or electric/pneumatic ventricular assist device, replacement only | |
| Q0480 | Driver for use with pneumatic ventricular assist device, replacement only | |
| Q0481 | Microprocessor control unit for use with electric ventricular assist device, replacement only | |
| Q0482 | Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only | |
| Q0483 | Monitor/display module for use with electric ventricular assist device, replacement only | |
| Q0484 | Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only | |
| Q0489 | Power pack base for use with electric/pneumatic ventricular assist device, replacement only | |
| Q0491 | Emergency power source for use with electric/pneumatic ventricular assist device, replacement only | |
| V2623 | Prosthetic eye, plastic, custom | |
| V2627 | Scleral cover shell | |